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Tissue engineering aims at regenerating damaged tissue by using synthetic or natural 
materials and has applications across the different tissue types, including bone. A 
major challenge in bone tissue engineering includes the availability of materials that 
possess desirable properties including osteogenic potential, as well as osteoconductive 
and osteoinductive features to support bone regeneration, this challenge is magnified 
in the case of critical bone defects. The gold-standard treatment for such defects is 
autologous bone grafting, which suffers from issues related to the availability of 
material and the morbidity associated with surgeries to harvest the tissue. Therefore, 
it is important to consider alternative materials and therapeutic options that may 
contribute to improving the outcomes of bone tissue engineering issues.  
The overall aim of this thesis was to investigate the therapeutic potential of the small 
drug molecule, siponimod, to influence key cell process inherent in bone regeneration 
and to investigate the formulation design, functionality and regenerative potential of 
suitable scaffold constructs that exert spatiotemporal control over siponimod delivery 
both in vitro and in an in vivo critical defect model. 
Chapter 1 provided a general introduction of key concepts discussed throughout the 
thesis including a background on bone anatomy and biology. Thereafter, the chapter 
introduced tissue engineering in general with a focus on intrinsic aspects of bone tissue 
engineering namely scaffolds, cells, and signals. It described the key requirements in 
the design of scaffolds suitable for bone regeneration and provided an overview of the 
materials and techniques used in the fabrication of scaffolds for bone tissue 
engineering. In particular it highlighted, the materials used throughout this thesis, such 
xiv 
 
as the natural and synthetic polymers collagen and poly lactide-co-glycolide (PLGA) 
used in Chapter 4 & 5, and the bioactive ceramic hydroxyapatite (HA) used in 
Chapter 5. This first chapter also addressed the use of protein and small molecule 
signal therapeutics in bone tissue engineering, including a brief introduction of 
sphingosine 1-phosphate.  
Chapter 2 thus followed with an in-depth review of the role of sphingosine 1-
phosphate (S1P) in bone biology and its potential therapeutic use in bone repair. The 
role of S1P in nervous, cardiovascular, and immune systems is well established, 
however, knowledge regarding its role in bone biology and the utility of specific S1P 
receptor modulation in bone repair was lacking. Therefore, Chapter 2 not only aimed 
to add to the available literature on the role of S1P signalling in bone repair, but also 
to contribute to the identification of S1P mediated processes that could be targeted 
therapeutically. The culmination of the review in Chapter 2 was the selection of S1P1 
receptor modulation as a target, and siponimod as a selective agonist for further 
investigation. 
Thereafter, Chapter 3 investigated the in vitro bone regenerative potential of the S1P 
receptor modulator, siponimod. Specifically, it aimed to identify the impact of 
siponimod on key cellular processes including cell viability, proliferation, 
differentiation and migration using human foetal osteoblasts (hFOB), as well as cell 
proliferation and migration using human umbilical vein endothelial cells (HUVEC). 
The hypothesis underpinning Chapter 3 was that selective S1P1 signalling using the 
S1P1/5 agonist, siponimod would stimulate osteoblast proliferation, differentiation, and 
migration as well as endothelial cell proliferation and migration. The results of this 
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chapter showed for the first time that siponimod indeed promotes osteoblast 
differentiation while having no influence on viability and proliferation. Siponimod 
was also shown to promote the chemokinesis of endothelial cells, whereby it interfered 
with cell attachment and migration in the short-term (4 hrs) and caused a delayed (8 
hrs) stimulation of endothelial migration. Taken together these results suggested that 
siponimod was worthy of further investigation in the context of bone regeneration. 
However, the balance of evidence in the bone repair literature supports the use of a 
localised delivery approach for sphingolipids, rather than systemic administration. 
This was the motivation supporting the research in Chapter 4 and Chapter 5, which 
investigated suitable scaffold constructs for the localised delivery of siponimod.  
Therefore, the hypothesis underpinning Chapter 4 was that the design of a 
biocompatible and biodegradable polymeric scaffold would control the presentation 
of siponimod in a stable and functional manner at appropriate concentrations and over 
relevant timeframes to exploit its potential for enhanced bone regeneration. This 
chapter thus detailed the preparation, characterisation and in vitro assessment of 
PLGA-based electrospun material coupled with collagen and loaded with siponimod 
at different concentrations (0.5-2 % w/w). The physicochemical characteristics 
including drug stability in the solid and liquid state as well as drug loading and release 
properties were investigated. Additionally, in vitro cell-based investigations were 
carried out on the electrospun material to assess its compatibility with the cellular 
populations of interest, hFOB and HUVEC, and whether the released siponimod 
maintained the functional effects determined in Chapter 3. Results confirmed our 
hypothesis that siponimod could be successfully loaded with high efficiencies (80-94 
%) and its release could be controlled in a stable manner (> 3 months), which was in 
xvi 
 
line with a planned 12-week in vivo cranial defect study. Furthermore, the released 
siponimod maintained its differentiation and migration effects on hFOB and HUVEC 
in vitro. The scaffolds were then implanted in rat critical cranial defects for 12-weeks 
to assess in vivo effectiveness of the siponimod loaded scaffold. Results showed that 
while there was some reduction in defect size, there was no statistically significant 
differences between the experimental groups regarding the histomorphometrically 
determined area of mineralisation within the defect space.  
The scaffold described in Chapter 5 was designed contemporaneously with the 
electrospun scaffold in Chapter 4, although only the latter design was progressed to 
the stage of in vivo analysis. Acknowledging this, Chapter 5 provided a preliminary 
description of the design and characterisation of another scaffold design using 
electrospray-microparticles loaded with siponimod. As with the electrospun scaffold, 
this alternative design is based on a similar hypothesis that localised delivery of 
siponimod for bone regeneration was superior to systemic delivery. The microparticles 
were mould compressed with HA, the calcium phosphate mineral reminiscent of that 
found in native bone tissue, and a porogen, prior to high-pressure carbon dioxide (CO2) 
foaming and porogen leaching. The morphological properties of the microparticles 
and the completed scaffolds were assessed using scanning electron microscopy 
(SEM). Physicochemical properties investigated included porosity, mechanical 
properties, siponimod drug loading and release, and cell culture studies to assess the 
scaffold’s effect on hFOB and HUVEC. Results of SEM showed that the diameters of 
microparticles was increased by the inclusion of siponimod, while scaffolds possessed 
a highly porous internal structure, with morphology affected by the inclusion of HA. 
Drug loading efficiency was lower than those seen in Chapter 4, which was expected 
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due to the method employed, although drug release was still sustained over 3 months. 
The scaffolds were found to be compatible with hFOB and HUVEC, whether seeded 
in direct or indirect contact with scaffolds and no significant changes to cell metabolic 
activity were observed.  
In conclusion, this thesis showed that S1P receptors have a clear impact on the biology 
of bone repair, with novel findings contributing to our understanding of siponimod’s 
in vitro effect on osteoblasts and endothelial cells, which could lead to siponimod-
based therapeutic options for bone and other tissue regeneration applications. This 
thesis also detailed the first designs of controlled release scaffolds for siponimod, with 
the S1P1 agonist successfully incorporated into two different scaffolds using both 
electrospinning and electrospraying production methods, which enabled constructs 
with different compositions and physical properties to be designed. Although in vivo 
results of cranial defect studies did not provide statistically significant evidence of 
improved bone regeneration, both scaffold designs demonstrated promising cell 
compatibility and drug release properties, that can be further optimised to fully utilise 















1.1 Bone tissue  
Bone is a highly specialised connective tissue characterised by its mineralisation in its 
mature state. Bone fulfils several important functions, acting as a static protective 
frame supporting structural, and locomotor activities (Walsh, 2015). In addition, bone 
is a highly metabolically dynamic tissue that acts as a mineral reservoir (Copp and 
Shim, 1963), which is in a constant state of remodelling to repair damaged tissue and 
maintain mineral homeostasis (Raggatt and Partridge, 2010).  
On an anatomical level, bone is divided into cortical (compact) and cancellous 
(spongy) bone. Cortical bone forms the hard exterior surface including the shafts of 
long bones (e.g. femur) and the exterior of flat bones (e.g. skull), while cancellous 
bone is present in the marrow cavities of long bone and the centres of flat bones (Kim 
et al., 2019a). The external surface of cortical bone is covered by the periosteum, 
which is made up of the outer fibrous layer and the inner cambium layer populated 
with progenitor and differentiated osteogenic cells (Dwek, 2010). 
Looking more closely at composition, bone’s dry weight composition consists of a 
70/30 split between inorganic and organic materials. The inorganic fraction consists 
mainly of calcium phosphates, while the organic fraction is predominantly comprised 
of collagen (≈90 %) as well other non-collagenous proteins and lipids (Shekaran and 
García, 2011, Mohamed, 2008).  
Bone remodelling relies on the close coupling of bone formation and bone resorption, 
which is mediated by key cell populations, together termed the basic multicellular unit 
(Feng and McDonald, 2011). These include osteoblasts and osteocytes derived from 




progenitors (Mohamed, 2008). Osteoblasts are responsible for the formation and 
deposition of new bone matrix and are subject to several fates, including becoming 
entrapped within the bone matrix as osteocytes, wherein they continue to regulate bone 
remodelling and repair through a process of mechanotransduction (Hinton et al., 
2018). Osteoblasts can also develop into bone lining cells, which are quiescent cells 
that line the surfaces of bone that is not actively undergoing remodelling; their function 
is not fully understood but they appear to be involved in the supply of osteoblast cells 
(Matic et al., 2016). Osteoclasts are large multi-nucleated cells of haematopoietic 
origin that are responsible for the resorption of bone during remodelling (Teitelbaum, 
2007). The bone remodelling process is an essential stage in bone repair, details of 
which are detailed in the following chapter (Section 2.3 Bone repair). 
The structure of bone tissue is organised on a hierarchical scale from the molecular to 
macro-scales and is summarised in Figure 1.1. Primary collagen molecules are 
interstitially packed with HA and form oriented collagen fibrils, which are the basic 
component of collagen fibres. Concentric layers of collagen fibres arrange to form 
osteons (also known as Haversian systems), each of which is centred by a Haversian 
canal providing blood vessels and nerves (Nijsure and Kishore, 2017, Rho et al., 
1998). At this level osteocytes are dispersed throughout the bone matrix along with 
the proteins that are essential for calcium binding and normal bone function such as 





Figure 1.1 Structural organisation of bone. (A) Bone (B) Osteons and haversian canals 
(C) Collagen fibres (D) Bone mineral crystals with molecular collagen. Adapted from 
(Ahern et al., 2013). 
  
1.2 Current state of bone defect repair  
Bone is a highly robust tissue capable of self-repair in most events of bone injury, and 
while only a small number (20 per 100 000 per annum) of injurious events are cases 
of non-union (Mills and Simpson, 2013), this type of injury can constitute a significant 
financial burden on health services, and severely impact on patients’ quality of life 




patients who receive the gold standard therapy, autologous bone grafts, complain of 
significant side effects (Dahabreh et al., 2008). Furthermore, the frequency of bone-
related medical conditions is on the rise, especially with ageing populations, this has 
led to a rise in the cost and impact that bone injuries and diseases have had on societies 
globally (Tatangelo et al., 2019). Conditions such as osteoporosis, bone loss after 
metastasis, and critical bone defects are notoriously challenging to manage. 
In the case of critical bone defects, the current gold-standard for treatment includes 
the use of autologous bone grafts as well as allogenic bone grafts (Baldwin et al., 
2019). Autologous bone grafts or autografts, involve the surgical excision of bone 
(typically from the iliac crest) to be used as an implantable material, with the main 
benefits being excellent biocompatibility and biological activity without the risk of 
immune rejection (Koons et al., 2020). Autografts are beneficial because they provide 
a matrix for bone growth (osteoconductive), they promote mesenchymal stem cell 
(MSC) differentiation along the osteoblast lineage (osteoinduction) due to the 
presence of growth factors (e.g. Bone morphogenetic proteins (BMP), vascular 
endothelial growth factor (VEGF), and platelet derived growth factor (PDGF)) 
(Schmidmaier et al., 2006), cancellous autograft in particular also possesses excellent 
osteogenic potential arising from the abundance of transplanted osteogenic precursors 
with bone producing potential (Sun et al., 2019), and ultimately results in a high fusion 
rate at the transplant site. However, autografts are not without issue, as morbidity and 
logistical complications of procuring sufficient, easily accessible bone can arise 
(Goulet et al., 1997, Arrington et al., 1996). The morbidity risks include perioperative 
artery and nerve injuries and deep wound infections, as well as delayed complications 




Allogenic bone grafts involve the receipt of donor or cadaver bone for use as a 
replacement material, this method alleviates some of the logistical concerns associated 
with the availability of autograft. However, the preference for freshly frozen allogenic 
bone may increase the risk of viral disease transmission (Wimmer et al., 1999). 
 
1.3 Bone tissue engineering 
Tissue engineering is generally defined as the use of synthetic or natural materials to 
regenerate the form and function of damaged tissue (Vacanti and Vacanti, 2014). The 
field of bone tissue engineering (BTE) aims to apply the principles of engineering and 
biology to the development of functional tissue substitutes for damaged tissue, thereby 
overcoming the inherent limitations of autograft and allograft procedures, while 
attempting to replicate an equivalent level of biological activity in the designed 
replacement material (Montoro et al., 2014). 
Tissue engineering has been applied across a range of tissue types including skin 
(Falanga et al., 2014), bone (Montoro et al., 2014), tendons and ligament (Goulet et 
al., 2014), and vascular tissue (Brewster et al., 2014), all of which have their own 
specific goals and challenges. Although significant progress has been made in the field 
as a whole, most notably the Dermal Regeneration Template, Integra® (Integra 
LifeSciences, USA) and the spinal fusion bone grafts, INFUSE® (Medtronic, USA) 
(Hoffman et al., 2019), it is clear that there is still much work required. For instance, 
INFUSE®, contains the osteoinductive growth factor, recombinant human BMP 
(rhBMP) -2 and has been associated with ectopic bone growth and increased 




Tissue engineering methods require a collaboration between the existing infrastructure 
of the damaged tissue and the three pillars of tissue engineering: cells, scaffolds, and 
signals (Nerem and Schutte, 2014) (Figure 1.2). ‘’Cells’’ represent the important 
cellular populations involved in the regeneration of a particular tissue, ‘’scaffolds’’ is 
a material that mimics the natural extracellular matrix of the regenerating tissue upon 
which cells can act, and finally ‘’signals’’ are natural or synthetic molecules that 
induce one or more biochemical activities in any or all of the cellular populations 
involved (Nerem and Schutte, 2014). A general overview of these three pillars will be 
presented in the following sections, beginning with the considerable research that has 
been dedicated to investigating different materials and techniques suitable for the 
preparation of ‘’scaffolds’’ for BTE (Turnbull et al., 2018, Roseti et al., 2017).  
 
 
Figure 1.2 Schematic of the key pillars of bone tissue engineering design (Hoffman 




1.4 Properties of an implantable scaffold 
Any implantable scaffold designed to support the regeneration of critical bone defects 
will need to fulfil several criteria, all of which are inspired by the qualities of natural 
bone tissue (Figure 1.3). 
 
 
Figure 1.3 Schematic highlighting the ‘’Scaffolds’’ pillar of tissue engineering design. 
 
The scaffold should be non-toxic and biocompatible (Kohane and Langer, 2010), 
allowing the natural growth and behaviour of the native cell populations in the injured 
tissue. Stimulating a favourable interaction can be further manipulated by combining 
natural materials such as collagen or HA with inexpensive and abundant base materials 
such as biodegradable polymers, which should ideally not induce an immune response 
(Jin et al., 2019). The completed scaffold must also be compatible with an appropriate 
method of sterilisation, whether by heat (autoclave), irradiation (UV, Gamma), or 




It is important that the architecture of the scaffold achieves a degree of biomimicry, 
approximating the architecture of natural bone. For example, the porosity of the 
material is essential for initial cell adhesion, preventing cell aggregation on the 
scaffold surface, and improving cell infiltration and should be in the range of hundreds 
of microns (Murphy et al., 2010). Micropores in the range of tens of microns are also 
important in increasing surface area for protein adsorption and influencing scaffold 
degradation (Zhang et al., 2018). Degradation is another design factor in BTE 
scaffolds (Rezwan et al., 2006), and therefore it is important to note that just as the 
process of bone regeneration develops over a period of several months (Loi et al., 
2016), it must similarly be the case that an implanted scaffold closely match this 
timeframe in its degradation (Polo-Corrales et al., 2014). Additionally, much research 
has taken inspiration from the cues inherent in native bone tissue e.g. cortical or 
cancellous bone, and scaffolds have been designed to approximate bone in terms of its 
mechanical, and biological behaviour (Wang et al., 2016b) (Table 1.1). From an 
economic perspective, all materials and methods must eventually represent cost-
effective and viable alternatives to autograft procedures while maintaining efficacy 









Table 1.1 Summary of mechanical properties of cortical and cancellous bone, adapted 
from (Hench, 2013). Compressive and tensile strength are the ability of a material to 
withstand the application of compressive and tensile stress without breakage or 
deformation. Strain to failure is the ratio between the change in sample length and the 
initial length, following breakage. Youngs modulus measures a materials stiffness by 
quantifying the relationship between the force applied to a material (stress) and its 
deformation (strain) (Beer et al., 1999). 
 
 
1.5 Types of materials in bone tissue engineering 
There are a number of materials that have been used to prepare scaffolds in BTE 
projects, but most can be placed into categories of polymers, ceramics and composites 
of the two (Roseti et al., 2017, Koons et al., 2020) (Table 1.2), these materials are the 
topics of the following sections. Metals (alloys of titanium and magnesium) (Malladi 
et al., 2018), and carbon-based nanomaterials (carbon nanotubes) (Eivazzadeh-Keihan 
et al., 2019) are interesting materials that should be mentioned, these materials possess 




to induce bioactivity (Cheng et al., 2016, Arnold et al., 2019). However, metal and 
carbon-based materials are somewhat outside the scope of this thesis, due to their 
specialised processing requirements and non-degradability. 
  
Table 1.2 Overview of polymer and ceramic materials, adapted from (Koons et al., 




Polymers, long chains of covalently bonded repeating units, have a long history of use 
as biomaterials for the preparation of tissue engineering scaffolds (Dhandayuthapani 
et al., 2011). Polymers can be of synthetic or natural origin (Asghari et al., 2017). 
Natural polymers such as collagen (Dong and Lv, 2016), gelatin (derived from acid or 
alkaline hydrolysis of collagen) (Hoque et al., 2015) and hyaluronic acid (Collins and 
Birkinshaw, 2013) have been shown to have good biocompatibility, being generally 
hydrophilic and exhibiting low immunogenicity (Gasperini et al., 2014). Collagen, as 
the main organic constituent in bone, is a fundamental component of autograft and 




Furthermore, collagen is the component that adds flexural strength to bone and amino 
acid sequences within the protein structure act as sites for cellular attachment (Di Lullo 
et al., 2002). These properties have led to collagen being widely investigated in BTE 
(Stuckensen et al., 2018). Collagen despite its excellent biocompatibility and cell 
adhesion properties lacks rigidity and osteoinductivity and is often used in 
combination with other materials (Glowacki and Mizuno, 2008). Recent examples of 
collagen based scaffolds include a porous bioactive construct doped with strontium 
and silver that resulted in improved regeneration of a rat cranial defect (Liu et al., 
2020). Another group prepared silica coated collagen scaffolds that successfully 
induced repair of a rabbit cranial defect without the addition of exogenous cells and 
growth factors (Wang et al., 2019).  
Synthetic or semi-synthetic polymers are generally less hydrophilic and less 
biocompatible than natural polymers. However, their tuneable degradation and 
mechanical properties are key advantages (Roseti et al., 2017). Examples include 
polyanhydrides, and polyesters including polycaprolactone (PCL), poly (lactic acid) 
(PLA), and copolymers poly (lactide-co-glycolide) (PLGA) (Sabir et al., 2009). In 
particular PLGA has been extensively investigated for BTE applications, and has been 
prepared in a variety of forms, such as films, microspheres, and porous scaffolds 
(Gentile et al., 2014). PLGA has well documented biocompatibility, and its 
degradation products (lactic and glycolic acids) are ultimately excreted from the body 
as carbon dioxide (CO2) and water (Elmowafy et al., 2019). Degradation rate is 
affected by several factors related to the polymer including monomer ratio, molecular 
weight, stereochemistry and solid-state properties. For example, degradation rate is 




hydrophobicity (e.g. PLGA 85:15 degrades more slowly than PLGA 65:35) (Makadia 
and Siegel, 2011). Other properties that slow degradation include physical features of 
the construct e.g. reduced surface-area to volume by altering the size and shape of a 
scaffold matrix (Makadia and Siegel, 2011). The slowly degrading copolymer, PLGA 
85:15 is already used in several maxillofacial bone fixation devices including 
RAPIDSORB® (DePuy Synthes Companies, USA), and LactoSorb® (Zimmer Biomet, 
USA), among others (Gilardino et al., 2009).  
While PLGA is biocompatible it does not possess strong osteoconductive or any 
osteoinductive properties, therefore most recent applications of PLGA in cases of 
challenging bone defects are composite materials. An example being a PLGA porous 
scaffold coupled with magnesium powder and β-tricalcium phosphate resulting in 
enhanced osteogenic and angiogenic properties of the scaffold compared to PLGA 
controls (Lai et al., 2019). Another scaffold using similar materials, β-tricalcium 
phosphate and magnesium hydroxide, improved bone regeneration in a rat humoral 
defect through the added materials’ respective impacts as osteoconductive and anti-
inflammatory agents (Go et al., 2020). PLGA also has utility for controlled release of 
potent osteogenic agents in BTE scaffolds, for example the controlled release of BMP-
2 from PLGA scaffolds which resulted in significant new bone formation in mouse 
cranial defects (Rahman et al., 2014).  
1.5.2 Ceramics 
The first generations of ceramic implants were based on zirconia and alumina, and 
while non-toxic, they did not interact with the surrounding tissue and so were termed 




Later generations consisted of implantable materials that react with the surrounding 
tissue in order to form new bone and degrade gradually as the natural tissue 
regenerated (bioresorbable), these are bioactive ceramics and include calcium 
phosphates (CaP) and bioactive glasses (Vallet-Regí and Ruiz-Hernández, 2011, 
Hench, 2013). Calcium phosphates including HA (Ca₁₀(PO₄)₆(OH)₂), and α- and β-
tricalcium phosphate (TCP) (Ca₃(PO₄)₂) share a chemical similarity to the inorganic 
phase of bone, which has led to their extensive investigation in preparing BTE 
scaffolds (Ben-Nissan, 2003, Hoppe et al., 2011). Both HA and TCP are 
osteoconductive (Kokubo, 1998), and both support the adhesion (Annaz et al., 2004, 
Ergun et al., 2008) and differentiation of osteoblast progenitors (Shu et al., 2003, Chen 
et al., 2014). The degradation or resorption of CaP can be controlled by their Ca/P 
ratio with monocalcium phosphates (0.5 Ca/P ratio) being more resorbable than TCP 
(1.5 Ca/P ratio), which is turn resorbs quicker than HA (1.67 Ca/P ratio) (Dorozhkin, 
2010). Bioactive glasses (BG), such as the prototypical 45S5 Bioglass® (Hench et al., 
1971), are another bioactive ceramic based on compositions of sodium, calcium, 
phosphate, and silicate oxide glasses that form a strong adhesive bond to bone and to 
soft tissue (Hench et al., 2004). The BGs slowly bond with existing soft and hard tissue 
as they dissolve in biological fluids forming a carbonated HA layer, which adsorbs 
growth factors and supports cell growth, ultimately resulting in the formation of 
healthy and functional bone tissue (Rahaman et al., 2011). 
Some recent applications of bioceramics in BTE included a study that described a 
composite ceramic scaffold design composed of HA/TCP, that was 3-D printed and 
implanted into canine mandibular defects for up to 8 weeks, and resulted in a 




investigated a 3-D printed BG (AP40) seeded with bone marrow progenitor cells 
implanted in a rabbit mandibular defect for up to 9 months that resulted in near 
complete coverage of the defects by new bone and the formation of blood vessels 
within the pores of the implanted scaffold (Xu et al., 2020).  
1.6 Fabrication techniques 
The choice of material is clearly an important aspect of designing a BTE scaffold. 
Equally important is the fabrication technique used to manipulate the material into the 
potential form with key structural features. Some conventional techniques include 
solvent casting/particulate leaching, freeze drying, and gas foaming (Roseti et al., 
2017). Advances in fabrication techniques, particularly the advent of nanotechnology 
and additive manufacturing including 3-D printing and bioprinting (Masaeli et al., 
2019), have enabled scaffolds with more precisely controlled and sophisticated 
features to be produced. Electric field-assisted techniques, such as electrospinning and 
electrospraying, although not considered an additive manufacturing technique, share 
more in common with additive manufacturing than the earlier conventional techniques 
(Dalton et al., 2013). Given their major role in the work conducted herein, electric 
field-assisted techniques are more thoroughly described alongside an overview of 
some of the other techniques in the following sections.  
1.6.1 Solvent casting and particulate leaching  
This technique generally involves dissolving the polymer in an organic solvent, an 
insoluble salt (the porogen) is then admixed into the solution. Thereafter the organic 
solvent is evaporated leaving a solid polymer-salt construct, leaching out the salt 




method are tuneable porosity, by manipulating salt grain size, as well as the relative 
simplicity and low cost of the technique (Roseti et al., 2017). One example of this 
technique involved the preparation of a porous composite scaffold of poly (glycolic 
acid) (PGA) and β-TCP, which contributed a small but significant increase in bone 
volume in a rat femoral defect (Cao and Kuboyama, 2010). Another example involved 
the preparation of PCL/HA scaffolds, that stimulated the expression of markers of 
osteogenic differentiation in vitro and showed significant new bone formation in a 
murine cranial defect study (Chuenjitkuntaworn et al., 2010). The limitations of the 
solvent casting technique include production of scaffolds with simple architectures, as 
well as the possibility of residual solvent and porogen material in the final scaffold 
(Prasad et al., 2017). 
1.6.2 Gas foaming 
Gas foaming is a process through which polymers are expanded to create foams 
(Costantini and Barbetta, 2018), either chemically by using additives (e.g. sulfamic 
acid and sodium nitrite) that react or decompose to release gas, or using physical 
blowing agents (e.g. CO2, pentane, argon, nitrogen) directly injected or pressurised 
into the polymer (Costantini and Barbetta, 2018). 
For BTE, the main driving force behind using gas foaming is the preparation of 
scaffolds with a porous matrix while eliminating the risk of potentially dangerous 
residual solvents and porogens (Mooney et al., 1996). However, this method alone can 
lead to a non-interconnected pore structure, and a non-porous surface layer (Roseti et 
al., 2017, Prasad et al., 2017). To overcome these issues, foaming can be coupled with 




foaming has also been coupled with other techniques including freeze drying (the topic 
of the following section). In one case, gas foaming (in combination with freeze-drying) 
was used to prepare a chitosan/agarose/HA scaffold that supported the adhesion and 
growth of osteoblasts in vitro (Kazimierczak et al., 2020). 
1.6.3 Freeze-drying 
Freeze-drying or lyophilisation is a process by which a solution or slurry of a scaffold 
material is frozen, followed by sublimation of the solvent under vacuum resulting in a 
complex porous structure (Deville et al., 2006). The main advantages of freeze-drying 
are the avoidance of high temperatures that can reduce the activity of any incorporated 
biological factors, and the potential to manipulate pore size by controlling the rate of 
freezing (Roseti et al., 2017). As an example of a freeze-dried scaffold, a 58S-
BG/collagen/phosphatidylserine composite scaffold was shown to support the 
formation of new bone in a rat femoral defect (Xu et al., 2011). A more recent example 
can be seen with a strontium doped HA/chitosan scaffold that improved the adhesion, 
spreading, and proliferation of bone marrow mesenchymal stem cells (Lei et al., 2017). 
The major limitation of freeze-drying remains the long timescales required for 
fabrication, with the previous two examples requiring 13 and 36 h of lyophilisation, 
respectively.  
1.6.4 3-D printing 
Following the original description of stereolithography in the latter half of the 1980s 
(Hull, 1984), 3-D printing and bioprinting have been categorised as types of additive 
manufacturing and are defined as the printing of structures using biomaterials, 




techniques are some of the fastest growing fabrication methods for BTE as 
accessibility to equipment and cost-effectiveness improve (Koons et al., 2020, 
Derakhshanfar et al., 2018, Haleem et al., 2020). There are several well-known 
printing techniques, including inkjet, extrusion, and laser-assisted methods (Kačarević 
et al., 2018). Some of the earliest and most common examples of 3-D printing were 
inkjet-based, and while they benefit from relatively low cost, high availability and 
high resolution, they are still limited by unreliable droplet directionality and 
inconsistent viability of live-cell encapsulation (Murphy and Atala, 2014). For 
comparison, Table 1.3 contrasts the different 3-D printing techniques. 
 




1.6.5 Electric-field assisted techniques 
Electric-field assisted techniques, also known as electrohydrodynamic processing, 
consisting of electrospinning and electrospraying, are two related techniques used in 
biomedical and tissue engineering applications (Haider et al., 2019). Electrospinning 




structures for BTE (Correia et al., 2014, Jeyhani et al., 2017, Jiang et al., 2015, Koons 
et al., 2020). 
1.6.5.1 Electrospraying 
Electrospraying is a process by which a sufficiently high electric field applied to the 
surface of a liquid results in the emission of charged droplets (Cloupeau and Prunet-
Foch, 1990). The most important parameters involved in the formation of droplet 
particles include the solution viscosity, applied voltage, solution flow rate, and 
working distance from collector plate (Cloupeau and Prunet-Foch, 1990, Haider et al., 
2019). In general, once a polymer solution reaches a concentration that produces 
sufficient polymer entanglement, particles will be formed once the build-up of charge 
overcomes surface tension (Coulomb fission after exceeding Rayleigh limit). If 
polymer entanglement increases further (by increasing solution concentration), this 
can ultimately reach an upper limit whereby fibres rather than particles are formed 
after the surface tension is overcome (Almería et al., 2010). 
Electrospraying is not extensively used in bone tissue engineering specifically, 
however, its utility as a highly efficient method of encapsulating therapeutic molecules 
gives weight to its potential use in biomedical and regenerative medicine as a whole 
(Bock et al., 2012). Aside from therapeutic molecules, electrospraying can also be 
used to encapsulate cellular cargoes for tissue engineering purposes (Xu et al., 2019). 
For example, electrosprayed alginate/gelatin microspheres have been embedded with 
bone marrow-derived stem cells (BMSC), these cell-laden microspheres were then 





Electrospinning is more commonly used than electrospray methods in tissue 
engineering applications (Soares et al., 2018). It involves extrusion of an electrically 
conductive solution from a hollow needle under the influence of an applied voltage, 
and deposition on a collector plate. Generally, solutions of polymeric materials 
dissolved in volatile solvents are used (Zhu and Chen, 2013). As the extruded solution 
travels towards the electrically grounded collector plate, the solution jet extends, 
rapidly increasing its surface area and rate of evaporation, leaving behind micro- and 
nano-sized fibres of solid polymer material (Agarwal et al., 2009, Agarwal et al., 
2008). Figure 1.4 shows a graphical representation of the electrospinning process. 
 
 
Figure 1.4 Graphical illustration of the electrospinning process, listing the progression 
of the electrospinning solution from the needle tip until collection as dry fibres. 




There are several variables in the electrospinning process (voltage, viscosity, flow 
rate) that may influence the physical characteristics of the electrospun material. 
Research has indicated that increasing voltage increased the density of ‘’beading’’ 
defects in fibres, while increasing or decreasing solution viscosity directly influenced 
fibre diameter (Deitzel et al., 2001). A more recent study showed that fibre diameter 
is primarily controlled by voltage and that the relationship is inversely proportional. 
Solution viscosity was a secondary factor that influenced fibre diameter in a directly 
proportional manner, with flow rate considered as a minor contribution to fibre 
diameter (Korycka et al., 2018). Another study investigated the effects of voltage, flow 
rate, and needle-to-collector distance on fibre diameters, and showed that increasing 
voltage resulted in reduced fibre diameters, as did increasing flow rate, and increasing 
the tip-to collector distance (Akturk et al., 2020).  
Different electrospinning methodologies exist in the preparation of electrospun 
membranes. Simple polymer blend electrospinning is the simplest technique, which 
can be used to produce fibres with a drug randomly distributed throughout (Hall 
Barrientos et al., 2017). A more organised drug distribution can be obtained from 
emulsion blends, whereby two immiscible solvents are used to compartmentalise a 
desired drug or additive (Wei et al., 2012). Increasing the structural complexity further 
has relied on co-axial electrospinning techniques, whereby a concentric needle system 
is used to extrude an electrospun material with a core-sheath morphology (Wang et 
al., 2014). This approach has the potential to produce a two or more phased fibre or 




There are a number of recent reviews detailing the application of the electrospinning 
technique in preparing biomaterial scaffolds in general (Ding et al., 2019), as well as 
in BTE specifically (Bhattarai et al., 2018). Some recent examples include a tri-
component PLA/gelatin/RKKP-BG scaffold where the polymeric components were 
dissolved in hexafluoroisopropanol and the glass ceramic was added in suspension. 
The glass-ceramic was shown by dispersive X-ray spectrometry to be dispersed 
throughout the fibrous matrix and it led to a 15-30 % increase in fibre diameter, which 
was attributed to increasing the viscosity of the electrospinning preparation 
(Bochicchio et al., 2020). Results showed the fibre scaffold supported the growth and 
osteogenic differentiation of canine adipose derived MSC in vitro (Bochicchio et al., 
2020). Another study describes the preparation of a PLGA electrospun structure 
coated with HA/collagen that improved cell spreading, differentiation, and osteogenic 
gene expression in MSC (Yang et al., 2018).  
The main advantages of electrospinning are its versatility in processing different 
materials (Roseti et al., 2017), and its ability to mimic the fibrillar properties and 
dimensions of bone extracellular matrix (Hendrikson et al., 2017), thus simulating an 
hospitable environment for the spread, growth, and infiltration of cells during the 
repair process (Jang et al., 2009). Another advantage is the possibility of using 
electrospinning in combination with growth factors (Zhang et al., 2019b), or natural 
components of the extracellular matrix such as HA and collagen (Yang et al., 2018). 
The main disadvantage of electrospinning is its use of organic solvents and the 





1.7 Clinical considerations 
The choice or design of an implantable material is dependent on the defect site and the 
nature of the defect (Roseti et al., 2017, Koons et al., 2020). Indeed, the results seen 
with any particular scaffolds may differ depending on the anatomical site and the 
scaffold interaction with cortical or cancellous bone (Walsh et al., 2019). Similarly, 
when formulating a plan for the repair of a long bone defect, it is important to consider 
optimal vascularisation (Johnson et al., 2011), and the potential need of load bearing 
capacity (Bao et al., 2017). In contrast, when considering flat bones, a more critical 
issue than functional weight-bearing may be the complexity of the defect, with regard 
to its shape and the close interaction of numerous tissue types (nerves, muscle, blood 
vessels) (Kretlow et al., 2009). 
In cases of osteoporotic defects, it may be preferable to target the limitation of bone 
resorption, as described by one study using a bisphosphonate/gelatin/45S5-BG 
injectable gel that supported the regeneration of osteoporotic femoral defects in rats 
while also enhancing bone density in the periphery of the defect (Diba et al., 2017). In 
cases of bone defects related to malignancy, where growth factors may need to be 
avoided, studies have described magnetically induced hyperthermic scaffolds that can 
be activated to damage malignant cells while simultaneously acting as thermally 
activated drug delivery devices (Wu et al., 2011, Bañobre-López et al., 2014). 
Similarly, scaffolds have been designed to specifically target defects secondary to 
conditions of infection (Pearson et al., 2020) or inflammation (Zhao et al., 2019). 
Finally, regulatory considerations must be taken into account, especially when 
utilising scaffold designs that span multiple regulatory categories, whether medical 




studies involved in their clinical translation and the associated costs (Hunter and 
Sherman, 2017). 
  
1.8 Cell-based therapies in BTE 
The cellular populations involved in bone healing change over the course of the repair 
process (Section 2.3 Bone repair), from the initial inflammatory response of 
neutrophils and macrophages removing debris, setting the stage for an angiogenic 
response (Perez et al., 2018), to revascularisation and essential recruitment of MSC, 
the progenitors of bone forming osteoblasts (Marsell and Einhorn, 2011). 
It is possible to incorporate primary osteoblasts into BTE scaffolds, as described in a 
study, which pre-loaded a silk fibroin scaffold with mature mineral forming 
osteoblasts and implanted them in mice. In this system, the cells acted as a driver of 
scaffold vascularisation alongside the host immune cells, ostensibly by osteoblast-
derived pro-angiogenic growth factors (Ghanaati et al., 2011). However, directly 
seeding mature osteoblasts is uncommon due to difficulties associated with harvesting 
and maintaining meaningful cell numbers (Perez et al., 2018). Therefore, most cell-






Figure 1.5 Schematic highlighting the ‘’Cells’’ pillar of bone tissue engineering 
design.  
 
Well-established sources of MSC include adipose tissue- and bone marrow-derived 
stem cells (Secunda et al., 2015). A recent example described a gelatin/HA/45S5-BG 
scaffold pre-seeded with BMSC that significantly improved new bone formation in 
rat, 5 mm radial bone defects, with the cell-seeded scaffold producing new bone 
volume comparable to autograft controls (Oryan et al., 2018).  
Other potential cell-based therapies utilise embryonic stem cells (ESC), whose 
differentiation pathways span all germ layers (Thomson et al., 1998), and have 
previously been seeded on PLGA/HA scaffolds and found to result in bone formation 
when subcutaneously implanted in mice (Kim et al., 2008). Induced pluripotent stem 
cells (iPSC), which have comparable differentiation potential to ESC (Takahashi and 
Yamanaka, 2006) have also been investigated. Some examples include the pre-seeding 




implantation, resulting in mineralisation and the expression of osteocalcin and bone 
sialoprotein (Bilousova et al., 2011). Another study describes a more direct approach, 
whereby iPSC were seeded on PLGA/HA scaffolds and implanted in murine critical 
cranial defects, resulting in a 49% regeneration of the defect (as determined by 
microCT) (Levi et al., 2012). That result was further improved to 96%, when the 
scaffold surface was coated with rhBMP-2. 
  
1.9 Growth factors in BTE 
There are several protein growth factors stored and released from the bone 
extracellular matrix following injury and during the bone repair process including 
BMP, VEGF, and PDGF, among several others (Perez et al., 2018). This abundance 
of growth factors in bone material plays a major role in the efficacy of autograft in 
contributing to bone repair (Schmidmaier et al., 2006). The initial phases of 
inflammatory bone repair are dominated by interleukins, and prostaglandins 
(Hankenson et al., 2015), followed by revascularisation and significant increases in 
PDGF, VEGF, and angiopoietin. Thereafter, rising levels of BMP are the major 
contributor to the bone formation phase (Hankenson et al., 2015). A more detailed 
description of the bone repair process is shown in Chapter 2 (Section 2.3, Bone 
repair). 
First reported in 1965, BMP are osteogenic growth factors (Urist, 1965). There are 
more than 30 different BMP, several of which, including BMP-2, -4, -5, -6, -7, and -9 
have well documented roles in bone processes (Dumic-Cule et al., 2018). BMP-2 has, 




while BMP-7 is a component of the collagen/cellulose based OP-1® Putty (Stryker, 
USA) (Vaccaro et al., 2003).  
Some recent studies utilising BMP include a HA/collagen/carbon-nanotube scaffold 
loaded with BMP-9 and seeded with BMSC that significantly promoted new bone 
formation in rat cranial defects (Zhang et al., 2019a). Another recent study describes 
a β-TCP/PLGA/CaCO3 electrospun scaffold loaded with BMP-2, that promoted MSC 
proliferation and differentiation in vitro and increased bone volume in a rat 
posterolateral spinal fusion (Glaeser et al., 2020). The main concerns associated with 
the use of BMP include the need for large doses due to challenges related to stability 
and controlled release, heterotopic ossification and inconclusive evidence of post-
operative cancer occurrence (Cahill et al., 2015).  
Revascularisation is an essential phase of bone regeneration and VEGF is a 
fundamental factor involved during this phase (Hankenson et al., 2015). This can be 
seen in several studies utilising the growth factor in combination with implantable 
scaffolds. For example, one study described a gas-foamed, particulate leached 
PLGA/alginate scaffold loaded with VEGF that was implanted in rat cranial defects 
and produced significant increases in new blood vessel formation and new bone 
formation (Kaigler et al., 2006). Another study showed the design and in vitro 
evaluation of an electrospun PLGA/gelatin scaffold sequentially releasing both VEGF 
and BMP-2 that promoted the adhesion, proliferation and differentiation of BMSC 
(An et al., 2017). VEGF used alone is not sufficient to produce mature and stable 
vasculature, rather requiring a combinatorial approach with angiopoietin and PDGF 




formed blood vessels (Caplan and Correa, 2011). PDGF has for a long time been 
investigated as a component of implantable scaffolds for BTE, an early example 
described PDGF mixed with an injectable collagen implant having a stimulatory effect 
on rabbit tibial fracture healing (Nash et al., 1994). A more recent study utilised an 
electrospun PCL/collagen/HA scaffold that adsorbed and released PDGF over 8 
weeks, with the released PDGF eliciting a significant chemotactic response from MSC 
in vitro (Phipps et al., 2012b). As with BMP, other growth factors are limited by their 
biologic stability, PDGF and VEGF have half-lives of 2 and 50 mins, respectively 
(Chen and Mooney, 2003). Furthermore, whether using a single growth factor or a 
combinatorial approach, several variables must be considered including: the 
concentration of the growth factors and formation of local gradients, local cell 
populations, the presence of other local growth factors, and the interaction between 
these variables (Mehta et al., 2012). Therefore, any attempt at using growth factors 
requires vehicles to ensure stable and spatiotemporal control over their delivery. A 
possible alternative to the use of protein and peptide growth factors is the use of more 







Figure 1.6 Schematic highlighting the ‘’Signals’’ pillar of bone tissue engineering 
design. 
 
1.10 Pharmacological options in BTE 
As discussed in the previous sections BMP are to date the only protein growth factors 
licensed for bone regenerative purposes. And although some of their drawbacks can 
be mitigated by alternative peptide techniques, such as BMP protein fragments (Kim 
et al., 2012, Kim et al., 2017), the focus of this section is on the option of using small 
molecule therapeutics with osteoinductive properties as an alternative to protein 
growth factors (Carbone et al., 2014, Laurencin et al., 2014). The pros and cons of 






Table 1.4 Comparing the advantages and disadvantages of protein- and small 
molecules-based therapeutics, adapted from (Carbone et al., 2014). 
 
 
Small molecule therapeutics generally possess greater stability and longer biological 
half-life. Furthermore molecules smaller than 1000 Da are less likely to induce an 
immune response (Kadow et al., 2009). The major limiting factor for small molecule 
therapies is their lack of specificity and off-target side effects. Hence, the need to 
develop methods for their localised and controlled delivery. Several small molecule 
therapeutics, many marketed for other clinical indications, have shown potential in 
impacting key processes integral to bone regeneration.  
Alendronate, a bisphosphonate indicated in osteoporosis that acts by reducing bone 
turnover, has been incorporated into collagen scaffolds and released in a sustained 
manner resulting in improved bone regeneration of a critical cranial defect in 
ovariectomised rats (Zeng et al., 2020). Another class of small molecule drugs includes 
the cholesterol lowering ‘statins’ simvastatin, rosuvastatin, and lovastatin that have 
shown an osteoinductive effect associated with inhibition of the mevalonate pathway 
intermediates (farnesyl and geranyl pyrophosphates), which produces an increased 




scaffold combined with simvastatin-loaded nanoparticles that stimulated BMSC 
differentiation in vitro and showed improved bone regeneration in a critical cranial 
defect in vivo (Xue et al., 2019b). Dexamethasone, a corticosteroid, is known to 
stimulate the differentiation of MSC and pre-osteoblastic cells (Mostafa et al., 2012, 
Igarashi et al., 2004), and is associated with increased expression of osteogenic 
proteins RUNX2, Osterix and bone matrix proteins (Igarashi et al., 2004). A recent 
article coupled dexamethasone with a gas foamed silk fibroin/PCL scaffold that 
promoted bone regeneration in a rat cranial defect (Goimil et al., 2019). The 
micronutrients vitamin D3 and ascorbic acid (vitamin C) possess osteoinductive 
properties, vitamin D3 stimulates the expression of osteogenic markers in MSC 
including alkaline phosphatase, osteopontin, and osteocalcin (Lou et al., 2017). 
Vitamin C has been shown to increase gene expression of BMP-2, RUNX2, 
osteocalcin, and type-1 collagen (Choi et al., 2019). A study using a solvent cast PLGA 
scaffold loaded with vitamin D3 and MSC, showed the formation of new osteoid and 
calcium deposition in a rabbit femoral defect (Yoon et al., 2007). Vitamin C is less 
common in the BTE literature and rarely used in isolation, for example one study 
investigated a polyurethane foam scaffold loaded with vitamin C, dexamethasone, and 
β-glycerophosphate. The scaffolds were implanted subcutaneously, and excised tissue 
showed histological and immunohistochemical evidence of mineralisation (Wang et 
al., 2017). There are several other small molecules that have shown interesting 
osteoinductive effects, including rolipram (Tokuhara et al., 2010), retinoic acid 
(Cowan et al., 2005), purmorphamine (Gellynck et al., 2013), tetracycline (Farzamfar 




included in Table 1.5, which lists small molecule therapeutics that have been 
investigated using in vivo preclinical trials. 
S1P and fingolimod, are of interest in this thesis due to evidence showing that their 
local administration via polymeric scaffolds can contribute to bone regeneration of 
critical defects in vivo (Das et al., 2014a, Petrie Aronin et al., 2010a, Petrie Aronin et 
al., 2010b, Sefcik et al., 2008). Both these molecules together with related analogues 
including siponimod motivated much of the work in the following chapters. Chapter 
2 is dedicated to the role of S1P and its associated receptors in bone biology and repair 
in more specific detail. A general summary of S1P receptor pharmacology and 
function in tissues outwith bone is shown in Table 1.6 and Figure 1.7.   
      
Table 1.5 Summary of small molecule agents investigated using in vivo preclinical 
studies. 
 Mechanism References 




↑ BMP mRNA 
↓ Mevalonate signalling pathway 
(Xue et al., 2019b) 
(Petit et al., 2020) 
(Türer et al., 2016) 
Dexamethasone ↑ RUNX2, Osterix (Goimil et al., 2019) 
Vitamin D3 
Vitamin C 
↑ ALP, osteopontin osteocalcin (Yoon et al., 2007) 






↑ BMP-2, RUNX2, osteocalcin, and type-1 
collagen 
↑ activity of co-administered rhBMP-2 
(Cowan et al., 2005) 
Rolipram ↑ activity of co-administered rhBMP-2  (Tokuhara et al., 2010) 
Purmorphamine ↑ Hedgehog signalling pathway (Gellynck et al., 2013) 




↑ Sphingosine 1-phosphate pathway (Sefcik et al., 2008) 
(Das et al., 2014b) 
 
Table 1.6. S1P receptor subtype distribution, and examples of receptor-specific 
functions in different cell types and tissues, adapted from (Cannavo et al., 2017, Rosen 
et al., 2009, Patmanathan et al., 2017, Hla and Brinkmann, 2011, Takuwa et al., 2012). 
Receptor Distribution Functions 
S1P1 
 
(Widespread), brain, heart, 
spleen, liver, lung, thymus, 
kidney, skeletal muscle, 
lymphoid tissue 
Endothelial and pericyte cell development. 
Astrocyte and neural stem cell migration. 




(Widespread), brain, heart, 
spleen, liver, lung, thymus, 
kidney, skeletal muscle 
Cardiomyocyte protection in ischemia. 
Endothelial cell junction disruption. 







(Widespread), brain, heart, 
spleen, liver, lung, thymus, 
kidney, testis, skeletal muscle 
Endothelial cell development. 
Cardiomyocyte protection in ischemia. 
S1P4 
 
Lung, and lymphoid tissue T cell migration 
S1P5 
 
Brain, skin, spleen Lymphocyte trafficking. 
Oligodendrocyte survival. 







Figure 1.7. Schematic representation of S1P receptor signaling in relation to 
proliferation and motility effects, adapted from (Takuwa et al., 2012, Cannavo et al., 
2017, Rosen et al., 2009).  
1.11 Thesis aim and objectives  
The aim of the research presented in this thesis can be condensed into two concepts. 
Firstly, the work aimed to improve our understanding of S1P signalling in bone 
biology, which duly led to a thorough investigation of the small molecule siponimod 
and its potential role in bone repair. And secondly, the development of implantable 
scaffolds for the spatiotemporal control of siponimod to augment bone regeneration.  
Further to this a number of primary objectives were identified: 
I. To review the role of S1P signalling in bone repair and identify S1P1 receptor 




II. To determine the effect of siponimod on key cell players, osteoblasts and 
endothelial cells, implicated in bone regeneration using cell proliferation, 
differentiation, and migration as metrics (Chapter 3). 
III. To develop and characterise drug-loaded electrospun scaffolds composed of 
PLGA and collagen for controlled release of siponimod over timeframes 
relevant for bone regeneration (Chapter 4). 
IV. To investigate the ability of the electrospun scaffold design to promote bone 
regeneration in rat critical cranial defects using fluorescent labelling and bone 
staining histomorphometry (Chapter 4). 
V. To develop porous drug-loaded scaffolds composed of electrosprayed PLGA 
microparticles and HA, using gas foaming and porogen leaching, for 
controlled release of siponimod over timeframes relevant for bone 
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The lipid mediator sphingosine 1-phosphate (S1P) affects cellular functions in most 
systems. Interest in its therapeutic potential has increased following the discovery of 
its G protein-coupled receptors and the recent availability of agents that can be safely 
administered in humans. Although the role of S1P in bone biology has been the focus 
of much less research than its role in the nervous, cardiovascular and immune systems, 
it is becoming clear that this lipid influences many of the functions, pathways and cell 
types that play a key role in bone maintenance and repair. Indeed, S1P is implicated 
in many osteogenesis-related processes including stem cell recruitment and 
subsequent differentiation, differentiation and survival of osteoblasts, and coupling of 
the latter cell type with osteoclasts. In addition, S1P’s role in promoting angiogenesis 
is well-established. The pleiotropic effects of S1P on bone and blood vessels have 
significant potential therapeutic implications, as current therapeutic approaches for 
critical bone defects show significant limitations. Because of the complex effects of 
S1P on bone, the pharmacology of S1P-like agents and their physicochemical 
properties, it is likely that therapeutic delivery of S1P agents will offer significant 
advantages compared to larger molecular weight factors. Hence, it is important to 
explore novel methods of utilizing S1P agents therapeutically and improve our 






The incidence of non-union fractures is relatively low (20 per 100000 cases) (Mills 
and Simpson, 2013). However, in severe fractures or in limb salvage following bone 
cancer, the incidence can be many fold higher (Gomez-Barrena et al., 2015). Current 
therapeutic options for non-union and other critical bone defects, mainly autologous 
grafts and allografts, suffer from drawbacks of both medical and logistical natures 
(Laurencin et al., 2006). There has been much hope that novel treatments based on the 
use of peptide or protein growth factors, mainly in combination with bone grafts or 
scaffolds, would show clinical benefit. Despite showing positive results, these 
strategies are limited by the need for high doses, as well as related ectopic growth 
(Kim and Tabata, 2015, Martino et al., 2015, Curry et al., 2016). A potential promising 
alternative is the manipulation of lower molecular weight, non peptidic mediators, 
such as the bioactive lipid S1P (Binder et al., 2015). 
S1P is the product of sphingosine kinase (SK)-mediated phosphorylation of 
sphingosine, itself derived from cell membrane sphingolipids (Spiegel and Milstien, 
2002, Spiegel and Milstien, 2003). S1P is an important player in cell death (Olivera 
and Spiegel, 1993) and proliferation (Zhang et al., 1991), with evidence that the 
balance between S1P and its pro-apoptotic precursors (sphingosine and ceramide) 
critically controls cell fate (Cuvillier et al., 1996). Furthermore, S1P signalling is 
involved in cell adhesion and motility, smooth muscle contraction, and platelet 
aggregation (Takuwa, 2002). 
S1P and its 5 known receptors (S1P1-5) are expressed in several systems, including the 




have been detected in blood vessels and mesenchymal cells around day 12 of 
embryonic development (Chae et al., 2004). Their genetic deletion leads to defective 
limb chondrocyte development, and embryonic lethality from defective vasculature. 
Limb defects occur both following non-specific deletion and in mice specifically 
lacking endothelial S1P1 receptors, and there is evidence that S1P1 receptors may play 
a role in chondrocyte organization. Indeed, by day 16 of murine embryogenesis, S1P1 
receptor mRNA expression is abundant in bones undergoing ossification (Liu and Hla, 
1997). As will be seen throughout this chapter, S1P receptors have also been identified 
in the key cells involved in bone remodelling and repair, including S1P1-3 receptors 
expressed in osteoblasts, and S1P1 and S1P2 receptors in osteoclast precursor cells. 
The therapeutic potential of interfering with S1P signalling has mostly been explored 
in the immune (Hisano et al., 2012), nervous (Choi and Chun, 2013), and 
cardiovascular systems (Waeber and Walther, 2014). The function of S1P receptors in 
the immune system especially is increasingly better understood, with apparent roles in 
cell trafficking (Chi, 2011), allergic responses (Oskeritzian et al., 2010), and 
coagulation secondary to inflammatory conditions (Niessen et al., 2008). The role of 
S1P in maintaining vascular integrity is also linked to inflammatory cell trafficking 
(Camerer et al., 2009), suggesting that the effect of S1P on the immune and 
vascularization responses could contribute to bone repair, and could be exploited for 
therapeutic purposes in this context.  
The focus herein will be on the role of S1P in bone regeneration, teasing out its 
interaction with the various cellular components of bone repair. It will evaluate 




defects, bearing in mind the complexity of S1P signalling, and the uncertainty 
regarding the specificity of the pharmacological tools used in the studies in question 
(Salomone and Waeber, 2011). Table 2.1 lists the S1P receptor agonists and 
antagonists frequently mentioned in this chapter, with their presumed subtype 
selectivity/specificity. 
Other agents activating or blocking S1P receptors or interfering with S1P metabolism 
have been described (Bigaud et al., 2014, Sanllehi et al., 2016). To the best of our 
knowledge, they have not yet been used to characterize the role of S1P signalling in 
bone biology and are therefore not listed here. 
 
Table 2.1 List of S1P associated agents mentioned in the chapter. Of note, many of 
these agents only show subtype selectivity with a narrow range of concentrations and 
have known non S1P receptor targets. 
Agent Selectivity/specificity Notes 
S1P S1P1-5 Agonist Endogenous agonist 
Fingolimod Activates all S1P subtypes 
except S1P2, although recent 
evidence suggests S1P2 might 
also be a target (Sobel et al., 
2015). 
Fingolimod is a prodrug (activated by 
sphingosine kinase 2). Phosphorylated 
fingolimod is likely to act as a functional 
antagonist of S1P1 in its approved therapeutic 
role, as it rapidly downregulates S1P1 
receptors. 
It is also a potent protein phosphatase 2A 




sphingosine kinases and S1P lyase have also 
been shown. 
Sew2871 S1P1 Agonist First described S1P1-selective agonist. At 
variance with fingolimod, it demonstrates S1P1 
agonist activity without long-term decrease in 
surface receptor expression (Jo et al., 2005). It 
is 10 to 50 times less potent than CYM5442 
and poorly water-soluble (Gonzalez-Cabrera et 
al., 2008). 
JTE013 S1P2 Antagonist Most commonly used S1P2 receptor antagonist, 
but its selectivity is questionable (Adada et al., 
2013). 
VPC23019 S1P1, S1P3 Antagonist pKB values of 7.5 and 6.0 for S1P1 and S1P3 
receptors, respectively (Davis et al., 2005). 
VPC01091 S1P1 partial agonist, S1P3 
antagonist 
The 1R,3S diastereomer is a conformationally 
constrained fingolimod analogue activated by 
sphingosine kinase 2 (Zhu et al., 2007). 
W146 S1P1 Antagonist W146 is an antagonist, but it’s in vivo effect 
often mimic those of S1P receptor agonists 
(Tarrason et al., 2011). 
Cay10444 S1P3 Antagonist Also known as BML-241. Low potency and 
aqueous solubility agent. May also non-
selectively inhibit increases in intracellular 





2.3 Bone repair 
Bone is exceptionally proficient at self-repair, often able to avoid the formation of 
fibrous scar tissue in favour of complete regeneration (Petite et al., 2000). The cells 
responsible for bone development and repair are the same. Stem cells of mesenchymal 
origin are the source of bone forming osteoblasts and cartilage forming chondrocytes 
(Long, 2011) whereas haematopoietic stem cells are the source of the monocytes and 
macrophages that differentiate into multinucleated osteoclasts, responsible for bone 
resorption (Florencio-Silva et al., 2015). These cells collaborate in the formation of 
functional bone through intramembranous and endochondral ossification (Karaplis, 
2002). The intramembranous pathway (IO) involves the direct differentiation of 
mesenchymal stem cells into osteoblasts and the deposition of bone, as occurs during 
the formation of bones of the skull. The endochondral pathway (EO), typical of long 
bone formation, involves an intermediary step, the formation of chondrocytes, and the 
deposition of cartilage, which acts as a template for osteoblasts as cartilage is 
systematically replaced by bone (Loi et al., 2016).  
The process of bone repair echoes osteogenesis and resembles either EO or IO, 
depending on the size and location of the defect encountered. When the defect is 
sufficiently small and rigid, and adjacent bone cortices are in contact, deposition of 
bone may take place directly via IO, without intermediate cartilage formation. This 
direct, or primary, repair process requires the recruitment of osteoprogenitor cells, 
osteoclasts and undifferentiated mesenchymal stem cells to the fracture site. In 
contrast, indirect repair is similar to EO and involves the formation of a cartilaginous 
template (soft callus) that undergoes calcification into a hard callus and is eventually 




acute inflammatory phase, which includes haematoma formation at the defect site, an 
early response by platelets, and neutrophils, followed soon after by monocytes and 
macrophages, resulting in thrombus formation, debris removal and the eventual 
formation of granulation tissue. Inflammation is continuously supported by positive 
feedback from the release of interleukins (primarily IL-1, and -6, along with -11, and 
-18) and tumour necrosis factor α (TNF-α) mainly in the first 24 hrs after injury 
(Marsell and Einhorn, 2011). Other important factors include PDGF and macrophage 
colony-stimulating factor (M-CSF), which, together with stromal cell-derived factor 1 
(SDF1, CXCL12) contribute to the recruitment of stem cells from the immediate bone 
environment and from the circulation (Loi et al., 2016, Marsell and Einhorn, 2011). 
These stem cells are essential for the next stage of regeneration, the formation of the 
soft callus. Hypoxic conditions in the haematoma may contribute to the promotion of 
chondrocyte differentiation from progenitor stem cells, and subsequent cartilage 
deposition (Amarilio et al., 2007, Mangiavini et al., 2015). Angiogenesis and blood 
vessel infiltration controlled by angiopoetin-1 and -2 and by VEGF increase until 
hypoxic conditions begin to resolve (Marsell and Einhorn, 2011). Improved 
circulation, as well as the activation of M-CSF, receptor activator of nuclear factor 
kappa B ligand (RANKL) and TNF-α, stimulate chondroclastogenesis and cartilage 
mineralization (Leijten et al., 2015). The resolution of hypoxic conditions is followed 
by osteoblast proliferation and differentiation, leading to the deposition of woven 
bone. Cytokines such as transforming growth factors (TGF) β2 and 3 and BMP -2, -5, 
and -6 exert control over the healing process by supporting continued proliferation, 
differentiation, and activity of osteoblasts, as well as the long term remodelling and 




Schindeler et al., 2008). The cell types and processes involved in bone repair are 
shown in Figure 2.1. 
 
Figure 2.1 (A) Simplified representation of the lineages of the cells involved in bone 
repair. Mesenchymal stem cells (MSC) differentiate into the major bone and cartilage 
forming cells, osteoblasts and chondrocytes (later replaced by osteoblasts), depending 
on whether ossification occurs through the intramembranous or endochondral 




osteoclasts through the myeloid pathway. (B) Process of bone repair divided into 4 
phases: inflammatory, soft callus, hard callus, and remodelling. Briefly, an early 
inflammatory response results in the removal of debris and the eventual recruitment 
of mesenchymal stem cells, initiating the soft callus phase and cartilage deposition. 
Improving vascularization leads to cartilage mineralization and deposition of bone, 
which is then slowly remodelled, restoring function. 
 
The role of several mediators and signalling pathways in bone repair (e.g., BMP, 
VEGF, Wnt and Notch pathways) and therapeutic attempts at harnessing them to 
improve bone repair have been the subject of various reviews (Kim and Tabata, 2015, 
Long, 2011, Chen et al., 2004, Chen and Alman, 2009, Secreto et al., 2009). Less 
attention has been paid to the role of S1P signalling in bone disorders and repair 
(Meshcheryakova et al., 2017). This chapter therefore summarises the key findings in 
this field, with emphasis on the effects of S1P on the migration, differentiation and 
survival of the cellular components of bone repair and their respective precursors. In 
addition to the well-known role of S1P in vascularization and immune cell trafficking, 
these effects are likely to underlie any observed improvement in repair of bone defects 
following pharmacological intervention targeting S1P signalling. 
 
2.4 S1P effect on progenitor stem cells 
After injury, bone healing relies not only on differentiated bone cells but also on the 
recruitment of undifferentiated cells from bone and adjacent tissues. S1P regulates cell 




(where S1P is found in nanomolar concentrations) and the blood (where it is found at 
micromolar concentrations), a gradient which may arise due to high levels of S1P 
degrading enzymes in the tissue compared to the blood (Maceyka and Spiegel, 2014). 
In general S1P functions as a chemoattractant for quiescent stem cell populations (Liu 
et al., 2011), and also participates in their differentiation into specialist bone forming 
and bone resorbing cells, as will be explored in more detail in the forthcoming 
sections. 
  
2.5 S1P and stem cell migration 
The balance between the major chemo-attractants CXCL12 (also known as SDF-1), 
predominantly found in bone marrow, and S1P, mainly found in the blood, 
dynamically regulates haematopoietic stem cell recruitment to the circulation versus 
their retention in the bone marrow. The principal chemoattractant retaining progenitor 
stem cells in a quiescent state in the bone marrow is CXCL12. Dissipating the S1P 
gradient between the blood and bone marrow by inhibiting S1P degradation in tissues 
or downregulating stem cell S1P1 receptors using fingolimod both reduce the number 
of circulating progenitor stem cells (Bendall and Basnett, 2013). The S1P3 receptor 
has been shown to have the reverse effect, whereby S1P3 agonism stimulates 
CXCL12-based retention of haematopoietic stem cells within the bone marrow, and 
S1P3 antagonism contributes to increased stem cell egress (Ogle et al., 2017). Stress, 
such as that occurring in a fractured bone, induces the downregulation of CXCL12 in 
the bone marrow and an increase in circulating S1P levels, leading to stem cell 




observations support a role for S1P in the exit of cells from the bone marrow, a finding 
reminiscent of S1P-mediated lymphocyte egress from lymph nodes (Hisano et al., 
2012). Therefore, by manipulating S1P levels in the local environment of a tissue 
injury site, it may be possible to draw more of the local progenitor resources into the 
repair process. 
S1P-treated stromal cells show increased expression of extracellular matrix protease 
(e.g., Matrix metalloproteinase (MMP) 1) (Annabi et al., 2003), which are important 
in breaking down collagen during the cell migration process (Ho et al., 2009). S1P 
also induces stromal cell migration and formation of capillary-like structures (Annabi 
et al., 2003) and Rho-dependent formation of stress fibres, followed by lamellipodia 
and filopodia, in bone marrow derived cells. MMP or MEK1-ERK1/2 inhibition 
reduces S1P-induced actin stress fibre formation, with no impact on lamellipodia or 
filopodia. MMP inhibition also interferes with S1P activation of RhoA and ERK, 
while Rho kinase blockage produces sustained S1P activation of ERK. This shows the 
intricate interplay downstream of S1P stimulation in the pathways involved in cell 
migration (Meriane et al., 2006). 
Osteoclast-conditioned medium contains S1P that stimulates chemotaxis of MSC 
(Quint et al., 2013). Two parallel signalling pathways seem to be involved in this MSC 
migratory response: S1P1 receptors activating the JAK/STAT pathway and S1P2 
receptors activating the FAK/PI3K/AKT pathway (Quint et al., 2013). Contrasting 
with these findings, a recent study showed that S1P2 receptors played a critical role in 
the inhibition of MSC migration through ERK phosphorylation (Price et al., 2015), an 




receptors (Kong et al., 2014). Confirming the effects of S1P signalling on the 
recruitment of endogenous stem cells, exposure of bone marrow derived MSC to the 
S1P agonist fingolimod released from biodegradable polymer scaffolds enhanced 
MSC migration toward CXCL12 (Das et al., 2014a), but the pharmacological profile 
of this response was not assessed. In these experiments fingolimod also led to cellular 
mineralization, an indicator of differentiation into the osteoblast lineage, and promoted 
vascularization (Das et al., 2014a). 
 
2.6 S1P and stem cell differentiation 
MSC can differentiate into osteoblasts and adipocytes; commitment to one lineage 
inhibits commitment to the other due to the existence of negative feedback loops. S1P 
reduced adipogenic differentiation in MSC (Hashimoto et al., 2015) and increased 
their differentiation into osteoblasts as shown by increases in alkaline phosphatase and 
osteocalcin mRNA, and the appearance of calcified deposits (Hashimoto et al., 2015). 
While the MSC cell line expressed both S1P1 and S1P2 receptors, the inhibition of 
C/EBPβ expression by S1P was sensitive to pertussis toxin (a specific Gi protein 
inhibitor), and W146 (a specific S1P1 antagonist) suggesting that Gi-coupled S1P1 
receptors played a key role (Hashimoto et al., 2015). A recent study further defined 
the nature of the Wnt pathway involved in S1P-induced osteogenic differentiation of 
MSC, implicating the Wnt5a ligand and LRP5/6 receptor (Hashimoto et al., 2016). In 
another study, S1P-functionalized titanium oxide coated stainless steel used as a 
growth substrate for human adipose derived stem cells also fostered their osteogenic 




and blocking of BMP-6 with a neutralising antibody, polyclonal IgG reduced the 
mineralization response of human MSC to osteoclast-conditioned media, and similarly 
interferes with MSC migration. Indicating that osteoclasts and associated S1P release 
(among other osteoblast-osteoclast coupling factors) stimulate MSC differentiation 
and migration (Pederson et al., 2008).  
 
2.7 S1P and osteoblasts 
2.7.1 Proliferative effect 
Short (10-45 min) but not protracted (24 hr) treatment with S1P induces ERK-
dependent proliferation of both rat and human osteoblasts (Carpio et al., 1999, 
Lampasso et al., 2001). This time dependence has been tentatively explained by the 
possibility that S1P might first induce an early phase of cell growth, but, upon longer 
stimulation, lead to a phase of differentiation in which proliferation stops. 
Alternatively, the differential increase in the protein kinase C (PKC) alpha isoform 
following short- vs. long-term exposure to S1P might also have played a role 
(Lampasso et al., 2001). This possibility is supported by the observation that, in 
response to a 10 min S1P stimulation, PKC-α immunoreactivity was redistributed 
from the cytosol to the nucleus (Lampasso et al., 2002). Osteoblasts are known to 
express S1P1, S1P2 and S1P3 receptors (Grey et al., 2004, Ryu et al., 2006, Keller et 
al., 2014), but none of the studies mentioned above addressed the identity of the 
receptor involved in the proliferation response; while pertussis toxin sensitivity 
pointed to an S1P1-mediated effect (Lampasso et al., 2001), the S1P concentration 




study reported increased DNA synthesis at S1P concentrations of 1 µM (Grey et al., 
2004); S1P induced activation of p42/44 MAP kinases, in a Gi- and calcium-
dependent manner, but independently of PKC, and proliferation was observed in 
response to 24 hrs S1P treatment. When the effects of S1P were studied in human 
primary osteoblastic cells and the human osteosarcomal cell lines, G292 and MG-63, 
10 min incubations with 10 nM S1P increased proliferation in a pertussis toxin-
sensitive manner, while the effect of 24 hrs incubation were less consistent. In G292 
cells, this longer exposure produced significant increases only with subnanomolar 
S1P, while higher doses had no effects; no proliferation was observed at any 
concentration in the other cell types (Dziak et al., 2003). Both proliferation and 
apoptosis control the number of osteoblasts, and Gi proteins are not only involved in 
S1P-induced osteoblast proliferation but also in their survival. However, the role of 
PI3K appears to be restricted to the latter effect, since PI3K inhibition does not prevent 
the proliferative actions of S1P in osteoblastic cells (Grey et al., 2002). 
2.7.2 Osteoblast differentiation 
Differentiation of osteoblast precursors into mature osteoblasts is accompanied by an 
increase in sphingosine kinase 1 (SK1) expression and enzyme activity, decreased 
levels of S1P1 and S1P2 receptor proteins, and increased levels of S1P3 receptor 
proteins (Brizuela et al., 2014). Sphingosine kinase inhibitor (SKI-II), an anti-S1P 
antibody and the S1P1/3 receptor antagonist VPC23019 all reduce alkaline phosphatase 
activity, while blocking S1P1 receptors with W146, or S1P2 receptors with JTE013, 
has no effect (Brizuela et al., 2014). A similar pharmacological profile was observed 




differentiation), suggesting the existence of an autocrine SK1/S1P/S1P3 signalling 
pathway during osteoblastic differentiation (Brizuela et al., 2014).  
Other S1P receptors and signalling pathways may also mediate osteoblastogenesis. 
Activation of S1P receptors in C2C12 myoblasts enhanced BMP-2-induced 
expression markers of osteoblast differentiation (Sato et al., 2012). The expression of 
RUNX2 was likewise increased in the presence of S1P or fingolimod, as were Smad 
transcription factors and ERK1/2 (Sato et al., 2012). S1P and fingolimod also 
enhanced BMP-2-stimulated Smad1/5/8 phosphorylation in C2C12 cells, and cell 
differentiation was sensitive to Pertussis toxin, to a MEK1/2 inhibitor, to the S1P1 
receptor antagonist W146, and, to a smaller extent, to the S1P2 antagonist JTE013, 
whereas an S1P3 antagonist (CAY10444) had no effect. A similar pharmacological 
profile was observed for the effects of S1P on other osteoblast-like cell lines (human 
Saos-2 and murine MC3T3-E1). In these cells, S1P activated PI3K/Akt signalling, 
inhibiting GSK-3β, promoting nuclear translocation of β-catenin and expression of 
osteoprotegerin (that inhibits osteoclastogenesis by acting as a soluble decoy receptor 
for RANKL), and enhancing ALP activity (Matsuzaki et al., 2013). In a more recent 
study by the same group, S1P stimulation of Smad1/5/8 phosphorylation was 
attributed to S1P2-G12/13-RhoA activity, leading to the nuclear translocation of the 
Smad complex, up-regulation of RUNX2 leading to increased ALP (Higashi et al., 
2016). Of note, this (Matsuzaki et al., 2013) and another study (Ryu et al., 2006) found 
that S1P also increased RANKL mRNA in osteoblasts, but the OPG/RANKL ratio 
was higher after S1P treatment, which should lead to an overall inhibition of osteoclast 
maturation (Matsuzaki et al., 2013). Increased SK activity indeed reduces 




osteoblast/osteoclast co-culture system, which better reflects the reality of a healing 
bone, S1P stimulated osteoclastogenesis (Ryu et al., 2006). 
As mentioned above, S1P is a key coupling factor between osteoclasts and osteoblasts, 
and is referred to as a clastokine (Teti, 2013). Osteoclasts lacking the bone degrading 
enzyme cathepsin K show increased SK 1 expression and culture media conditioned 
by these cells were shown to induce a larger increase in ALP and mineralized nodules 
in osteoblast cultures, due to their higher S1P content. This response was blocked by 
the S1P1/3 antagonist VPC23019, in agreement with the studies described above 
(Lotinun et al., 2013). 
2.7.3 Osteoblast precursor migration 
Together with its activity on their proliferation and differentiation (Carpio et al., 1999, 
Lampasso et al., 2001, Lampasso et al., 2002, Grey et al., 2002, Grey et al., 2004, 
Dziak et al., 2003, Brizuela et al., 2014, Sato et al., 2012, Matsuzaki et al., 2013, 
Higashi et al., 2016, Lotinun et al., 2013), S1P also affects the migration of osteoblast 
precursors (Roelofsen et al., 2008). Treatment of mouse primary pre-osteoblasts with 
S1P drives cells toward the bone surface environment (Roelofsen et al., 2008). 
However, when precursors differentiate into mature osteoblasts, they become 
insensitive to S1P, although they retain their chemotaxis to PDGF (Roelofsen et al., 
2008). The response to S1P is not sensitive to pertussis toxin, suggesting that a subtype 
other than S1P1 is involved in the chemorepellent response to S1P. Indeed, expression 
studies and experiments with JTE-013 or with anti S1P2 siRNA point to a 
developmental stage specific role of S1P2 receptors. The chemorepellent effect of S1P2 




associated with chemotaxis to S1P in other cells important for bone repair: MSC that 
give rise to cells of the osteoblast lineage (see (Quint et al., 2013) above), endothelial 
cells (Waeber et al., 2004) or osteoclasts (see below). The lack of S1P1-mediated 
positive chemotactic response in osteoblasts, despite high S1P1 expression levels in 
these cells, is therefore unusual. 
  
2.8 Other effect of S1P signalling in osteoblasts 
S1P has long been known to release calcium from intracellular stores in pre-
osteoblasts (Lyons and Karin, 2001, Liu et al., 1995). Because of calcium’s central 
role in cell signalling, it is therefore not surprising that S1P is implicated in many 
osteoblast functions. Indeed, S1P stimulates IL-6 synthesis in these cells in a p42/p44 
MAPK dependent manner (Kozawa et al., 1997), induces the synthesis of heat-shock 
protein 27 (HSP27) via p38 activation (Kozawa et al., 1999), and enhances PGF2α-
induced phosphoinositide hydrolysis by phospholipase C through p38 MAPK 
(Kozawa et al., 2000, Di Paolo and De Camilli, 2006).  
Administration of epidermal growth factor, a known mitogenic factor for osteoblasts, 
increased S1P levels which coincided with increased cell proliferation (Carpio et al., 
2000). There is also evidence for the involvement of S1P signalling in calcitonin 
activity (Martin and Sims, 2015). Calcitonin is an anti-resorptive hormone previously 
indicated in osteoporosis, however it may also influence bone formation through its 
interactions in S1P signalling. By decreasing the expression of the S1P transporter 




and osteoblasts, and so also limiting S1P- or fingolimod-induced bone formation by 
osteoblasts which was found to be mediated by S1P3 receptors (Keller et al., 2014).  
S1P may also influence mature osteoblasts following their entombing as osteocytes in 
the bone matrix, whereby S1P signalling has been shown to play a role in osteocyte 
mechanotransduction via an S1P2 receptor mediated mechanism (Zhang et al., 2015). 
 
2.9 S1P and osteoclasts 
Osteoclasts are multinucleated, resorptive cells whose development is influenced by 
osteoblast lineage cells (Alford et al., 2015). Osteoclasts are responsible for the 
continuous remodelling of bone, working in tandem with bone forming osteoblasts 
(Walsh, 2015). The coupling between osteoclasts and osteoblasts in osteoclastogenesis 
is a clear example of the functional relationship between the two cell populations, and 
S1P plays an important role in the crosstalk between these two cell populations and 





Figure 2.2 Simplified illustration of the effects of S1P and its receptors on osteoblasts, 
osteoclasts, their respective precursors, and the role of S1P in osteoblast-osteoclast 
coupling. The involvement of the 3 major S1P receptor subtypes (red: S1P1, green: 




Briefly, osteoclast and osteoblast precursor migration is influenced by S1P1-mediated 
chemoattraction and S1P2-mediated chemorepulsion in response to the S1P 
concentration gradient (larger quantities of S1P are generated in serum mainly by red 
blood cells and endothelial cells, while lower S1P concentrations predominate in tissue 
compartments, such as bone). S1P, produced locally by osteoclasts or osteoclast 
precursors (Lotinun et al., 2013, Pederson et al., 2008, Keller et al., 2014), directly 
stimulates the proliferation of osteoblast precursors and their differentiation into 
mature osteoblasts, while increasing RANKL mRNA in osteoblasts, indirectly 
stimulating osteoclast precursor differentiation via RANK. The RANKL/RANK 
signalling pathway also upregulates SK in osteoclast precursors.  
 
2.10 S1P and osteoclast recruitment 
S1P can regulate the migration of osteoclast precursors both in vitro and in vivo. Bone 
marrow derived monocytes (an in vitro model of osteoclast precursors) express both 
S1P1 and S1P2 receptors. Upon exposure to RANKL, these cells differentiate into 
osteoclast-like cells and show decreased S1P1 expression, with concomitant loss of 
chemotactic response to S1P (Ishii et al., 2009). Knockout mice with specific S1P1 
deletion in the monocyte lineage are osteoporotic, a phenotype that has been attributed 
to the loss of S1P1 control of osteoclast precursor migration and increased residency 
time at the bone surface (Ishii et al., 2009). The potential therapeutic significance of 
these findings was confirmed in an ovariectomy-induced osteoporosis model: 
fingolimod prevented bone loss in ovariectomized mice but had no effects in sham-




surfaces (Ishii et al., 2009). In a rat model of periodontitis, fingolimod was found to 
reduce the number of osteoclast precursors and mature osteoclasts at the defect site, 
and increase the number of precursors in blood, an effect attributed to S1P1-induced 
positive chemotaxis (Lee et al., 2017). 
S1P2 receptor deficient mice show higher bone density than control mice (Ishii et al., 
2010), and S1P2 receptors seem to antagonize the effect of S1P1 receptors on osteoclast 
precursor migration. Positive and negative chemotaxis are attributed to S1P1-mediated 
activation of Rac via Gi, and S1P2-mediated activation of Rho via G12/13, respectively 
(Ishii et al., 2010). An in vitro migration assay of osteoclast precursors expressing both 
receptors subtypes showed that lower S1P concentrations stimulate positive 
chemotaxis, while higher concentrations stimulate negative chemotaxis, or 
chemorepulsion, suggesting that S1P2 receptors may only be active at high S1P 
concentrations. S1P1-deficient osteoclast precursor cells show very little motility, 
while S1P2-deficient cells showed positive chemotaxis, even at high S1P 
concentration (Ishii et al., 2010). Intravital imaging confirmed the chemotactic effect 
of S1P2 by showing that the antagonist JTE013 mobilised a small subset of monocytic 
lineage cells from the calvarium and led them to enter the blood circulation (Ishii et 
al., 2010).  
 
2.11 Therapeutic manipulation of osteoclast trafficking 
While approved or investigational anti-resorptive agents (e.g., bisphosphonate or 
cathepsin K inhibitors) target mature osteoclasts, manipulating osteoclast precursors 




of S1P1 and S1P2 receptors on precursor recruitment might underlie therapeutic 
interventions (i.e., activation of S1P1 or blockade of S1P2 receptors) that could prevent 
bone loss in conditions associated with inflammation and/or remodelling imbalance. 
This potential was ascertained using murine models of rheumatoid arthritis (in which 
fingolimod was as effective as prednisolone) and osteoporosis (fingolimod improved 
bone loss, but prednisolone had no effect) (Kikuta et al., 2011). In a model of 
periodontitis, a bacteria-driven inflammatory bone loss disease, fingolimod inhibited 
osteoclastogenesis and pro-inflammatory cytokines involved in osteoclast precursor 
recruitment (Yu et al., 2015).  
Vitamin D analogues are used for the treatment of osteoporosis, but their mechanism 
of action is not completely clear. For instance, in vitro calcitriol increased RANKL 
expression in bone marrow stromal cells, thereby activating osteoclasts and bone 
resorption (Kikuta et al., 2013). A recent study showed that vitamin D’s effect on 
osteoclast precursor migration might underlie its anti-resorptive activity. Indeed, 
calcitriol and its analogue eldecalcitol were found to uniquely reduce S1P2 receptor 
expression in monocytic osteoclast precursors (Kikuta et al., 2013), while circulating 
monocytes expressed fewer S1P2 receptors in mice treated with calcitriol or 
eldecalcitol, and monocyte mobility was observed to increase in eldecalcitol-treated 
mice after treatment with JTE013 (Kikuta et al., 2013).  
Whereas vitamin D analogues reduce S1P2 receptor expression, a recent study showed 
that the inflammatory cytokine IL-6 induced S1P2 mRNA, but not S1P1 mRNA 
expression in osteoclast precursor cells (Tanaka et al., 2014). This effect was 




precursors in tibial bone marrow. Systemic treatment with an anti-IL-6 receptor 
antibody prevented bone loss and decreased the number of precursors in tibial bone 
marrow via S1P2 receptor down-regulation (Tanaka et al., 2014), further validating the 
potential therapeutic value of S1P2 antagonists. 
The following table summarises some of the effects of S1P receptors 1, 2, and 3 on 
the cellular components of bone repair. The roles of S1P4 and S1P5 in bone biology 
are not extensive in the literature, and their expression is limited in both mature 






Table 2.2 Cell types involved in bone regeneration and some S1P receptor related effects. 
Cell type Agent Receptor Study  Effect Ref. 
Osteoblast cell models 
 
S1P as part of osteoclast conditioned 
medium 
S1P1/3 involvement determined using 
VPC23019 (2 µM and 10 µM) 
Murine long bone osteoblasts cultured 
in osteoclast conditioned medium 
↑ALP 
↑Mineralization 
(Lotinun et al., 2013) 
S1P (1-30 µM) 
 
 
No S1P receptors were investigated MC3T3-E1 cell line, treated with 1-30 
µM S1P, media contained 0.01% 
bovine serum albumin 
↑IL-6 (Kozawa et al., 
1997)  
S1P, various doses ranging from 1 nM 
to 10 µM 
S1P1 as determined by pertussis 
toxin (Dziak et al., 2003). The 
remaining articles do not identify 
individual receptors. 
 
Human osteoblast explant (Lampasso 
et al., 2001, Lampasso et al., 2002, 
Dziak et al., 2003), Foetal rat 
osteoblasts (Carpio et al., 1999, Grey 
et al., 2002, Grey et al., 2004), Saos-2 
cell line (Grey et al., 2004), thymidine 
incorporation proliferation assays 
↑Proliferation (Carpio et al., 1999, 
Lampasso et al., 
2001, Lampasso et 
al., 2002, Grey et al., 
2002, Grey et al., 
2004, Dziak et al., 
2003)  
S1P (100 nM) added to top and/or 
bottom compartments of migration 
chamber 
S1P2 as determined using pertussis 
toxin (200 ng/mL), JTE013 (10-8-10-
5 M), and RNA interference 
MC3T3-E1 cell line, migration assay 
for PDGF and S1P pre-and post-
differentiation 





Endogenous S1P S1P3 as determined using W146, 
JTE013, and VPC23019 (All 2 µM) 
MC3T3-E1 cell line cultured in 
osteoblast differentiation media, 
contained 10% serum 
↑Maturation (Brizuela et al., 
2014)  
S1P (0.01-0.1 µM) or fingolimod* 
(0.01-0.1 µM) 
S1P1 as determined by the pertussis 
toxin (100 ng/mL), W146, JTE013, 
and CAY10444 (All 10 µM) 
C2C12 murine osteoblast precursor 
cultured in media containing 10% 
serum. 
S1P and fingolimod used 




(Sato et al., 2012) 
S1P (0.1-2 µM)  S1P1 as determined using W146, 
JTE013, and CAY10444 (BML-
241) 
Human Saos-2 and murine MC3T3-E1 






Nuclear localization of β-catenin 
(Matsuzaki et al., 
2013) 
S1P (1 µM for proliferation, 200 nM 
for differentiation) 
S1P1/2 as determined by western blot 
analysis and selective S1P1 agonist 
SEW2871. 
Human osteoblasts incubated with 24 









S1P (100 nM) S1P3 as determined by western blot. Osteosarcoma cell lines MNNG-HOS 
and U-2OS incubated with S1P for up 
to 120 hrs. 
↑Proliferation 
↓Apoptosis 
(Shen et al., 2019) 
Osteoclast cell models 
 
 
S1P (0.1 µM and 1 µM) No receptors were investigated Osteoclast from minced rabbit bones 
incubated on dentine slices. Treated for 
16 hrs with S1P in media containing 
10% serum 
↓ Resorption (Takeda et al., 1998) 
S1P (10-10-10-7 M) S1P1 as determined by osteoclast 
lineage specific conditional S1P1 
knockout 
Murine monocyte cell line migration 
assay 
Cells cultured in media containing 
10% serum 
Positive chemotaxis (Ishii et al., 2009, 
Ishii et al., 2010) 
fingolimod (3 mg/Kg) intraperitoneal 
injection 
S1P1 determined from S1P1 
knockout osteoclasts collected from 
transgenic mice 
Murine model of osteoporosis ↓Bone density loss 
Positive chemotaxis 
(Ishii et al., 2009, 
Kikuta et al., 2011) 
S1P2 receptor deficiency or blockade S1P2 as determined in vitro by 
targeting with RNA interference. 
And in vivo by use of JTE013 3 
mg/Kg 
 
In vitro and in vivo investigation of the 




↓Negative chemotaxis (osteoclast 
precursors remain in circulation) 




fingolimod (3 mg/Kg/Day) 
intraperitoneal injections 
S1P1 as determined using 
immunohistochemistry and an anti-
S1P1 receptor antibody 
Rat model of periodontitis Positive chemotaxis 
 
(Lee et al., 2017) 
Calcitriol and eldecalcitol (In vitro: 10-
9-10-8 M 
In vivo: 50 ng/Kg) effect on S1P (10-6 
M) chemotaxis 
S1P2 receptor expression as 
determined by PCR 
Monocytoid cell line migration assay 
 
In vivo osteoporosis model  
↓S1P2 receptor expression 
Positive chemotaxis 
↑Bone mineral density 
 
(Kikuta et al., 2013) 
IL-6 (1-10 ng/mL) effect on S1P (10-7 
M) chemotaxis 
S1P2 receptor expression as 
determined by PCR 
Murine osteoclast precursors cultured 
in media containing fatty-acid free 
bovine serum albumin, migration 
assay. 
In vivo arthritis model 
↑S1P2 Receptor expression  
Negative chemotaxis  
 
↓Bone volume 
(Tanaka et al., 2014) 
S1P2 receptor antagonism S1P2 as determined by JTE013 Bone marrow cells exposed to 
osteoclastogenic agents. 
↓Size and number of osteoclasts 
↓Resorption pits (In vitro) 
(Hsu et al., 2019) 
Mesenchymal stem cells S1P (1 µM) No receptors were investigated Murine bone marrow stromal cells 
cultured in 10% inactivated serum 
↑Stress fibre formation 
↑Migration 





S1P as part of murine osteoclast 
conditioned medium 
S1P1 as determined using 
VPC23019 (1 µM), without any 
discussion of S1P3 antagonism 
Human mesenchymal stem cells 
cultured in media containing 10% 




(Pederson et al., 
2008) 
S1P as part of osteoclast conditioned 
medium, and S1P1 agonist VPC24191 
(5 µM) 
S1P1/2 as determined using 
VPC23019 (100 nM), and JTE013 
(20 nM), and S1P1 antagonist W143 
(1 µM) 
Human bone marrow derived MSC, 
cultured in media containing 10% 
serum 
↑Migration  
(Both S1P1/2 led to increased 
migration although through 
different pathways) 
(Quint et al., 2013) 
S1P (1 µM) S1P1 as determined by pertussis 
toxin (100 ng/mL), and W146 (10 
µM) receptor blockade 
C3H10T1/2 murine MSC incubated 
with S1P for 15 mins to 24 hrs. Media 





No effect on proliferation 
(Hashimoto et al., 
2015) 
S1P (40 mg/mL and 80 mg/mL) S1P1/2 as determined by changes in 
gene expression 
Human adipose derived stem cells 
cultured on titanium oxide coated 
stainless steel doped in S1P, cells were 
exposed to S1P for 120 hrs 
↑Proliferation 
↑Mineralization 
↑Expression of S1P1 and S1P2 at 
80 mg/mL 




↑Expression of S1P2 only at 40 
mg/mL 
Antagonism of endogenous S1P S1P1 antagonist W146. Bone marrow derived stromal cells 
incubated with S1P1 agonists and 
antagonists. 
↓F-actin structure assembly 
↓MMP-2 expression and activity 
↓Cell proliferation 
(Sassoli et al., 2018) 
Chondrocytes S1P (0.1-3 µM) S1P1-3 receptors exhibit increased 
expression as determined by PCR 
Bovine and human cartilage explants 
(monolayer culture), proliferation 
assay 
↑Proliferation (Stradner et al., 
2008) 
S1P (0.1-10 µM) Broad S1P receptor expression, 
though no specific receptor roles 
were identified, although Gi protein 
blockade with pertussis toxin 
reduced PGE2 induction by S1P 
Human articular chondrocytes from 
osteoarthritis patients. Treated 
following serum starving (0.5% 
serum) 
↑PGE2 release  
↑Cartilage degradation 
No effect on proliferation and 
viability 
(Masuko et al., 
2007) 
S1P as part of murine osteoclast 
conditioned medium 
S1P2 as determined by JTE013. Femoral head explants and primary 
murine chondrocytes cultured in 
osteoclast conditioned medium. 
↓Extracellular matrix production 
↑Osteoarthritis development in 
mice. 
(Cherifi et al., 2016) 
Osteocytes Mechanical stimulation-S1P (100 nM) S1P2 as determined by pre-treatment 
with JTE013 (10 µM) 








2.12 S1P in the vasculature and the role of angiogenesis 
The repair of cranial bone defects by scaffold-mediated delivery of S1P agents 
involves not only the recruitment of bone cell progenitors, but also production of new 
vessels in the defect space (Sefcik et al., 2008, Petrie Aronin et al., 2010a). Hence, 
while the previous sections focused on bone cells and their interactions, it is important 
to remember that bones are highly vascularized, perfused by up to 20 ml of blood/100 
g of bone every minute (Tondevold and Eliasen, 1982). Blood vessels are not only an 
essential conduit for blood, providing minerals, nutrients, growth factors and 
osteoprogenitors, but the endothelium also acts as a paracrine and endocrine organ 
involved in growth factor production, coagulation, inflammation and the immune 
response (Inagami et al., 1995). Fracture disrupts the bone’s vasculature, leading to 
hypoxia and necrosis of adjacent tissue. Re-establishment of the circulation and 
neovascularization in the tissue formed in response to injury are critical for successful 
fracture healing (Tomlinson and Silva, 2013). Unfortunately, bone repair strategies 
based on bone grafts or scaffolds have so far shown limited success due in part to the 
lack sufficient blood vessel supply during the early stages of the repair process (20, 
21). 
There are three main mechanisms for producing new vessels (Semenza, 2007). 
Vasculogenesis refers to the de novo generation of blood vessels that occurs for 
instance during embryogenesis. It differs from angiogenesis, which is the generation 
of new vessels from pre-existing ones. Angiogenesis occurs during physiological (e.g., 
wound healing or menstrual cycle) or pathological processes (e.g., neovascular 
disorders, rheumatoid arthritis and cancer). It can result from the formation of a new 




of a blood vessel into two or more vessels (intussusceptive angiogenesis). Finally, 
arteriogenesis is the remodelling of an existing artery to increase its luminal diameter. 
While arteriogenesis, and possibly angiogenesis (Gaengel et al., 2012, Jung et al., 
2012, Duran et al., 2017), occurs in response to physical forces such as increased blood 
flow, angiogenesis is initiated in poorly perfused tissues when low oxygen levels lead 
to increased levels of the transcription factor Hypoxia-Inducible Factor (HIF)-1α in 
parenchymal cells.  
VEGF is the main HIF-1α–dependent pro-angiogenic factor, and inhibiting VEGF 
signalling impairs healing of femoral fractures and cortical bone defects in mice 
(Street et al., 2002). Although VEGF is the archetypical pro-angiogenic factor, it 
promotes by itself the formation of immature and leaky vessels (Yancopoulos et al., 
2000). In contrast, angiopoetin-1 produces vessels that are resistant to leak (Thurston 
et al., 1999), suggesting that different vascular growth factors play complementary 
and coordinated roles in new vessel formation, and that therapeutic strategies aimed 
at promoting angiogenesis should target more than one mediator. Indeed, when 
surgically implanted in the ear of mice, chemically modified hyaluronan hydrogels 
pre-loaded with both VEGF and angiopoetin-1 promote a larger angiogenic response 
than delivery of single growth factors (Riley et al., 2006). More recently, sequential 
delivery of VEGF and S1P using a porous hollow fibre in a skin Matrigel plug assay 
was shown to lead to more endothelial cell recruitment and a higher maturation index 
than single factor delivery, reverse sequential delivery or even co-delivery (Tengood 
et al., 2010). The concept that temporal control of growth factor release produces more 




similar experiments using Basic Fibroblast Growth Factor and Platelet-Derived 
Growth Factor (Tengood et al., 2011). 
These sequential release experiments were conducted over the course of a week, but 
the bone repair process takes months. Scaffold-mediated delivery of a low molecular 
weight, more lipophilic factor such as an S1P agent might be preferable to the delivery 
of recombinant proteins. The role of S1P in the vasculature and new vessel formation 
is well documented and has been the subject of numerous reviews (Waeber, 2013a, 
Takuwa et al., 2010, Lucke and Levkau, 2010). Endothelial cells express the same S1P 
receptor subtypes as intrinsic bone cells (S1P1>S1P2≈S1P3); these receptors mediate 
generally similar cellular responses (proliferation, differentiation and migration), in 
addition to effects more specific to endothelial cells (modulation of cell adhesion and 
of the inflammatory/immune response). 
S1P seems to play a key role in both vasculogenesis and angiogenesis. In a mouse hind 
limb ischemia model, S1P stimulates angiogenesis (Oyama et al., 2008), while 
postischemic blood flow recovery and angiogenesis are accelerated in transgenic mice 
overexpressing SK1 (Takuwa et al., 2008). At variance with the effects of VEGF 
however, the angiogenic response to S1P is not associated with increased vascular 
permeability in the ischemic limb, and many studies have shown that S1P actually 
enhances endothelial barrier integrity (Waeber, 2013a). In fact, in this model, S1P-
containing PLGA microparticles not only stimulated post-ischemic angiogenesis at 28 
days but also blocked oedema induced when VEGF was co-administered (Qi et al., 
2010). The effects of S1P1 and S1P3 receptors on adherens junctions in endothelial 
cells were documented soon after the identification of these receptors (Lee et al., 




junctions (Singleton et al., 2007, Singleton et al., 2005, Singleton et al., 2009, Camerer 
et al., 2009), S1P2 receptors increase vascular permeability in vitro via disruption of 
adherens junctions (Sanchez et al., 2007, Lee et al., 2009). In vivo, S1P1 receptor 
activation inhibit VEGF-induced vascular leakage in skin capillaries (Sanchez et al., 
2003), whereas S1P1 receptor antagonists have shown that they induce capillary 
leakage in the lung, kidney, skin, and intestine (Rosen et al., 2008, Sanna et al., 2006, 
Foss et al., 2007).  
S1P1 receptors promote vascular stabilization by regulating the interactions between 
endothelial and mural cells during the maturation process (Allende and Proia, 2002, 
Liu et al., 2000), and, in apparent contradiction with their pro-angiogenic effects 
mentioned above, S1P1 receptors were recently shown to inhibit sprouting 
angiogenesis during vascular development (Ben Shoham et al., 2012), by stabilizing 
VE-cadherin at endothelial junctions and inhibiting VEGFR2 (Gaengel et al., 2012, 
Jung et al., 2012), suggesting the existence of an alternative mechanism that helps 
stabilize the newly formed vascular network and improves its barrier function. 
These data showing that S1P plays a role both at the early stages of angiogenesis and 
at the stage of new vessel stabilization, taken together with the effects of this lipid on 
bone cells, suggest that scaffold-mediated delivery of S1P (most likely S1P1) agonists 
might promote bone repair via pleiotropic and possible synergistic mechanisms. 
 
2.13 Current efforts in S1P delivery 
The importance of S1P as a chemoattractant, and in coupling the activity of osteoblasts 




disorders such as osteoporosis (Meshcheryakova et al., 2017). However, a study of 
daily subcutaneous fingolimod (6 mg/kg) did not lead to any improvement in fracture 
healing, either by influencing bone formation or erosion, of a murine femoral defect 
after 3 weeks (Heilmann et al., 2013). The authors highlighted that a failure to 
demonstrate if fingolimod could influence bone healing by impacting inflammatory 
cell recruitment may have been a cause of the lack of effect compared to studies that 
utilised a localised delivery of fingolimod (Petrie Aronin et al., 2010a, Petrie Aronin 
et al., 2010b, Sefcik et al., 2011). Indicating that a more localised approach of 
delivering S1P and related analogues, may lead to more promising results. 
Local administration of S1P has typically involved the use of scaffolds, which often 
have the dual role of acting as drug delivery device and mimicking native tissue to 
elicit functional tissue development. Hence a range of biocompatible materials, 
including natural polymers (collagen, chitosan, silk), synthetic polymers (PLGA and 
PCL) and inorganic materials (ceramics and glasses) have been investigated to 
fabricate scaffolds that are conducive to tissue regeneration, and allow temporal 
control over the release of therapeutic cargoes (Ahern et al., 2013). Biodegradable 
PLGA is among the commonest copolymers investigated (Galvin et al., 2012) and has 
been used to control the release of S1P (Sefcik et al., 2008) and fingolimod (Das et al., 
2014b), resulting in increased new bone formation post-implantation in a rat cranial 
defect model, an effect that was attributed to increased development of vasculature 
and the possible dose-dependent initiation of bone progenitor cell migration towards 
the defect site (Das et al., 2014b). The underlying mechanism was probed in a similar 
study investigating the delivery of S1P agonists and antagonists (S1P, fingolimod or 




et al., 2010a). Although S1P is subject to much more rapid in vivo degradation than 
fingolimod, scaffolds loaded with either agonist were equally effective in generating 
new bone over 6 weeks, while VPC01091-loaded scaffolds did not differ from 
unloaded controls (Petrie Aronin et al., 2010a). This study suggests that sustained 
release from scaffolds may offset the challenges of employing therapeutic cargoes 
(e.g. S1P) with short half-lives, and that S1P3 receptors synergize with S1P1 receptors 
to influence the various processes underlying repair (i.e., vascular remodelling, cell 
proliferation and migration, inflammation), albeit to differing extents. fingolimod has 
been incorporated into electrospun nanofibers composed of PLGA and biodegradable 
PCL and showed significant improvement in defect healing and vascularization in a 
rat critical mandibular defect (Das et al., 2013). These fingolimod-loaded nanofibers 
increased neovascularization and enhanced the proportion of macrophages with an 
anti-inflammatory phenotype (M2) (Das et al., 2013), a cell population that is also 
known to play an important role in tissue repair (Ogle et al., 2016), and had been 
previously shown to be selectively attracted by fingolimod (Ogle et al., 2014). A 
similar result of anti-inflammatory macrophage stimulation was found in another 
study using a PLGA coated allograft (Das et al., 2015), and whilst SEW2871 was also 
observed to stimulate macrophage recruitment, details regarding phenotype were not 
reported (Murakami et al., 2014). An electrospun amphiphilic copolymer was 
developed to act as a carrier for S1P to promote vascularization in tissue repair 
applications, the amphiphilic nature of the copolymer was anticipated to mimic the 
binding of S1P to apolipoprotein M. S1P was first applied directly to endothelial cells 
(HUVEC) and showed pro-angiogenic effects in a tube formation assay. Tube length 




amphiphilic scaffold, additional evidence of new vessel formation was shown in a 3 
day chorioallantoic membrane assay (Zhang and Song, 2014). 
Whether small molecule delivery alone will achieve sufficient and effective bone 
repair remains to be established, but it is worth noting that fingolimod PLGA 
microspheres in a chitosan gel improved bone regeneration in a rat cranial defect 
study, with no substantial improvement upon addition of BMP-2 to fingolimod-loaded 
microspheres (Das et al., 2014a), despite fingolimod being known to enhance BMP-2 
mediated osteoblast differentiation in vitro (Sato et al., 2012). Conversely, SEW2871 
alone failed to improve bone regeneration, but co-administration with platelet rich 
plasma improved the latter’s performance, by enhancing macrophage recruitment and 
cell debris clearance (Kim et al., 2014). Combining S1P with low-cost, biocompatible, 
biodegradable polymers represents an enticing alternative prospect for current bone 
graft treatments. Unfortunately, results to date still show most polymeric biomaterials 
cannot match the efficacy of bone grafts, because they lack both the osteogenic and 
osteoinductive properties that make grafts so successful. Consequently, bioactive 
polymer-graft composites are a potential solution to recapitulate mechanical and 
biological properties of host tissue in an effort to repair critical-sized defects. In one 
case, fingolimod elution from a PLGA-coated devitalized-bone allograft in a critical 
rat tibial defect improved elastic modulus and ultimate compressive strength of the 
bone, outcomes attributed to evidence of enhanced active remodelling at the defect 
site (Petrie Aronin et al., 2010b). The same procedure was investigated further, and 
similarly attributed tissue regeneration to improved vascularization, while also 
presenting a more detailed discussion of the role of bone marrow derived cells in 




system for fingolimod showed a dose-dependent increase in bone volume in a cranial 
defect model at 2 and 4 weeks. Although differences in bone volumes were no longer 
significant at 8 weeks, fingolimod still enhanced host-graft integration at this time 
point (Huang et al., 2012). Notably, direct adsorption of fingolimod onto implanted 
allograft improved bone deposition and vascularisation (Wang et al., 2016a). 
Predictably, this method produced higher local concentrations of fingolimod, but 
lower increases in bone density compared to polymer-based delivery discussed above 
(Huang et al., 2012, Wang et al., 2016a). 
 
2.14 Conclusion 
Although the role of S1P in bone biology has been the focus of much less research 
than its role in the cardiovascular and immune systems, it is becoming clear that this 
lipid influences many of the functions, pathways and cell types that play a key role in 
bone repair. Indeed, S1P has a well-established role in promoting angiogenesis (Hla, 
2004, Sefcik et al., 2008, Sefcik et al., 2011, Kono et al., 2004, Zhang and Song, 2014), 
but is also implicated in many other bone related processes including stem cell 
recruitment (Annabi et al., 2003, Quint et al., 2013, Ratajczak et al., 2014) and 
subsequent differentiation (Hashimoto et al., 2015). S1P stimulates the differentiation 
and survival of osteoblasts (Sato et al., 2012, Matsuzaki et al., 2013), and contributes 
to their intricate coupling with osteoclasts (Ryu et al., 2006). S1P is not only a key 
factor in its own right, it also seems to mediate the functions of critical bone growth 
factors, such as BMP (Pederson et al., 2008, Sato et al., 2012). Although the use of 




those related to supra-physiologic doses (Tannoury and An, 2014), short half-lives 
(Yamamoto et al., 2003), an inability to maintain osteogenicity due to slow vascular 
integration of grafts (Gomez-Barrena et al., 2015), not to mention high costs (Garrison 
et al., 2007). As summarized in earlier sections, various groups have therefore begun 
to explore the use of non peptidic agents, such as S1P and analogues, to promote bone 
repair in vivo, with generally promising results. Remaining issues regarding 
pleiotropic activity (Maceyka et al., 2012), solubility (Murakami et al., 2014) and the 
need to maintain local concentrations over a number of weeks (Maceyka et al., 2012) 
may be addressed by using more specific agents and/or novel delivery options. A 
number of such delivery methods have been studied in the field of bone repair to 
enhance delivery of growth factors (Garrison et al., 2007, Dimitriou et al., 2005, 
Hankenson et al., 2015), small molecule drugs, and stem cell therapies (Leijten et al., 
2015, Klontzas et al., 2016, Henkel et al., 2013). They have generally involved 
biomaterials for controlled release of drugs including biocompatible, biodegradable 
polymers, and bio-ceramics (Kim and Tabata, 2015, Henkel et al., 2013) and the use 
of high affinity delivery systems, which have led to reductions in required doses 
(Martino et al., 2015).  
The use of S1P agents for bone repair is likely to be greatly accelerated by the much 
more active translational and clinical research of the role of S1P signalling in other 
fields, such as inflammation or cancer. The number of active clinical trials involving 
S1P receptor ligands in inflammatory conditions ranges from 2 and 3% of trials for 
inflammatory bowel disease and psoriasis, up to 32% of all trials for new multiple 
sclerosis therapies (Hanke et al., 2016). S1P1 receptors have been the focus of most 




of agents such as ponesimod, siponimod, and ozanimod, with improved specificity 
compared to fingolimod. Whilst other possible targets, such as S1P lyase inhibition 
have been less well investigated (Chew et al., 2016). In the field of bone repair, further 
basic and translational research will be needed to better define which S1P metabolic 
enzymes or receptors should be targeted, when and for what duration, and whether an 
agonist or an antagonist would be preferable. The latter issue is particularly critical 
considering that S1P1 receptor agonists seem to exert their action as functional 
antagonists, with S1P1 agonists and antagonists showing similar therapeutic effects 
(Quancard et al., 2012). Furthermore, some of the work quoted in this chapter has been 
based on qualitative or semi-quantitative data, and the pharmacological profile of the 
response was sometimes unclear, either due to incomplete dose response studies, or 
the use of agents with questionable specificity (Salomone and Waeber, 2011, Adada 
et al., 2013) . 
To conclude, the manipulation of S1P signalling using systemic administration of 
therapeutic agents seems promising for the management of inflammatory or 
hormonally related bone loss, as S1P agents can be used to affect osteoblast/osteoclast 
coupling, the unbalancing of which manifests as conditions such as osteoporosis. In 
contrast, local administration of S1P agents has shown more compelling results in 
bone defect studies, and so improving local delivery of these agents will be key to 
optimising their regenerative potential. Critically, this may be achieved by not only 
increasing the recruitment of osteogenic cell precursors but also by inducing and 
supporting vascularization and modulating the immune response; S1P agents may be 
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The repair of critical bone defects remains a significant therapeutic challenge. While 
the implantation of drug-eluting scaffolds is an option, a drug with the optimal 
pharmacological properties has not yet been identified. Agents acting at sphingosine 
1-phosphate (S1P) receptors have been considered, but those investigated so far do not 
discriminate between the five known S1P receptors. This work was undertaken to 
investigate the potential of the specific S1P1/5 modulator siponimod as a bone 
regenerative agent, by testing in vitro its effect on cell types critical to the bone 
regeneration process.  
hFOB and HUVEC were treated with siponimod and other S1P receptor modulators 
and investigated for changes in intracellular cyclic AMP content, viability, 
proliferation, differentiation, attachment and cellular motility. 
Siponimod showed no effect on the viability and proliferation of osteoblasts and 
endothelial cells, but increased osteoblast differentiation (as shown by increased 
alkaline phosphatase activity). Furthermore, siponimod significantly increased 
endothelial cell motility in scratch and transwell migration assays.  
These effects on osteoblast differentiation and endothelial cell migration suggest that 
siponimod may be a potential agent for the stimulation of localised differentiation of 







The restoration of tissue function after damage, involves complex interactions 
between various cell types, local tissue matrix, and chemical mediators, in various 
combinations. 
The creation of new vasculature via angiogenesis is essential for the regeneration of 
any tissue, and in the case of bones, regeneration also involves the recruitment of 
osteoblast and osteoclast precursors to the defect area, their differentiation into their 
mature phenotypes as well as interaction between the two cell types, with bone-
forming osteoblasts stimulating the maturation of bone resorbing osteoclasts, which in 
turn stimulate osteoblast recruitment and maturation (Chen et al., 2018). 
S1P is a lipid mediator that modulates many biological processes, including calcium 
signalling, cell growth, differentiation, survival, motility and cytoskeleton 
organization (Spiegel and Milstien, 2000). It acts via 5 known G Protein-Coupled 
Receptors (S1P1-5), which are widely expressed throughout the body (Hla, 2004). The 
role of S1P in promoting angiogenesis is well-established (Waeber, 2013b). This, 
taken together with the pleiotropic effects of S1P on bone cells (Sartawi et al., 2017), 
suggests that modulating S1P signalling may promote bone repair. However, systemic 
administration of S1P agents did not improve fracture healing in a murine femoral 
defect (Heilmann et al., 2013), indicating that more localised approaches of delivering 
S1P and related analogues may be needed (Das et al., 2014b). 
The pharmacological characterization of the various S1P-mediated responses, in bone 
and other tissues, has been hampered by the lack of well-characterized specific agents 




well as the S1P receptor modulator fingolimod (aka FTY720 or Gilenya®) have been 
investigated in in vitro and in vivo models of bone repair (Sartawi et al., 2017), but 
these agents do not discriminate between the 5 different receptor subtypes. 
Fingolimod, used clinically for the management of relapsing remitting multiple 
sclerosis, is a potent agonist at all S1P receptor subtypes except S1P2 (Brinkmann et 
al., 2010). Its mechanism of action relies, at least in part, on the redistribution of 
lymphocytes to secondary lymphoid tissues following fingolimod-induced S1P1 
receptor internalization, resulting in their depletion from the peripheral blood and 
immunosuppression. Although fingolimod is relatively safe, activation of S1P3 
receptors by this agent may be associated with adverse effects (DiMarco et al., 2014, 
Cugati et al., 2014). Although the role of S1P3 receptors in cardiac side effects may be 
unique to rodents (Gergely et al., 2012), these off-target effects led to the discovery 
and development of the S1P1/5 selective agonist siponimod (aka BAF312, or 
Mayzent®) (Behrangi et al., 2019). In addition to its improved selectivity profile, 
siponimod is not a pro-drug (fingolimod must first be phosphorylated by sphingosine 
kinase 2) and has a shorter half-life that still allows once-daily oral dosing but enables 
rapid recovery of lymphocyte counts upon treatment cessation.  
The effects of S1P and of fingolimod on cells relevant to bone repair have been 
extensively investigated (Sartawi et al., 2017), but far less is known on the effect of 
siponimod on these cells. The goal of these studies was therefore to test the effect of 
siponimod on the viability, proliferation, differentiation, and chemotactic behaviour 
of osteoblast and endothelial cells, with the aim of better understanding the potential 
of selective modulation of S1P1 (or S1P5) receptors via localised delivery to repair 




3.3 Materials and methods 
3.3.1 Materials 
Siponimod hemifumarate and fingolimod hydrochloride were kindly gifted from 
Novartis. D-erythro-Sphingosine 1-phosphate was acquired from Enzo Life Sciences. 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham, foetal bovine 
serum (FBS), L-Glutamine, penicillin-streptomycin, Thiazolyl Blue Tetrazolium 
Bromide (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT), 
dimethyl sulfoxide (DMSO), neutral buffered formalin (NBF), Fast Blue BB and 
Naphthol AS-MX phosphate, Roche Bromodeoxyuridine (BrdU) cell proliferation kit 
were acquired from Sigma-Aldrich. Endothelial cells (HUVEC) and endothelial cell 
growth medium (ECGM) with associated supplements were acquired from PromoCell. 
Pierce™ PNPP Substrate Kit was acquired from Thermo Fisher Scientific. cAMP-
Glo™ Max Assay was acquired from Promega. Cell culture plasticware was acquired 
from Sarstedt Ltd. Human foetal osteoblasts (hFOB 1.19 (ATCC® CRL-11372™)) 
cell line was acquired from ATCC. 
3.3.2 Cell culture 
hFOB were maintained in DMEM/F12 supplemented with FBS (10%), L-glutamine 
(1%), and penicillin-streptomycin (1%). Incubation was at 34 °C and 5% CO2. 
HUVEC were maintained in supplemented ECGM as per supplier’s instruction at 37 
°C and in 5% CO2. Although this medium contains only 2% serum, some HUVEC 
experiments were performed under reduced serum conditions (1/10th standard cell 




3.3.3 Siponimod solution 
Siponimod was dissolved in DMSO and then diluted in PBS as required. DMSO 
concentration were limited to <0.5% v/v in cell culture experiments. The potential 
toxicity of exceeding this concentration of DMSO was explored using hFOB and 
HUVEC (2.5*104 cell/well in 24 well plates) incubated with increasing concentrations 
of DMSO (0.32 - 3.2% in cell culture medium) for two and three days respectively. 
Thereafter, resazurin 60 µl of a 560 µM stock solution was added to wells for 3.5 hrs 
before acquiring fluorescence at excitation 488 nm/emission 595 nm. 
3.3.4 Viability and proliferation 
To estimate the effect of siponimod on cellular viability, cells were seeded at a density 
of 2.5*104 cells per well in 24-well plates, the following day test drugs (100 nM 
siponimod or PBS vehicle) were added to cell culture medium. Following two- and 
three-days incubation (HUVEC and hFOB, respectively), 60 μl MTT solution (5 
mg/ml stock) was added directly to wells and incubated for two hrs away from light. 
Wells were then rinsed with PBS. Formazan crystals were dissolved with DMSO and 
absorbance acquired at 570 nm using a Wallac Victor 2 plate reader (Perkin Elmer). 
To determine the effect of siponimod on cellular proliferation, cells were seeded in 
24-well plates at a density of 2.5*104 cells per well. Siponimod (100 nM) or PBS 
vehicle were added to the cell culture medium for two- and three-days (HUVEC and 
hFOB, respectively). Thereafter, cells were detached using trypsin-EDTA 0.25%, 
diluted with cell culture medium, and individual well cell numbers manually counted 
using a haemocytometer. Additional cell counting experiments were conducted using 




As an additional measure of proliferation, a BrdU cell proliferation assay was 
conducted. BrdU is an analogue of pyrimidine and incorporated in its place into the 
DNA of proliferating cells and detected as part of a colorimetric enzyme-linked 
immunosorbent assay. In brief, cells were seeded in 96-well plates at densities of 1*104 
per well. Increased concentrations of siponimod, fingolimod, and S1P (all 1000 nM) 
and a PBS control were added the following day with fresh medium, and incubation 
continued for a further two days. Following treatment, BrdU was diluted in fresh 
medium and added to cells for 24 hrs. Thereafter cells were fixed for 30 mins, then 
incubated for 90 mins in a BrdU antibody solution, rinsed thoroughly with PBS 
followed by incubation with anti-BrdU substrate until sufficient colour development 
for plate reading at 405 nm. 
3.3.5 Osteogenic differentiation 
3.3.5.1 Para-nitrophenylphosphate 
Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation. In vitro 
osteoblast differentiation was estimated using para-nitrophenylphosphate (pNPP) as a 
substrate of alkaline phosphatase that is dephosphorylated into a yellow product (p-
nitrophenol), detectable by absorbance at 405 nm. 
hFOB (5*104) were seeded in 24-well plates and treated on day 0, 2, 4, and 6 with 
1000 nM of either siponimod, fingolimod or S1P, with PBS vehicle as a control. Test 
agents and controls were added directly to standard hFOB medium. As a positive 
differentiation control, cells were treated with osteogenic medium containing 50 μg/ml 
ascorbic acid and 7.5 mM β-Glycerophosphate. After 7 days, cells were detached with 




haemocytometer. The cells were then transferred to 1.5 ml tubes and centrifuged at 
3000 relative centrifugal force (rcf) for 5 mins. Medium was aspirated from each tube 
and replaced with 100 μl pNPP substrate solution, allowing 30 mins for yellow colour 
development. Absorbance was recorded at 405 nm using a Wallac Victor 2 plate reader 
(Perkin Elmer). The absorbance value of each sample was divided by its respective 
cell count, to normalize for differences due to cell numbers. Data are presented relative 
to the positive osteogenic medium control in each independent replicate. 
3.3.5.2 Fast blue staining 
Because the pNPP-based assay above does not allow the determination of the fraction 
of differentiating cells, as a complimentary measure of ALP, staining was performed 
using Fast Blue BB and Naphthol AS-MX phosphate. hFOB (5*104) were seeded in 
24-well plates and treated every other day with siponimod (10-1000 nM), PBS, or 
osteogenic medium for 7 days. Thereafter, cells were equilibrated in an alkaline buffer 
followed by incubation with fast blue dye for 60 mins. Using a BX51 microscope 
(OLYMPUS), three images were acquired per well (with a 4x objective). Using 
ImageJ analysis software, the number of stained cells and total cells was manually 
counted and expressed as a percentage of the total cell number. 
3.3.6 Migration 
Cell migration assays were conducted for HUVEC and hFOB using the same 
techniques but using cell type specific media.  
3.3.6.1 Wound healing (scratch) assay 
Cells were seeded at 1*105 cells/well in 24-well plates and grown overnight to produce 




pipette tip, wells were rinsed with PBS to remove debris and the cell culture medium 
was replaced as follows: for hFOB, DMEM/F12 supplemented with 0.1% FBS was 
used to reduce serum bioactive lipid effects. Likewise, for HUVEC, ECGM was 
supplemented with 1/10th the usual supplement. Siponimod and S1P (delivered in 20 
µl PBS), and PBS control were then added directly to cell culture medium. Brightfield 
images (4x objective) were acquired immediately and after 8 hrs using a BX51 
microscope (OLYMPUS). Using the associated software, Stream (OLYMPUS), the 
distance between the edges of the scratch wound was measured and the change over 
time attributed to cellular migration into the empty space.  
3.3.6.2 Transwell migration 
Transwell migration was conducted to assess chemotactic activity of S1P agents. Cells 
were seeded at 5*104 cells in 100 μl of medium in the upper chamber of 8 µm pore 
polyethylene terephthalate transwell inserts. Siponimod, S1P, fingolimod (delivered 
in 20 µl PBS), or PBS control were then added to the bottom chamber of the transwell 
system, which contained 600 μl of medium. After 4, 8, or 24 hrs of incubation, culture 
medium was aspirated from the upper chamber, inserts were fixed with 10% NBF for 
15 mins at room temperature, then stained with 0.5% crystal violet for 30 mins at room 
temperature. Thereafter inserts were rinsed with water to remove excess dye and the 
top side of the membrane was wiped with a cotton bud to remove non-migrated cells. 
Finally inserts were dried on the bench, before the membrane was visualized by light 
microscopy (BX43 microscope (OLYMPUS)). Five brightfield images per insert were 





3.3.7 Cell attachment 
The influence of siponimod on HUVEC attachment was investigated by seeding 5*104 
cells in 24 well plates using ECGM that was supplemented with 1/10th standard 
supplement to reduce serum lipid effects. Siponimod and S1P (delivered in 20 µl 
PBS), and PBS control were then added immediately to wells. After 4 hrs incubation, 
non-attached cells were removed by washing with PBS. Remaining cells were fixed 
with 10% NBF for 15 mins, followed by staining with crystal violet 0.5% w/v for 30 
mins. Three brightfield images per well were acquired (10x objective), with stained 
cells manually counted using ImageJ analysis software. 
3.3.8 Cyclic AMP assay 
The effect of siponimod on intracellular cAMP levels was determined using the 
cAMP-Glo™ Max Assay (Promega). hFOB were seeded at 2*104 cells per well in 96 
well plates and cultured overnight. Cells were washed with PBS, then treated with 
forskolin, siponimod, forskolin & siponimod combined, and a control containing the 
DMSO vehicle (concentration 0.32 %) for 1 hr. All conditions included 500 µM IBMX 
to inhibit phosphodiesterases. Luminescence was measured and cAMP concentrations 
calculated using a standard curve as per the manufacturer’s protocol. 
3.3.9 Statistical analysis 
Results were expressed as mean ± standard deviation (SD), unless otherwise stated. 
Determining statistical significance was performed using one-way analysis of variance 
(ANOVA) followed by Bonferroni post-test for multiple comparisons. Differences 
were considered significant at p < 0.05. We used extra-sum-of-squares F tests as 




responses were concentration-dependent (with the null hypothesis that data points 





3.4.1 Siponimod solution 
Siponimod was applied to cells in in vitro experiments as an aqueous solution of PBS 
containing a small concentration of DMSO as a cosolvent (0.32 % v/v). In order to 
determine whether the use of DMSO as a cosolvent would negatively impact hFOB 
and HUVEC used throughout this work, increasing concentrations of DMSO were 
applied to cells and their viability determined by resazurin assay (Figure 3.1). For 
hFOB there was no statistically significant change in cell viability when using 0.32 % 
DMSO compared to PBS control (91.5 ± 24.2 % compared to 100 ± 26.7 %). With 
increasing concentration of DMSO, cell viability trended downwards albeit without 
achieving statistical significance until a DMSO concentration of 3.22 % produced a 
significant fall in hFOB viability compared to PBS control and the 0.32 % condition 
(4.8 ± 2.7 % compared to 100 ± 26.7 % and 91.5 ± 24.2 %, p < 0.05). For HUVEC 
incubated with a concentration of 0.32 % DMSO there was no statistically significant 
change in cell viability over the experimental duration compared PBS control (99.4 ± 
9.3 % compared 100 ± 4.2 %). As before DMSO showed a statistically significant 
reduction in cell viability at increased concentrations of 3.22 % compared to PBS and 






Figure 3.1 Viability assay for hFOB and HUVEC incubated with increasing 
concentrations of DMSO. (A) hFOB resazurin assay after 72 hrs, (B) HUVEC 
resazurin assay after 48 hrs. Data is expressed as a percentage of PBS control and is 
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replicates). For hFOB, increasing DMSO concentrations were added to cell culture 
medium containing 1/10th standard serum supplement. For HUVEC, DMSO 
concentrations were added to cell culture medium containing 1/3rd standard 
supplements. Statistical analysis was performed by one-way ANOVA. There was no 
statistically significant difference between any group except for 3.22% DMSO, which 
was statistically different from all other groups (***: p < 0.001). 
3.4.2 Viability and proliferation 
Siponimod effect on cell viability and proliferation was investigated using hFOB and 
HUVEC. MTT assays were used to determine cell viability, with results presented as 
absorbance at 570 nm expressed as a percentage of positive control (for hFOB, fully 
supplemented DMEM/F12, for HUVEC, fully supplemented ECGM). Manual cell 
counting was used to determine cell proliferation, with data presented as average cell 
numbers expressed as a percentage of positive control. Viability of hFOB treated with 
100 nM siponimod were not significantly different to those treated with PBS vehicle 
(42.1 ± 7.6 % compared to 36.9 ± 8.6 %), this lack of effect was also seen in manual 
cell counting experiments comparing 100 nM siponimod and PBS vehicle (49.1 ± 4.1 
% compared to 44.9 ± 0.8 %) (Figure 3.2 A & B). For HUVEC 100 nM siponimod 
produced no significant difference in viability compared to PBS vehicle (80.9 ± 8.8 % 
compared to 74.9 ± 8.2 %). There was similarly no statistically significant change in 
manual cell count results between 100 nM siponimod and PBS vehicle (68.1 ± 12.7 % 
compared to 59.1 ± 12.7 %) (Figure 3.2 C & D). Additionally, BrdU assay confirmed 
the absence of a proliferative effect for 1000 nM siponimod on both the hFOB and 
HUVEC (Figure 3.2 E & F). The BrdU assays also showed that there was no 




Over a 7 day experimental duration (Figure 3.2 G), none of siponimod, fingolimod or 
S1P (all 1000 nM) led to any statistically significant change in hFOB cell count 
compared to PBS control (87.9 ± 16.5 % for siponimod, 88.7 ± 10.3 % for fingolimod, 
and 72.5 ± 18.7 % for S1P compared to 100 ± 37.1 % for PBS control). Likewise, 
increasing concentrations of siponimod (10-1000 nM (Figure 3.2 H)) did not show any 
statistically significant changes in cell number compared to PBS control (91.2 ± 5.0 
% for 10 nM, 95.8 ± 15.5 % for 100 nM, and 82.2 ± 24.2 % for 1000 nM compared to 




Figure 3.2 Viability and proliferation assays for hFOB and HUVEC. (A & B) hFOB 
MTT assay and cell count after 72 hrs, n=3 (4 technical replicates) (C & D) HUVEC 
MTT assay and cell count after 48 hrs, n=3 (4 technical replicates) (E & F) hFOB and 
HUVEC BrdU assay, n=3 (4 technical replicates) (G & H) hFOB cell count after 7 
days incubation, n=4 (3 technical replicates). For A-F, data is expressed as a 
percentage (positive control set to 100%), for G & H data is expressed as a percentage 




containing 1/10th standard serum supplement, with standard growth medium 
(DMEM/F12) acting as positive control. For HUVEC (in A-F), factors were added to 
cell culture medium containing 1/3rd standard supplements, with standard growth 
medium (ECGM, containing 2% serum) acting as positive control. In G & H growth 
medium supplement was not altered. ‘’n=’’ represents the number of independently 
repeated experiments. Data is presented as mean ± SD, statistical analysis by one-way 
ANOVA. NS: No statistical significance. *: p < 0.05. **: p < 0.01. ***: p < 0.001. 
3.4.3 Osteogenic differentiation 
3.4.3.1 Para-nitrophenylphosphate 
hFOB were incubated in medium containing equal concentrations (1000 nM) of either 
siponimod, fingolimod, or S1P (Figure 3.3). Absorbance values for the ALP product 
p-nitrophenol were normalised according to manual cell counts. Data is expressed as 
a percentage of the osteogenic medium positive control across each replicate. Figure 
3.3 A shows the results of the comparison between the three investigated drugs 
(siponimod, fingolimod, and S1P). Whereas 1000 nM fingolimod showed no 
significant difference compared to PBS vehicle (44.8 ± 2.7 % compared to 39.8 ± 9.5 
%), siponimod (1000 nM) increased absorbance/count compared to PBS vehicle (68.4 
± 9.7 % compared to 39.8 ± 9.5 %, p < 0.05). This increase was not significantly 
different from that induced by 1000nM S1P (78.1 ± 10.3 % compared to 39.8 ± 9.5 % 
for PBS vehicle, p < 0.05) and the response to siponimod ranging from 10-1000 nM 





Figure 3.3 Alkaline phosphatase activity as an early marker of differentiation in 
hFOB. (A) Effect of siponimod, fingolimod, and S1P (1000 nM) after 7 days, n=4 (3 
technical replicates) (B) Siponimod concentration response over 10-1000 nM after 7 
days, n=4 (3 technical replicates). For A & B, data represents pNPP absorbance at 405 
nm divided by cell count, relative to the positive control (osteogenic medium 
























































































replicate. ‘’n=’’ represents the number of independently repeated experiments. Data 
is presented as mean ± SD, statistical analysis by one-way ANOVA. NS: No statistical 
significance. *: p < 0.05. **: p < 0.01. ***: p < 0.001. 
3.4.3.2 Fast blue staining 
Alkaline phosphatase staining (Figure 3.4) was performed to complement the pNPP-
based assessment above. Results represent the number of stained cells divided by the 
total number of cells, expressed as a percentage. hFOB were incubated with three 
concentrations of siponimod (10, 100, and 1000 nM). The concentrations 100 nM and 
1000 nM resulted in an increased fraction of stained cells (100 nM siponimod 3.7 ± 
0.6 (p < 0.05), and 1000 nM siponimod 4.2 ± 0.8 % (p < 0.05) compared to PBS 
vehicle 1.9 ± 0.6 %) and the response was concentration dependent (F statistic = 6.53; 
p = 0.038). 
 
Figure 3.4 Alkaline phosphatase (ALP) staining as an early marker of differentiation 




replicates). Data represents the average number of manually counted Fast blue-stained 
cells divided by the total cell number. Osteogenic medium (containing 50 µg/ml 
ascorbic acid & 7.5 mM β-glycerophosphate) was used as a positive control. ‘’n=’’ 
represents the number of independently repeated experiments. Data is presented as 
mean ± SD. Statistical analysis was done using one-way ANOVA. NS: No statistical 
significance. *: p < 0.05. **: p < 0.01. ***: p < 0.001. The percentage of ALP-stained 
cells in the presence of osteogenic medium was significantly different from the 
percentage of stained cells in all other conditions (p < 0.001). B, C, and D are 
representative brightfield photomicrographs of hFOB exposed to PBS (B), 100 nM 
siponimod (C), and osteogenic medium (D); blue cells are cells with higher alkaline 
phosphatase activity, and hence a higher level of differentiation. Scale bar is 500 µm. 
3.4.4 Migration 
3.4.4.1 Wound healing (scratch) assay 
Scratch assays were performed to investigate whether the migratory response of hFOB 
and HUVEC was increased by siponimod. While hFOB did not respond to 100 nM 
siponimod after 8 hrs (Figure 3.5 A), HUVEC scratch wound closure was doubled in 
the presence of 100 nM siponimod compared to PBS vehicle (45.8 ± 4.0 % compared 
to 22.5 ± 6.0 %, p < 0.05) (Figure 3.5 B). The concentration responsiveness of the 
effect was examined in a separate series of experiments; while all siponimod 
concentrations (1, 10, and 100 nM) produced a statistically significant increase in 
scratch wound closure compared to PBS vehicle (40.9 ± 5.0 %, 42.3 ± 3.5 %, and 45.9 
± 2.9 % compared to 22.7 ± 7.2 %, p < 0.05) (Figure 3.5 C), this response was found 
to not be concentration dependent (F statistic = 2.82; p = 0.14). The migratory response 




3.5 D); 40.6 ± 3.6 % for S1P compared to 18.1 ± 3.5 % for PBS, p < 0.05. However, 
these experiments were conducted independently, precluding a direct comparison. 
 
Figure 3.5 Wound healing (scratch) assay for hFOB and HUVEC. (A) Effect of 100 
nM siponimod on hFOB, n=4 (3 technical replicates), (B) Effect of 100 nM siponimod 
on HUVEC, n=7 (3 technical replicates), (C) Siponimod concentration response over 
1-100 nM on HUVEC, n=3 (3 technical replicates); (D) Effect of 100 nM S1P on 




scratch wound after 8 hrs. ‘’n=’’ represents the number of independently repeated 
experiments. Data is presented as mean ± SD, statistical analysis by one-way ANOVA. 
*: p < 0.05. **: p < 0.01. ***: p < 0.001. E-J: Representative photomicrographs for 
the experiment shown in (B) are shown at 0 and 8 hrs: (E, H) positive control (FBS), 
(F, I) Vehicle (PBS) control, and (G, J) 100 nM siponimod. The white arrowheads at 
the top and bottom of each photomicrograph show the edge of the manually created 
scratch wound. Images were acquired using a 4x objective, scale bars are 500 µm. 
3.4.4.2 Transwell migration 
Following the data obtained from scratch wound assays, transwell migration assays 
were conducted to test the hypothesis that siponimod-enhanced migration of HUVEC 
was due to a chemotactic effect. Due to lack of scratch assay effect, hFOB were not 
investigated. 
In transwell migration assays conducted under standard endothelial growth medium 
conditions (2 % v/v serum), 100 nM siponimod added to the bottom chamber of the 
transwell system resulted in a reduction in the number of migrated cells detected on 
the bottom side of the membrane compared to PBS vehicle (26.9 ± 7.4 % compared to 
71.6 ± 10.3 %, p < 0.05) (Figure 3.6 A). 
The concentration of S1P in serum is in the submicromolar range, i.e. sufficient to 
activate S1P receptors (Thuy et al., 2014). In contrast, much lower S1P concentrations 
are detected in tissues; this S1P gradient controls the trafficking of immune and 
hematopoietic stem progenitor cells (Liu et al., 2011). To test the hypothesis that the 
“repulsive” effect of siponimod added to the bottom chamber under high serum 




blocking serum-induced cell migration, we tested the effects of S1P and siponimod 
added to the bottom chamber under reduced serum conditions (0.2% v/v serum). 
Under these conditions, 100 nM siponimod produced no statistically significant 
change in the number of migrated cells compared to PBS vehicle after 4 hrs (40.3 ± 
11.0 % compared to 33.8 ± 10.1 %) (Figure 3.6 B). S1P (100 nM) alone resulted in an 
increased number of migrated cells compared to PBS vehicle after 4 hrs (111.5 ± 19.5 
% compared to 36.2 ± 16.7 %, p < 0.05) (Figure 3.6 C). When S1P was administered 
in combination with 100 nM siponimod, the number of migrated cells was 
significantly reduced (20.4 ± 22.8 % compared to 111.5 ± 19.5 %, p < 0.05) (Figure 
3.6 C). 
We then performed transwell migration assays over 8 hrs to more closely match 
scratch assay conditions. Here 100 nM siponimod produced a statistically significant 
increase in the number of migrated cells compared to PBS vehicle (34.7 ± 7.9 % 
compared to 10.8 ± 3.3 %, p < 0.05) (Figure 3.6 D). As in the 4 hr experiment, 100 
nM S1P increased the number of migrated cells compared PBS vehicle (106.3 ± 11.9 
% compared to 10.8 ± 3.3 %, p < 0.05), an effect that was antagonised by 100 nM 
siponimod (106.3 ± 8.0 % compared to 16.8 ± 7.3 %, p < 0.05) (Figure 3.6 D). 
Migration over 24 hrs was investigated (Figure 3.6 E) and showed a substantial fall in 






Figure 3.6 Transwell migration assay for HUVEC. (A) Effect of 100 nM siponimod 
under standard growth medium conditions (2 % serum) over 4 hrs, n=4 (3 technical 
replicates) (B) Effect of 100 nM siponimod under reduced serum conditions (1/10th 
standard cell culture supplement containing 0.2 % serum) over 4 hrs, n=5 (3 technical 
replicates) (C) Effect of 100 nM S1P alone and combined with 100 nM siponimod 
under reduced serum conditions for 4 hrs, n=3 (3 technical replicates) (D) Effect of 
100 nM siponimod under reduced serum conditions over 8 hrs, n=5 (2 technical 
replicates) (E) migration over 24 hrs, n=3 (2 technical replicates. Data, presented as 
mean ± SD, represents the number of cells counted on the bottom side of a transwell 
membrane, expressed as a percentage (positive control set to 100%). ‘’n=’’ represents 
the number of independently repeated experiments. Statistical analysis by one-way 
ANOVA; ns: No statistical significance. **: p < 0.01. ***: p < 0.001. (F-I) 
Representative photomicrographs for experimental conditions shown in (D): FBS (F), 






3.4.5 Cell attachment 
To further rule out the possibility that the siponimod-induced reduction of HUVEC 
migration (Figure 3.6 A) was caused by an effect on cell attachment, we examined the 
effect of various test agents on this parameter (Figure 3.7). Alone, 100 nM siponimod 
resulted in no statistically significant change in cell attachment compared to PBS 
vehicle (67.0 ± 0.6 % compared to 58.6 ± 5.0 %). S1P (100 nM) resulted in a 
statistically significant increase in cell attachment compared to PBS vehicle (88.4 ± 
6.4 % compared to 58.6 ± 5.0 %, p < 0.05). This effect was antagonised when 100 nM 
siponimod was added with 100 nM S1P (88.4 ± 6.4 % attachment for S1P compared 
to 51.3 ± 2.7 % for siponimod/S1P, p < 0.05). Attachment in the presence of siponimod 
and S1P was not statistically different from attachment in the PBS vehicle condition 
(51.3 ± 2.7 % compared to 58.6 ± 5.0 %). 
 
Figure 3.7 Cell attachment assay for HUVEC. Effect of siponimod, S1P, and 
siponimod + S1P (all 100 nM) on cell attachment after 4 hrs incubation under reduced 
serum conditions, n=3 (2 technical replicates. Data, presented as mean ± SD, 
represents the number of cells attached to the well, expressed as a percentage (positive 
control set to 100%). ‘’n=’’ represents the number of independently repeated 




***: p < 0.001). (B-E) Representative images for experimental conditions shown in 
cell attachment assay: FBS (B), PBS (C), 100 nM siponimod (D) and 100 nM 
siponimod + 100 nM S1P (E). Scale bar: 500 µm. 
3.4.6 Cyclic AMP assay 
Intracellular cAMP was quantified in an attempt to confirm the identity of the S1P 
receptor involved and to examine potential signalling mechanisms involved in the 
response to siponimod. Results showed that after 1 hr, siponimod significantly 
inhibited forskolin-stimulated increases in intracellular cAMP (30.0% ± 22.9% for 1 
µM forskolin + 100 nM siponimod compared to 100 % ± 11.5 % for 1 µM forskolin, 
p < 0.05) (Figure 3.8). Siponimod alone did not lead to any significant change in 
baseline cAMP (12.6 ± 8.6 % for 100 nM siponimod compared to 10.2 ± 10.1 % for 
untreated control). 
 
Figure 3.8 Effects of siponimod on intracellular cAMP in hFOB. The effect of 100 
nM siponimod alone and in combination with 1 µM forskolin, n=4 (3 technical 
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presented as mean ± SD, represents the concentration of intracellular cAMP, expressed 
relative to 1 µM forskolin. ‘’n=’’ represents the number of independently repeated 
experiments. Statistical analysis by one-way ANOVA. ***: p < 0.001. 
 
3.5 Discussion 
The overall aim of these studies was to assess the suitability of siponimod as a potential 
bone regenerative agent, to be eluted by a localised delivery device to stimulate repair 
in critical bone defects. With this goal in mind, we investigated the effect of siponimod 
on osteoblast and endothelial cells proliferation, differentiation and migration. 
Primarily, it was necessary to show that solutions of siponimod, prepared using DMSO 
as a co-solvent, did not negatively impact cell viability. Therefore, experiments were 
conducted showing that the concentration of DMSO used (0.32 %) was non-toxic in 
both hFOB and HUVEC. This concurs with the literature, that a concentration less 
than 0.5 % should not impact cell viability (Shah et al., 2019). Shifting focus to the 
viability assays proper, S1P is well established in promoting endothelial cell 
proliferation, viability and survival, likely via the S1P1 or S1P3 receptors (Lee et al., 
1999b, Wang et al., 1999, Lee et al., 2000, Rikitake et al., 2002, Kwon et al., 2001). 
Therefore, the lack of proliferative effect herein, as well as siponimod’s selectivity for 
receptors 1 and 5 may indicate that the S1P3 receptor plays the more important role. 
Another possibility is that siponimod is behaving like fingolimod, which at 
concentrations below 250 nM has no effect on HUVEC viability but exhibits toxicity 
above 250 nM (Schmid et al., 2007). Siponimod also had no effect on osteoblast 




differentiation, pushing the cells towards a post-mitotic phase precluding extensive 
proliferation (Long, 2011). 
ALP is commonly used as a marker of osteoblast differentiation. Here we show that 
exposure to siponimod (but not to fingolimod) increased ALP activity, an effect 
equivalent to that seen with the same concentration of S1P. Complementary ALP 
staining showed a corresponding siponimod-induced increase in the number of stained 
cells. S1P and fingolimod have previously been shown to increase markers of 
osteoblast differentiation as well as stimulating the osteogenic differentiation pathway 
of osteoblasts (Lotinun et al., 2013, Brizuela et al., 2014, Sato et al., 2012, Matsuzaki 
et al., 2013) and mesenchymal stems cells (Pederson et al., 2008, Hashimoto et al., 
2016, Hashimoto et al., 2015, Marycz et al., 2016), but it is unclear whether S1P1, 
S1P3 or both receptor subtypes mediate these effects. Studies of S1P on osteoblast 
differentiation with receptor antagonists have shown an exclusive role for S1P3 in 
osteoblast maturation (Brizuela et al., 2014), whereas S1P1 receptors were shown to 
mediate the effect of S1P and fingolimod on osteoblast differentiation, when used in 
conjunction with BMP-2 (Sato et al., 2012). There is conflicting evidence regarding 
the effect of fingolimod, which has recently been shown to reduce markers of bone 
formation (including ALP) in osteoblasts and chondrocytes (El Jamal et al., 2019). 
This study, which is more in line with our findings with fingolimod, taken together 
with the effects presented herein for the S1P1/5 selective modulator siponimod, and the 
lack of detectable S1P5 receptor mRNA expression in pre-osteoblasts and osteoblasts 
(Roelofsen et al., 2008), suggest that S1P1 receptor stimulation plays a role in the 




S1P is known to stimulate the migration of osteoblast precursors, osteoclasts, and 
endothelial cells (Pederson et al., 2008, Roelofsen et al., 2008, Lee et al., 1999b, Lee 
et al., 2000, Ryu et al., 2002, Ohmori et al., 2001). Here we found that siponimod had 
no effect on the migration of hFOB. This lack of effect suggests that previously 
reported effects of S1P on osteoblast migration were mediated by a receptor other than 
S1P1 or S1P5, or that this effect was dependent on the differentiation stage. While both 
S1P1 and S1P2 receptors have been shown to regulate the migration of cells of the 
osteoblast lineage, they only did so in MC3T3-E1 pre-osteoblasts (Roelofsen et al., 
2008). Upon reaching cell confluence, cultures of hFOB express high levels of 
phenotypic markers associated with osteoblast differentiation (Harris et al., 1995). It 
is therefore possible that the cells used in our studies were more differentiated than the 
pre-osteoblasts known to migrate in response to S1P, although the relatively small 
fraction of cells expressing ALP in our studies, even after one-week exposure to 
osteogenic medium, would seem to argue against this explanation, leaving open the 
possibility that species differences may account for the discrepant migration response 
in hFOB (of human origin) and in murine MC3T3-E1 cells. Our studies did however 
show a significant effect on endothelial cell migration, doubling HUVEC cell motility 
in scratch assays. The effect of siponimod was found to be similar to that of S1P (Lee 
et al., 1999b, Lee et al., 2000, Ryu et al., 2002, Ohmori et al., 2001). However, the 
extent of this response did not seem to depend on siponimod’s concentration (1-100 
nM). It is possible that a concentration response relationship may have emerged with 
further independent experiments. Alternatively, the effect may already have been 
maximal at 1 nM siponimod, reaching a plateau thereafter. Indeed, siponimod is a 





assays (Lukas et al., 2014, Gergely et al., 2012). However, while siponimod is often 
tested at 100 nM in published functional cell culture experiments (Gentile et al., 2016, 
Lupino et al., 2019), we found only two reports showing a concentration response 
curve in such preparations, in which siponimod mediated a response with an EC50 of 
15.8 nM (Gergely et al., 2012) and only showed a non-significant trend at 1 nM 
(O'Sullivan et al., 2016). 
In transwell assays designed to test whether the effect of siponimod in the scratch 
assay was due to increased chemokinesis or to chemotaxis, siponimod decreased the 
migration of endothelial cells under standard growth medium conditions (2% v/v 
serum). We hypothesized that siponimod may have internalized S1P receptors, 
blocking the effect of S1P present in the growth medium. Indeed, when transwell 
assays were conducted under low serum conditions (0.2% v/v serum), siponimod had 
no significant effect on cell migration, and S1P stimulated endothelial cell migration 
in a siponimod-sensitive manner and as effectively as serum. 
To understand how siponimod interfered with S1P-mediated transwell migration, cell 
attachment studies performed under similar conditions to the transwell assays showed 
that siponimod interfered with S1P-mediated increases in cell attachment over 4 hrs. 
It is therefore possible that decreased cell attachment may have contributed to the 
reduced transwell migration observed after 4 hrs. Given that the effect of siponimod 
in scratch assays was determined over 8 hrs, additional 8 hrs transwell assays were 
conducted and showed that while siponimod still antagonised S1P mediated migration, 
it also induced a statistically significant increase in cell migration when added on its 




persistent signalling after internalisation of the S1P1 receptor (Mullershausen et al., 
2009), which may only lead to migration after long exposure (8 hrs) to siponimod, but 
not after 4 hrs, and may also indicate that siponimod behaves similarly to fingolimod, 
which has been shown to induce cellular motility in scratch assays (Mullershausen et 
al., 2009) but impede HUVEC migration across a membrane (Ho et al., 2005, 
LaMontagne et al., 2006, Tanaka et al., 2013). The same experiments were conducted 
over 24 hrs, however the substantial drop in the number of cells migrating indicated 
that the extended experimental duration under low serum conditions may have 
impacted HUVEC viability. 
The role of intracellular cAMP in bone remodelling and bone cell differentiation has 
long been known (Rodan et al., 1975), but the relationship is complex. While some 
early studies have shown that parathyroid hormone stimulate the in vitro 
differentiation of osteoblasts via intracellular cAMP production (Nakatani et al., 
1984), other reports show that the influence of cAMP on ALP expression changes 
depending on the stage of osteoblast differentiation, and parathyroid hormone may 
preferentially inhibit the differentiation of more mature osteoblasts (Isogai et al., 
1996). Expanding on the complexity of the relation between cAMP and osteoblast 
differentiation markers, increasing levels of cAMP have been shown to result in 
decreased ALP but increased osteocalcin expression (Romanello et al., 2001). More 
recently, increasing cAMP levels have been shown to suppress osteoblast 
mineralisation (Nishihara et al., 2018). Forskolin-induced cAMP is known to be 
inhibited by both S1P and fingolimod after 1 hr incubation (Mullershausen et al., 
2009), with results similar to those shown for siponimod. This effect is most likely 




mechanism through which S1P and fingolimod produce the same inhibitory effect. 
Based on the somewhat contradictory existing literature, it is not straightforward to 
provide a mechanism linking the adenylate cyclase inhibiting effect of siponimod on 
our hFOB and the effects of this agent on hFOB cell differentiation. However, we 
hypothesize that siponimod may maintain a chronically low level of intracellular 
cAMP through its interaction with S1P1 receptors, resulting in increased ALP activity, 
indicative of increased osteoblast differentiation.  
Fingolimod, and now siponimod, both antagonise the chemotactic effect of S1P on 
endothelial cells. Fingolimod has shown proangiogenic effects in vivo, ultimately 
improving recovery of bone defects (Huang et al., 2012, Li et al., 2019b). Therefore, 
given siponimod’s effect on osteoblast differentiation, it may be useful to incorporate 
siponimod into a localised delivery device to investigate the effects of siponimod in 
vivo towards the same end.  
One of the limitations of the current study is that it does not consider osteoclasts, or 
the coupling between osteoblasts and osteoclasts (Pederson et al., 2008). This 
communication is known to involve S1P receptors and would likely impact 
significantly on healing outcomes in any potential in vivo studies. Also, our ALP 
staining studies showed that the total fraction of stained cells was relatively small, 
being less than 10% of the total number of cells. This may be due to the use of a 
relatively early time point for analysis (7 days). Conducting the experiment over a 
longer duration, more consistent with the effect of a drug eluting scaffold (Das et al., 





The aim of this work was to investigate the potential of siponimod in a bone 
regenerative context, ultimately towards its use in conditions of critical bone defects, 
as part of a localised delivery device, but improving on the specificity of the eluted 
drug (Das et al., 2014a, Das et al., 2014b, Huang et al., 2012, Li et al., 2019b). These 
studies add to the relatively small amount of literature on the functional effects of 
siponimod in cell culture models. In the context of bone repair, the differentiation 
effect of siponimod on osteoblasts, taken together with its effects on endothelial cells 
suggest that this selective S1P1 modulator may be useful, particularly in conditions of 
critical defects that remain a significant therapeutic challenge. However, more robust 
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Sphingosine 1-phosphate (S1P) receptor modulators can influence bone regeneration 
owing to their positive impact on osteoblast differentiation, and neovascularisation. 
While previous studies have utilised non-specific S1P and fingolimod, this study aims 
to design and characterise a controlled release vehicle to deliver the specific S1P1/5 
receptor modulator siponimod and test its effectiveness in rat critical cranial defects. 
Electrospun scaffolds of PLGA were loaded with siponimod at drug:polymer mass 
ratios of 0.5:100 to 2:100. Where indicated, collagen was co-spun at collagen:polymer 
mass ratio of 2:100. Thereafter, scaffolds underwent in vitro physicochemical 
characterisation and in vivo assessment using a rat cranial defect model. Drug-loaded 
scaffolds showed controlled release of siponimod, biocompatibility with endothelial 
and osteoblast growth in vitro, and furthermore, showed that released siponimod 
stimulated osteoblast differentiation and endothelial cell migration. The in vivo cranial 
defect repair study showed regeneration was occurring in the defect, although there 
was no significant difference in the extent of mineralisation between scaffold 
experimental groups. To our knowledge, this is the first study investigating siponimod 
bone regeneration. In vitro studies confirm a positive impact on key cells involved in 
bone regeneration, however, the scaffolds did not result in significant repair of critical 








Autograft and allograft procedures are gold standard treatments for non-union defects, 
however they present a number of challenges including limited supply, donor site 
morbidity and the potential for disease transmission (Schlickewei et al., 2019). This 
has made the search for alternative replacement materials an active field of research 
(Laurencin et al., 2006). Ideally, a replacement material should not only provide a 
structural substrate for new bone cells to grow on, its degradation should be 
contemporaneous with new bone growth and it should provide appropriate cues to 
stimulate bone formation (Ahern et al., 2013). 
Developing replacement materials that more closely mimic the natural bone 
environment and are thus more conducive to bone growth has focused on the addition 
of agents (chemical or biological) that induce or support bone regeneration. Potent, 
osteoinductive signalling molecules including the growth factor BMP-2 have attracted 
much attention in stimulating bone regeneration (Bal et al., 2020). Indeed BMP-2 has 
been used clinically to treat bone defects, although the use of supraphysiological doses 
and the rapid release from collagen scaffolds has resulted in abnormal bone formation 
(Krishnan et al., 2017). Strategies to address this problem have focused on better 
delivery modalities to enable control over the temporal presentation of BMP-2, 
thereby enabling lower doses to be administered (Kolambkar et al., 2011). More 
recently, alternative signalling molecules such as S1P, have been the object of 
increasing attention in the context of bone regeneration (Sartawi et al., 2017, 
Meshcheryakova et al., 2017). S1P is a lipid mediator that modulates calcium 




organization (Spiegel and Milstien, 2000), and acts via five known G Protein-Coupled 
Receptors (S1P1-5), which are widely expressed throughout the body (Hla, 2004).  
In the context of bone regeneration, S1P receptor modulation has been shown to 
improve outcomes in murine studies of bone defects, ostensibly by supporting 
vascularization and chemotaxis of specific cellular contributors to bone repair (Huang 
et al., 2012, Das et al., 2013, Das et al., 2014b, Wang et al., 2016a, Das et al., 2015, 
Das et al., 2014a). However, S1P and the analogue fingolimod act at several of the 
known S1P receptor subtypes, and much medicinal chemistry effort has been 
dedicated to developing more selective modulators, in particular for the S1P1 receptor 
(Marciniak et al., 2018). Although several S1P receptor subtypes are involved in bone 
physiology, there is evidence that S1P1 receptor modulation, and the newly developed 
S1P1/5 selective agent siponimod, may be advantageous in the context of bone repair 
(Sartawi et al., 2017). Siponimod (Mayzent®), was developed for secondary 
progressive multiple sclerosis (Behrangi et al., 2019), in response to side effects 
associated with the less selective agent fingolimod (DiMarco et al., 2014, Cugati et 
al., 2014, Gergely et al., 2012). Our own in vitro data has shown that siponimod 
increases endothelial cell chemokinesis and enhances pre-osteoblast differentiation 
(Sartawi et al., 2020a); these effects appear to be mediated through siponimod’s 
interaction with the S1P1 receptor.  
Previous research investigating S1P mediators has shown the importance of the 
method of administration in achieving bone regeneration. Systemic administration of 
fingolimod does not improve fracture healing (Heilmann et al., 2013), whereas 




based scaffold methodologies (Sefcik et al., 2008, Das et al., 2014b, Petrie Aronin et 
al., 2010a) resulted in significant increases in bone volumes in a cranial defect model 
(Das et al., 2014b). Scaffolds are a fundamental pillar in tissue engineering, and the 
materials from which they are composed impact on the scaffold’s degradation, 
controlled release of drug cargoes and interaction with the host tissue (Rezwan et al., 
2006, Roseti et al., 2017). Biomaterials commonly investigated for bone tissue 
engineering include natural and synthetic polymers, inorganic ceramics including 
calcium phosphates and bioactive glass, as well as ceramic-polymer composites 
(Iaquinta et al., 2019, Henkel et al., 2013). From a materials perspective, polymer-
based approaches are interesting due to their low cost and biodegradability over 
clinically relevant times frames. Synthetic polymers including PLGA are 
advantageous due to their solubility in common solvents, and their well-documented 
degradation properties (Gentile et al., 2014) and have been used to prepare controlled 
release protein therapies for bone regeneration (Fu et al., 2008, Lee et al., 2013) or 
implantable scaffolds pre-seeded with stem cells to stimulate regeneration (Zong et 
al., 2010). However, many synthetic materials are hydrophobic and do not readily 
promote cellular attachment. Efforts to overcome these limitations have included 
fabrication of scaffolds with components that more closely resemble the extracellular 
environment (structural proteins, glycosaminoglycans) and which act to enhance cell-
matrix interactions (Alsberg et al., 2002, Silva et al., 2020). The organic component 
of bone is primarily composed of type I collagen and consequently this biomaterial 
has been used in bone regeneration applications (Cen et al., 2008). The utilisation of 
relatively small quantities of collagen can result in significant changes to osteoblast 




2007). Furthermore, electrospun fibres of synthetic materials developed with the 
addition of collagen have been shown to stimulate gene expression associated with 
osteogenic differentiation of stem cells (Balaji Raghavendran et al., 2014). 
This study focused on an implantable PLGA-based scaffold for the controlled delivery 
of siponimod to enhance bone regeneration. We investigated the design of a scaffold 
system using electrospinning technology to achieve temporal control over drug 
release, and whether the incorporation of collagen would help to address limitations 
associated with hydrophobic polymer materials, and thereby enhance cellular 
interactions at the scaffold interface. Scaffolds were physicochemically characterised 
to understand important changes to morphological, chemical, and physical attributes 
caused by the formulation process, and the addition of siponimod and collagen. In 
vitro studies were carried out using osteoblast and endothelial cells to determine the 
potential of the scaffold composites to influence key cell processes implicated in bone 
regeneration, in particular cell proliferation, differentiation and migration. Finally, we 
investigated the ability of selected siponimod, fingolimod, and drug-free scaffolds to 





4.3 Materials and methods 
4.3.1 Materials 
Electrospinning materials included: poly (D, L-lactide-co-glycolide) Resomer® RG 
858 S (Evonik Industries, Germany), collagen type I (Elastin Products Company, 
USA), 1,1,1,3,3,3-Hexafluoro-isopropanol (Fluorochem, UK), chloroform and N, N-
dimethylformamide (Sigma Aldrich, USA). Siponimod hemifumarate was kindly 
gifted from Novartis (Basel, Switzerland). 
Dimethyl sulfoxide (DMSO), L-ascorbic acid, ß-glycerophosphate, Dulbecco’s 
phosphate buffer saline (PBS), foetal bovine serum (FBS), L-glutamine solution, 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM/F12), 
Thiazolyl Blue Tetrazolium Bromide (MTT), neutral buffered formalin (NBF), Fast 
Blue BB, Naphthol AS-MX phosphate, magnesium chloride (MgCl2), sodium chloride 
(NaCl2), Tween
® 20, and tris(hydroxymethyl)aminomethane (Tris-HCl) were 
acquired from Sigma Aldrich. Pierce™ pNPP Substrate Kit was acquired from 
Thermo Fisher Scientific, USA. Human umbilical vein endothelial cells (HUVEC) 
and their growth medium (ECGM) with associated supplements were acquired from 
PromoCell, Germany. The human foetal osteoblast cell line hFOB 1.19 was acquired 
from ATCC (ATCC® CRL-11372™). Cell culture plasticware was acquired from 
Sarstedt Ltd, Germany. Buprenorphine, bupivacaine, and isoflurane were purchased 
from Abbeyville Veterinary Hospital, Cork, Ireland. 
4.3.2 Electrospinning procedure 
Solutions of PLGA (85:15) were formulated as 8% w/w preparations in a mixture of 




hexafluoroisopropanol (HFIP) was used as the solvent in the case of collagen-
containing samples. Reagents were dissolved in glass vials overnight at 4 °C. Prior to 
starting the electrospinning process, solutions were equilibrated to room temperature 
to avoid viscosity changes. For siponimod loaded preparations, mass ratios of 
siponimod:PLGA 0.5:100, 1:100 and 2:100 (henceforth termed Si n:100, where ‘n’ 
indicates the ratio of siponimod in samples) were prepared in vials as before. The 
fingolimod loaded sample used exclusively in vivo was prepared in the same way, as 
fingolimod:PLGA 0.5:100 (henceforth termed Fi 0.5:100). Collagen was incorporated 
into samples of Si 0.5:100 at a mass ratio of 2:100 of the polymer resulting in samples 
termed SiCol 2:100. The electrospinning set-up consisted of a Spraybase® (Spraybase, 
Ireland) electrospray instrument kit (CAT000002), and an AL-2000 syringe pump 
(World Precision Instruments, USA). Sample solutions were decanted into a 10 mL 
glass syringe. The solutions were then primed in 1 mm diameter tubing connecting the 
syringe to the emitter nozzle (0.9 mm diameter). The syringe pump was set at a flow 
rate of 0.75 ml/h. A stainless-steel collection dish was covered in commercial 
aluminium foil and placed at a working distance of 15 cm from the emitter nozzle. A 
voltage of 16 kV was then applied, with samples processed continuously until a set 
volume of sample solution was dispensed. Collected samples were stored in the fume 
hood overnight to allow evaporation of any remaining solvent. Samples were then 
used immediately or stored at -20 °C. 
4.3.3 Scanning electron microscopy 
Images were acquired using a JEOL JSM-5510 Scanning Electron Microscope (SEM). 
Samples were mounted on stubs with double sided carbon tape and sputter-coated with 




spot size 20-25, 3-5 kV accelerating voltage, and magnification 4000x were used. 
Images were analysed using the Olympus Stream software (Mason Technology Ltd, 
Ireland) to investigate fibre morphology and acquire fibre diameter data. 2-4 images 
were captured per sample with 25 individual fibre measurements per image. 
4.3.4 HPLC methodology 
Liquid chromatography was used to detect and quantify the concentration of 
siponimod in the upcoming sections, the high pressure liquid chromatography (HPLC) 
method is detailed here. The protocol used an Agilent Technologies 1120 Compact 
LC instrument (max= 278 nm), the stationary phase consisted of a Zorbax Eclipse 
Plus C18 column (4.6 x 150 mm, 5 m). The mobile phase was composed of 
acetonitrile and water at a ratio of 65:35, supplemented with formic acid 0.5% v/v (pH 
≈ 3.0), and operating conditions included a flow rate of 1.2 ml min-1 and an injection 
volume of 10 µl. UV spectrometry of siponimod solutions was used to determine peak 
absorbance at 278 nm. 
4.3.5 Siponimod stability  
The stability of solutions of siponimod was monitored over 12 weeks at 4 °C and at 
37 °C. Solutions of siponimod were prepared in PBS (pH 7.4) and placed either in a 
refrigerator at 4 °C or a water bath set to 37 °C. At defined time-points over the 12-
week experimental period, 50 µl samples were taken and stored at -20 °C until HPLC 
analysis. The concentration of siponimod detected in solution over time was used as a 
measure of its stability in solution. 
The stability of siponimod in the polymer formulations was ascertained at 4 and 12 




(refrigerator), 20 °C (room temperature) and 37 °C (laboratory oven). The 
concentration of siponimod remaining in a scaffold sample was determined by 
disintegrating samples of known mass in HPLC mobile phase to release total 
siponimod content. The calculated drug content was divided by the drug loading 
values of freshly prepared samples, giving a percentage of the initial siponimod 
concentration. 
4.3.6 Loading efficiency and drug release 
For in vitro siponimod release, electrospun samples of known initial mass (1.5-2.5 mg) 
were placed in 1.5 ml plastic sample tubes and incubated in 1 ml PBS at 37 °C under 
gentle shaking (40 revolutions per minute (RPM)) in a GLS aqua 12 plus water bath 
(Grant Instruments, UK), the volume was sufficient to achieve sink conditions. The 
samples investigated included three samples of increasing siponimod concentration 
(Si 0.5:100, Si 1:100, and Si 2:100, all of which were prepared using CLF/DMF). In 
addition, two samples prepared in HFIP were investigated in a similar manner (Si 
0.5:100, and SiCol 0.5:100) in order to explore both the impact of collagen addition 
between Si 0.5:100 (HFIP) and SiCol 0.5:100, and the impact of using different 
solvents by comparing Si 0.5:100 (CLF/DMF) and Si 0.5:100 (HFIP). The complete 
release medium was collected at defined time-points over a 12-week period and stored 
at -20 °C prior to analysis. An equal volume of fresh PBS medium was replaced in the 
sample vial. Samples were vacuum-dried overnight, and the residue re-dissolved in 




4.3.7 Differential scanning calorimetry (DSC) 
In order to investigate any changes in the thermal properties of the polymeric 
constituent of the scaffolds due to processing, residual solvent, or drug loading, 
electrospun samples underwent thermal analysis using a TA Q1000 differential 
scanning calorimeter (TA instruments, USA). All samples were run using modulated-
DSC (MDSC) in aluminium pans (DSC Consumables, USA), using the following 
settings: modulation temperature amplitude ± 1.0 °C, modulation 60 seconds, ramp 
rate 3 °C/min and a temperature range of 0-150 °C.  
4.3.8 Fourier Transform Infra-red (FTIR) spectroscopy 
To analyse the molecular spectra of electrospun scaffolds containing siponimod and 
collagen, solid samples and starting materials were subject to FTIR analysis using a 
PerkinElmer Spectrum Two spectrometer. Measurements were performed at 4 scans 
per spectrum between 4500 cm-1-400 cm-1 at a resolution of 4 cm
-1.  
4.3.9 Contact angle 
Contact angle goniometry was conducted using an optical tensiometer (Biolin 
Scientific, Sweden). Samples of electrospun PLGA, Si 0.5:100, and SiCol 2:100 (8 
mm diameter) were immobilised on a glass slide using double-sided carbon tape. 
MilliQ water (7-10 µl) was dropped onto the sample surfaces and images were 
acquired at 7.6 frames per second for 30 seconds. Using the associated Attension 
software (Biolin Scientific, Sweden), the average contact angle was acquired across ≈ 




4.3.10 Tensile strength 
Electrospun samples (8 mm diameter and 0.5 mm thickness) were cut out with a 
commercial paper punch and loaded into miniature tensile grips. Prior to testing, the 
device was calibrated with a 100 g standard mass. Tensile strength of fibrous samples 
was acquired by pulling samples apart at a rate of 0.5 mm/sec until failure. The 
ultimate tensile strength was recorded for each sample (n=3) using the Exponent 
software (Stable Micro Systems, UK). 
4.3.11 Biological characterisation and in vitro functional experiments 
4.3.11.1 Cell culture 
hFOB were maintained in DMEM/F12 supplemented with FBS (10%), L-glutamine 
(1%), and penicillin-streptomycin (1%) at 34 °C and 5 % carbon dioxide (CO2). 
HUVEC were maintained in ECGM as per supplier’s recommendations at 37 °C and 
5 % CO2. All experiments were conducted within 10 passages for HUVEC and within 
20 passages for hFOB. 
4.3.11.2 Evaluation of metabolic activity 
4.3.11.2.1 Indirect assessment 
The metabolic activity of cells indirectly exposed to electrospun samples was 
evaluated in order to determine the impact of eluted compounds on cells in close 
proximity to the scaffold. PLGA, Si 0.5:100, and SiCol 0.5:100 samples were cut out 
using a commercial paper punch (8 mm diameter) and sterilised by UV irradiation for 
2 hrs. Thereafter, samples were added to 24 well plates pre-seeded with 5*104 
cells/well of hFOB or HUVEC. The samples were incubated with the cells for 5 days, 




5 days, the scaffolds were removed and 60 µl thiazolyl blue tetrazolium bromide (5 
mg/ml solution) was added directly to 600 µl of cell culture medium for 2 hrs. 
Resultant formazan crystals were solubilized with 600 µl DMSO. 100 µl of each well 
was transferred to a 96-well plate to measure absorbance at 570 nm using a Wallac 
Victor2 plate reader (Perkin Elmer, USA). 
4.3.11.2.2 Direct assessment 
The metabolic activity of cells directly seeded on electrospun samples was evaluated 
in order to determine the impact of physical, chemical and mechanical properties of 
the composite scaffold on hFOB cell behaviour. As above, 8 mm diameter samples of 
PLGA, Si 0.5:100, and SiCol 0.5:100 were cut out and UV-sterilised. The scaffolds 
were fitted to the base of 96-well plates replacing the original growth surface and 
hFOB (5*104 cells in 70 µl) were seeded directly onto the polymer surface for 10 mins 
before topping up with an additional 130 µl of medium. Incubation continued for 5 
days, with culture medium changed every other day. On days 1, 3, and 5 media was 
replaced with a combination of 100 µl of medium and 10 µl of resazurin (560 µM 
stock solution). After 3.5 h, 90 µl from each well was transferred to a new plate for 
fluorescent plate reading at excitation 488 nm/emission 595 nm. 
4.3.11.3 Haematoxylin and Eosin staining 
Samples used in the resazurin assay described above were subsequently fixed in 
neutral buffered formalin, embedded in Shandon™ M-1 Embedding Matrix (Thermo 
Fisher Scientific, USA) and frozen. Sections (20 µm) were cut using a Leica CM1900 
cryostat microtome (Leica Biosystems, Germany). In brief, staining was performed 




Olympus BX51 microscope and associated Olympus Stream software, images of 
stained sections were acquired using an extended depth of focus image and a 10x 
objective. 
4.3.11.4 Cell differentiation 
Electrospun samples (8 mm diameter) of PLGA, Si 0.5:100, Si 2:100, and SiCol 
0.5:100 were added to wells pre-seeded with hFOB at densities of 5*104 cells/well. 
Cells were incubated with the electrospun scaffolds for 7 days and culture medium 
was changed every other day. Differentiation of hFOB incubated in osteogenic 
medium containing 50 μg/ml ascorbic acid and 7.5 mM β-Glycerophosphate was used 
as a positive control (Bozycki et al., 2018). After 7 days, electrospun samples were 
removed and cells were detached using 100 µl of 0.25 % trypsin and resuspended with 
an additional 200 µl of cell culture medium. Cell numbers for each well were then 
determined using a haemocytometer. To determine alkaline phosphatase (ALP) 
activity, a solution of para-nitrophenylphosphate (pNPP) was added to the remaining 
cells, resultant paranitrophenyl formation was monitored at 405 nm with a Wallac 
Victor 2 plate reader (Perkin Elmer, USA). Absorbance values were then normalised 
against cell counts for each individual well. 
Osteogenic differentiation of hFOB incubated with electrospun scaffolds was also 
confirmed by staining for ALP. In brief, 5*104 hFOB were seeded in 24-well plates 
and incubated with electrospun scaffolds or osteogenic medium for 7 days. Thereafter, 
cells were equilibrated in 100 mM Tris-HCL pH 8.2, 100 mM NaCl, 0.1 % Tween® 
20, and 50 mM MgCl2, followed by incubation with a solution containing Fast blue 




were acquired per well (with a 4x objective). Using ImageJ analysis software 
(Schneider et al., 2012), both the number of stained and unstained cells were manually 
counted, and the number of stained cells expressed as a percentage of the total cell 
number. 
4.3.11.5 HUVEC Cell migration 
Siponimod has been found to influence the migration of endothelial cells (HUVEC) 
(Sartawi et al., 2020a). Therefore, in order to demonstrate the functionality of 
siponimod released from scaffolds, electrospun PLGA, Si 0.5:100, Si 2:100, and SiCol 
0.5:100 were incubated in cell culture medium for 16 hrs to precondition medium. 
Thereafter, 8 µm pore polyethylene terephthalate transwell migration inserts (Sarstedt, 
Germany) were set-up and seeded with 5*104 HUVEC. Following 8 hrs incubation, 
cells were fixed with 10 % neutral buffered formalin for 15 mins, then stained with 
0.5 % crystal violet for 30 mins. A cotton swab was used to remove non-migrated cells 
from the top side of the insert membrane. The bottom side of the membrane was 
visualised using a BX51 microscope and images (5 per insert) acquired using a 10x 
objective and associated Stream software. The images were used to manually count 
the number of cells on the bottom of the membrane, which were recognised as 
migrated cells. 
4.3.12 In vivo critical cranial defect 
4.3.12.1 Surgical procedure and scaffold implantation 
The critical cranial defect was generated based on a previously published method 
(Spicer et al., 2012), and the procedure was approved by the Animal Experimentation 




Authority of the Republic of Ireland (AE19130/P093). The investigators were first 
blinded to the nature of the experimental groups, and the different groups were then 
randomly allocated to the animals using Microsoft Excel random number generator. 
Blinding was maintained throughout the 12-week duration of the study and euthanasia, 
and subsequently during data collection and analysis.  
In brief, 11-week old male Sprague-Dawley rats (n=30) (Envigo RMS Ltd, UK) were 
anesthetised by isoflurane gas inhalation and given subcutaneous injections of 
buprenorphine (0.05mg/kg) for perioperative pain, and bupivacaine 0.25 % w/v (0.1 
ml) for local anaesthesia. A 1.5 cm incision was made exposing the coronal, sagittal, 
and lambdoidal sutures. The calvarium was scored using a 78001 microdrill (RWD 
Life Science, China) with an 8 mm diameter trephine. The microdrill headpiece was 
then replaced with a 1 mm burr attachment to thin the bone until a full thickness cut 
through the calvarium was achieved. Thereafter, the following electrospun samples of 
with masses of approximately 1.5 mg) were inserted into the defect and manually 
shaped and moulded to defect edges (n=6 per condition): PLGA, Si 0.5:100, Si 2:100, 
SiCol 0.5:100, and Fi 0.5:100, with the fingolimod loaded sample acting as a positive 
control (Huang et al., 2012). All scaffolds had been sterilised by UV irradiation for 2 
hrs and were only exposed to the surgical suite environment immediately prior to 
insertion. 
The incision was then sutured and cleaned with iodine and saline. Thereafter, animals 
were moved to heating pads and monitored until alert. Animals were assessed daily 




behaviour, and wound healing. Animals whose score exceeded a predetermined 
acceptable level were euthanised, as were any animals exhibiting haemorrhage. 
4.3.12.2 Administering Fluorescent labels, euthanasia, and histology 
One and three weeks after surgery, rats were given subcutaneous injections of alizarin 
25 mg/kg and calcein green 25 mg/kg (both were dissolved in 1.26 % w/v sodium 
bicarbonate solution), respectively. It was anticipated that fluorescent micrographs of 
alizarin and calcein would be used to determine differences in the rate of calcium 
deposition in the defect area by measuring the area between the fluorescent 
mineralisation fronts at weeks 1 and 3. However, we failed to observe alizarin-stained 
tissue in experimental tissue. Alizarin staining is therefore no longer mentioned in this 
paper. 
Twelve weeks after surgery, rats were euthanised by CO2 asphyxiation and confirmed 
by cervical dislocation. The cranium was then extracted and immediately added to 25 
mL neutral buffered formalin for 48 hrs fixation, followed by an additional 72 hrs in 
70 % ethanol. Upon embedding in methyl methacrylate, samples were sectioned 
transversely to produce 5 µm thickness undecalcified bone samples. These were then 
stained using von Kossa (VK) and Masson-Goldner (MG) trichrome, to determine the 
extent of mineralisation, osteoid formation and entrapped osteocytes. Briefly, VK 
samples were submerged in 1 % silver nitrate for 45 mins under a 100-watt tungsten-
halogen bulb at a distance of 20 cm, followed by 5 mins in 3 % sodium thiosulfate, 
and finally counterstained for 5 mins with van Gieson stain. Black/brown stained areas 
were representative of mineralised bone tissue. For MG trichrome, samples were 




Fuchsin solution, and 7 mins in phosphotungstic acid. The resulting green stained area 
represented mineralised tissue, while areas stained red were representative of osteoid. 
Fluorescent micrographs of unstained sections were used to detect calcein 
fluorescence, this was acquired with the application of a green fluorescent protein 
(GFP) optical filter. 
Light microscope images were acquired using a BX51 microscope, the images were 
analysed using MCID Core 7.1 software (Interfocus Imaging, UK). The extent of 
mineralisation within the defect area was determined using the VK and MG stained 
sections by measuring the area of the black stained tissue for VK, and the area of green 
stained tissue for MG. Furthermore, MG stained sections were used to manually 
enumerate osteocytes within the defect area using 4 images per section. The images 
were acquired at a higher magnification (20x objective), and within each image an 
area of approximately 0.31 mm2 was used to manually enumerate cells. As mentioned 
earlier it was anticipated that fluorescent labels would be used to determine differences 
in the rate of calcium deposition in the defect area by measuring the area between the 
fluorescent mineralisation fronts at 1 and 3 weeks. With the absence of alizarin, calcein 
labelling alone was used by measuring the area between the edge of the initial defect 
and the 3-week fluorescent calcein signal, and from that point to the 12-week position 
of the mineralisation front.  
4.3.13 Statistical analysis 
Results are expressed as mean ± standard deviation (SD), unless otherwise stated. 
Statistical analysis was performed using one-way analysis of variance (ANOVA) 




analysis was required, Kruskal-Wallis followed by Dunn’s multiple comparisons tests 
were used to determine statistical significance. In all cases differences were considered 
significant at p < 0.05. 
4.4 Results 
4.4.1 Properties of electrospun fibres 
Electrospinning was used to produce randomly aligned, fibrous constructs containing 
siponimod and collagen, as shown in Figure 4.1. The diameter of individual fibres of 
PLGA, Si 0.5:100, and SiCol 0.5:100 was measured using acquired SEM images. 
There was no statistically significant difference in fibre diameter distribution between 
unloaded PLGA samples (0.93 µm; 0.47 µm) and siponimod loaded Si 0.5:100 (0.92 
µm; 0.53 µm), (diameters given as median diameter; interquartile range). However, 
the diameter of SiCol 0.5:100 fibres (0.56 µm; 0.32 µm) was significantly lower than 








Figure 4.1 Fibre size distribution (A) PLGA (B) Si 0.5:100(C) SiCol 0.5:100. Image 
magnification 2000x (10 µm scale bar). Histograms represent the frequency 
distribution of fibre diameters as determined by manual measurements taken from 
SEM images (3 batches of electrospun material, 2-4 images per batch, 25 individual 
fibre measurements per image). Inset values represent the median and interquartile 
range. Statistical analysis of (A, B, and C) involved Kruskal-Wallis followed by 
Dunn’s multiple comparisons tests to determine statistical significance. 
4.4.2 Siponimod stability 
The concentration of siponimod solutions was monitored at defined intervals over a 
90 day period. HPLC analysis showed that at physiological temperatures (37 °C), 
siponimod solution concentration was 35.9 ± 1.6 % of initial concentration after 90 
days (Figure 4.2A). At 4 °C, the siponimod solution concentration was 81.0 ± 2.0 % 
of initial concentration after 90 days. 
Loading efficiency was ascertained by HPLC (Table 4.1), with samples exhibiting 
drug loading efficiencies ranging from 80-94 % of theoretically ideal loading. In most 
cases there was no differences between the different scaffolds, however there was a 
statistically significant difference in loading efficiency between Si 0.5:100 (HFIP) 
(80.7 ± 1.8 %) and Si 2:100 (91.7 ± 2.2 %, p<0.05), as well as between Si 0.5:100 
(HFIP) and SiCol 0.5:100 (93.9 ± 6.1 %, p<0.01). Freshly prepared Si 0.5:100 samples 
showed an average loading efficiency of 88.0 ± 4.7 % and were used as a baseline to 
compare the solid-state stability of incorporated siponimod after storage for 4 and 12 







Table 4.1 Loading efficiency of electrospun samples as determined by HPLC. Data 
represents the concentration of solutions prepared by dissolving scaffolds of known 








Si 0.5:100 (HFIP) 80.7 1.8 
Si 0.5:100 (CLF/DMF) 88.0 4.7 
Si 1:100 89.4 0.5 
Si 2:100 91.7 2.2 
SiCol 0.5:100 93.9 6.1 
SiCol 2:100 84.2 1.2 
 
Change in siponimod concentration in the stored samples relative to the freshly 
prepared sample are shown in Figure 4.2B. After 4 weeks, drug concentration in 
polymer samples was 93.2 ± 4.7 % at -20 °C, 91.4 ± 4.9 % at 4 °C, 87.0 ± 4.8 % at 20 
°C, and 83.6 ± 4.5 % at 37 °C, none of which were significantly different from each 
other. After 12 weeks the drug concentrations in the samples were 93.6 ± 3.0 % at -20 




drug concentration at 37 °C being statistically significantly lower than values at other 
storage temperatures (p<0.05).  
4.4.3 Drug release  
Release studies showed electrospun samples controlled the release of siponimod over 
the experimental timeframe (Figure 4.2C and D). Figure 4.2C shows the results of 
siponimod release from formulations prepared with and without collagen and 
compares the release from formulations prepared using different solvents, HFIP and 
CLF/DMF. The correlation between cumulative drug release profiles and zero-order 
release was indicated by R2 value. The zero-order equation for fitting the data was 
Ct=k0*t where Ct is cumulative drug release at time t, and k0 is the zero-order release 
constant. 
The presence of collagen had no statistically significant effect on the drug release 
profile over the 90 day release period, and at day 90 drug release corresponded to 41.0 
± 0.6 % for Si 0.5:100 (HFIP) (R2= 0.99) and 43.1 ± 0.6 % for SiCol 0.5:100 (R2= 
0.99) samples. There was a significant difference in siponimod release from samples 
prepared with HFIP compared to those prepared with CLF/DMF. Samples prepared 
using CLF/DMF produced biphasic release profiles and siponimod release was higher 
over the entire 90 day release period with 57.7 ± 0.25 % release at day 90 (Si 0.5:100 
(CLF/DMF)) (R2 = 0.88), compared to the result for Si 0.5:100 (HFIP) shown above.  
The impact of increased drug loading on release behaviour was also assessed using 
samples Si 0.5:100, Si 1:100, and Si 2:100, all of which were prepared using 
CLF/DMF. Comparison of the profiles (Figure 4.2D) showed similar biphasic release 




± 0.25 % for Si 0.5:100 (R2= 0.88), 48.3 ± 0.5 % for Si 1:100 (R2= 0.75), and 51.5 ± 
0.1 % for Si 2:100 (R2= 0.79). The apparent biphasic nature of the release profiles for 
CLF/DMF samples can be described by more rapid drug release up to day 30, which 
is then followed by a controlled, linear release profile thereafter. 
Following the terminal sampling point in all release studies, samples were 
disintegrated, and the remaining drug was dissolved in HPLC mobile phase to measure 
the remaining entrapped drug to account for all the drug loaded in the samples. 80.3 ± 
0.4 % and 87.8 ± 6.7 % of initial drug mass were accounted for in Si 0.5:100 (HFIP) 
and SiCol 0.5:100 samples, respectively (Figure 4.2C), while Si 0.5:100, Si 1:100, and 
Si 2:100 exhibited values of 91.7 ± 1.25 %, 87.3 ± 4.0 %, and 84.5 ± 2.6 %, 






Figure 4.2 Formulation design and its impact on siponimod stability and release. 
Temperature stability of (A) liquid- and (B) solid-state formulations of siponimod over 
time. Graphs show the change in concentration of siponimod within formulations over 
time relative to formulations at time zero. (C) Siponimod release from electrospun 
formulations prepared in HFIP (Si 0.5:100 and SiCol 0.5:100) compared to 
preparation using CLF/DMF (Si 0.5:100), n=2 (3 technical replicates). (D) Siponimod 
release from electrospun formulations prepared in CLF/DMF: Si 0.5:100, Si 1:100 and 
Si 2:100, n=2 (3 technical replicates). For figures C and D, data was multiplied by a 
correction factor taking into account each scaffold’s loading efficiency (See Table 
4.1). Additionally, in figures C and D, the hollow triangles represent the total amount 
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scaffolds in HPLC mobile phase). ‘’n=’’ represents the number of independent 
experiments. Data is presented as mean ± SD. 
  
Finally, for Si 0.5:100 (HFIP) and SiCol 0.5:100, SEM images were acquired at the 
end of the 90 day release period. Although the gross integrity of the fibrous construct 
is intact, Figure 4.3A-C appear to show evidence of degradation of the fibre matrix 
over time, as suggested by the ubiquitous formation of pores on the surface of the fibre 
and some evidence of small fissures and weakening of the structure (arrows in Figure 
4.3B). Figure 4.3C also shows a cross section of the SiCol 0.5:100 samples indicating 
that bulk degradation was occurring throughout the fibrous material. 
  
Figure 4.3 SEM images following 90 day release study. (A) Si 0.5:100 (HFIP) (B) 
SiCol 0.5:100 (C) Surface and cross section of SiCol 0.5:100. For A and B 
magnification at x4000 (scale bar = 5 µm), for C magnification at x1500 (scale bar = 
10 µm). White arrows indicate signs of general degradation.  
4.4.4 Physicochemical characterisation – DSC, FTIR, contact angle & tensile 
strength 
As part of an overall physicochemical characterisation of the electrospun formulation, 




solid electrospun formulations due to processing (Figure 4.4A). The unprocessed 
PLGA starting material showed a glass transition temperature (Tg) at 53.6 °C, and 
after processing using the solvent mixture CLF/DMF, exhibited a Tg at 52.2 °C. 
Samples prepared using the solvent HFIP showed a marked reduction in Tg (37.9 °C) 
compared to the unprocessed PLGA starting material. A reduction in Tg was observed 
for all samples prepared using HFIP including PLGA-Collagen (39.7 °C), and SiCol 
0.5:100 (40.4 °C). Samples containing siponimod processed using CLF/DMF 
exhibited polymer Tg (Si 0.5:100 (52.23 °C), and Si 2:100 (52.15 °C)) similar to the 
Tg of the PLGA base material (53.60 °C) 
FTIR spectroscopy was performed on electrospun samples to investigate any 
fundamental changes in chemical bond interactions between the constituent materials 
(PLGA, siponimod, and collagen) (Figure 4.4B-C). The electrospinning procedure did 
not produce any differences when compared to the spectrum of the PLGA starting 
material. Indeed, the addition of siponimod at 0.5:100 (Figure 4.4B-C), 1:100 and 
2:100 (data not shown) did not show any sign of the O-H and C-H stretching bands 
between 2800-3300 cm-1 associated with the siponimod spectrum shown in Figure 
4.4B. The low concentrations of siponimod used in these formulations may have made 
detection of drug-polymer interactions challenging. Therefore, samples were also 
prepared with higher drug concentrations (3.3:100), which showed the first indications 
of siponimod O-H and C-H stretching between 2500-3300 cm-1 (arrows in Figure 
4.4B). Collagen containing samples (Figure 4.4C) did not show any traces of known 




Contact angle goniometry was used to determine whether the addition of siponimod 
and/or collagen had any effect on the hydrophobicity of the electrospun scaffolds. All 
samples exhibited hydrophobic behaviour and θ > 90 °, irrespective of composition or 
processing solvent, PLGA (125.9 ± 13.5 °), Si 0.5:100 (135.2 ± 5.5 °), Si 2:100 (131.4 
± 10.7 °) and SiCol 0.5:100 (118.2 ± 6.9 °). There were no statistically significant 
differences in the sample wettability of electrospun samples (p = 0.32). 
Electrospun samples were investigated for tensile strength (Figure 4.4D). The ultimate 
tensile strength of samples Si 0.5:100 and Si 2:100 (0.169 ± 0.042 MN/m2 and 0.173 
± 0.014 MN/m2) showed no significant difference compared to electrospun PLGA 
control (0.144 ± 0.054 MN/m2). However, there was a significant increase in the 
ultimate tensile strength of SiCol 0.5:100 compared to electrospun PLGA control 








Figure 4.4 Physicochemical properties of electrospun scaffolds. (A) Differential 
scanning calorimetry of electrospun scaffolds and base materials using MDSC. (B) 
FTIR spectra of collagen and siponimod (C) FTIR spectra of electrospun samples. (D) 
Ultimate tensile strength of electrospun scaffolds. Scaffolds were exposed to tensile 
force until failure, n=3. For D, data is presented as mean ± SD, statistical analysis by 
one-way ANOVA. *: p < 0.05. 
4.4.5 Biological characterisation of electrospun material  
In vitro cell culture with hFOB and HUVEC was performed to determine the metabolic 
activity of cells incubated with electrospun scaffolds. Exposure was either indirect, by 
adding scaffolds to 24-well plates pre-seeded with cells, or direct, which involved 
seeding cells onto the surface of electrospun scaffolds inserted at the bottom of well 
plates. As shown in Figure 4.5A and B, indirect incubation of the electrospun scaffolds 
with both HUVEC and hFOB over the 5 day period did not significantly impact cell 
metabolism when compared to scaffold-free controls. 
Figure 4.5C shows the metabolic activity of hFOB seeded directly on the scaffold 
surface and incubated for a period of 5 days. For each scaffold type there were 
statistically significant increases in metabolic activity over time (shown in fluorescent 
units). For the PLGA control scaffolds, values on day 3 (126.2 ± 7.4, p<0.05) and 5 
(131.9 ± 9.5, p<0.01) were increased compared to day 1 (97.3 ± 28.1). The Si 0.5:100 
sample showed a significant increase between day 3 (128.8 ± 18.5, p<0.05) and day 1 
(102.7 ± 16.0), followed by a plateau by day 5 (127.1 ± 10.0). The sample SiCol 
0.5:100 showed a similar stepwise increase in metabolic activity, with a significant 




direct incubation assay, scaffolds were fixed, sectioned and stained with haematoxylin 
and eosin. Qualitative light microscopy indicated that by day 5, cell growth occurred 
mainly on the surface of scaffolds, with some evidence of infiltration observed in Si 










Figure 4.5 Indirect and direct metabolic activity of cells incubated with electrospun scaffolds. (A) HUVEC metabolic activity and (B) 
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(3 technical replicates). Direct assessment (C) involved hFOB directly seeded on PLGA, Si 0.5:100, and SiCol 0.5:100 scaffolds for 5 
days with assessments using the resazurin assay on days 1, 3, and 5, n=4 (4 technical replicates). For graph A and B, data represents the 
average absorbance values at 570 nm. For graph C, data represents the average fluorescence at excitation 488 nm/emission 595 nm, 
expressed as fluorescence units. (D, E, F) Light microscopy images of H&E stained cells on PLGA, Si 0.5:100 and SiCol 0.5:100, 
respectively. Images were acquired at 10x magnification (scale bar = 200 µm) using extended focal image acquisition, inset within each 
image is the same sample acquired at lower magnification using 4x objective magnification. Stained cells (pink) can be seen growing on 
the surface of electrospun polymer scaffold (grey). ‘’n=’’ represents the number of independently repeated experiments. Data is presented 
as mean ± SD. For (A & B) Statistical analysis was by one-way ANOVA. For (C) statistical analysis was by two-way ANOVA. *: p < 





4.4.6 In vitro functional experiments 
In order to test the functional effect of the released drug, scaffolds were incubated with 
hFOB and their ALP activity was used as a marker for cell differentiation, while 
migration of HUVEC in response to released siponimod was assessed using transwell 
migration assays Figure 4.6. Based on release data and known masses of scaffolds, 
local concentrations of siponimod would likely fall in the nanomolar to low 
micromolar range. For example, from the release data it was estimated that 6.9 % of 
siponimod was released from the scaffolds after one day of incubation, which for the 
Si 0.5:100 sample would produce a local concentration of 1.5µM. By day 5 of 
incubation, a further 1.7 % of siponimod in scaffolds was released which would equate 
to 0.37µM. These concentrations would be expected to exert functional effects based 
on past research (Sartawi et al., 2020a). 
Cells incubated with samples of Si 0.5:100 were found to exhibit significantly higher 
ALP activity compared to electrospun PLGA controls (92.2 ± 6.1 % compared to 61.5 
± 7.6 %, p < 0.05). While increasing drug concentration (Si 2:100) and the addition of 
collagen (SiCol 0.5:100) appeared to increase ALP activity compared to the 
electrospun PLGA control, differences were not statistically significant (78.0 ± 10.3 
% for Si 2:100, and 78.6 ± 5.3 % for SiCol 0.5:100 compared to 61.5 ± 7.6 % for 
electrospun PLGA control) (Figure 4.6A). Additionally, hFOB were stained at day 7 
using Fast Blue BB/Naphthol AS-MX phosphate to assess the number of cells with 
increased ALP activity (Figure 4.6B). Siponimod loaded scaffolds Si 0.5:100 and Si 
2:100 showed an increase in the number of stained cells compared to scaffold-free 
controls (80.1 ± 15.4 % and 77.6 ± 15.1 % compared to 43.2 ± 9.9 %, p < 0.05). 




drug-free PLGA scaffolds (63.6 ± 10.7 % and 51.5 ± 8.6 %, respectively) produced 
statistically significant increases in ALP activity compared to scaffold free controls 
(43.2 ± 9.9 %).  
Transwell migration results are shown in Figure 4.6C as the number of migrated cells 
per field of view (FOV), with Si 0.5:100 and Si 2:100 producing statistically 
significant increases in the number of migrated HUVEC compared to the electrospun 
PLGA control (17.6 ± 3.5 cells/FOV and 17.3 ± 1.3 cells/FOV compared 5.7 ± 0.5 
cells/FOV, respectively p < 0.05). Samples containing both siponimod and collagen 
SiCol 0.5:100 did not stimulate significant increases in cell migration compared to the 





Figure 4.6 In vitro functional experiments investigating differentiation and migration. 
(A) ALP activity after 7 days, n=3 (3 technical replicates. Data represents the average 
of pNPP absorbance at 405 nm divided by cell number, data is expressed relative to 
positive osteogenic control (hFOB incubated in cell culture medium containing 50 




7 days, n=4 (3 technical replicates), data is expressed relative to positive osteogenic 
control. (C) HUVEC transwell migration after 8 hrs, n=3 (2 technical replicates). (D, 
E) Representative images of transwell migration data for samples PLGA and Si 
0.5:100, respectively. Images were acquired at 4x magnification (scale bar = 500 µm). 
Data is presented as mean ± SD, statistical analysis by one-way ANOVA. *: p < 0.05, 
**: p < 0.01, ***: p < 0.001. 
4.4.7 In vivo critical cranial defect 
Following previous research demonstrating the effects of siponimod on osteoblast and 
endothelial cells (Sartawi et al., 2020a), and the in vitro research findings presented 
herein demonstrating the controlled release of siponimod from PLGA scaffolds on the 
same cell populations, the next step was to determine whether those cellular effects 
translated to in vivo efficacy in bone defect regeneration. 
Labelling with calcein was used with the aim of estimating the temporal progression 
of mineralisation (Blum et al., 2003). The extent of mineralisation depicted in Figure 
4.7 (fluorescent labelling (magnified)) represents the results of calcein administration 






Figure 4.7 Columns of images: representative images. Columns indicate VK staining 
(whole image), VK staining (magnified), Calcein fluorescent labelling (magnified), 




correspond to the different experimental groups used in critical cranial defect study 
PLGA, Si 0.5:100, Si 2:100, SiCol 0.5:100, and Fi 0.5:100. The black dashed lines in 
VK staining (whole image) give an approximation of the original defect area. The 
white arrows in the fluorescent micrographs indicate in progression from left-to-right, 
the original defect edge, the 3-week fluorescent signal, and the 12-week position of 
regenerating bone. The black arrows in the osteocyte enumeration micrographs 
indicate examples of counted osteocytes. Scale bars are indicated for each column of 
images. 
   
The images in Figure 4.7 were used to acquire the quantitative data shown in Figure 
4.8. For example Figure 4.8A shows the value for the area of early regeneration (0-3 
weeks), and late regeneration (3-12 weeks) determined from fluorescent labelling 
images. Of the investigated scaffolds, the greatest extent of regeneration by 12 weeks 
appeared to be associated with Si 0.5:100 when compared to PLGA control, however 
neither Si 0.5:100 nor any of the other scaffolds resulted in statistically significant 
increases in area of regeneration (26.1 ± 8.6 mm2 for Si 0.5:100 compared to 22.8 ± 
8.1 mm2 for PLGA control). Furthermore, the extent of early regeneration appeared to 
be greater than that of late regeneration. In the case of most scaffolds this difference 
was not statistically different, with the exception of Si 0.5:100, which showed a 
significantly greater area of regeneration at earlier stages (17.5 ± 6.0 mm2 for 0-3 week 
period compared to 8.6 ± 5.5 mm2 for the 3-12 week period, p<0.5).  
In Figure 4.8B and C, both MG trichrome and VK staining demonstrated that there 




groups. Indeed, in MG trichrome, the best performing scaffold, Si 0.5:100, resulted in 
an equivalent area of mineralised tissue compared to PLGA control (22.18 ± 6.0 mm2 
for Si 0.5:100 compared to 22.5 ± 7.6 mm2 for PLGA control). A similar result was 
found with VK staining, where Si 0.5:100 appeared to result in an equivalent level of 
mineralisation compared to PLGA control (25.7 ± 10.7 mm2 for Si 0.5:100 compared 
to 25.4 ± 10.7 mm2 for PLGA control). 
The MG trichrome staining images in Figure 4.7 were used to enumerate osteocytes 
within selected fields of view (an area of 0.31 mm2), the quantitative values of which 
are shown in Figure 4.8D. There was no significant difference between the 
experimental groups examined, with the greatest number of enumerated osteocytes 
associated with the Si 2:100 scaffold not statistically different from PLGA control 
(29.3 ± 5.8 cells/0.31 mm2 for Si 2:100 compared to 25.7 ± 5.3 cells/0.31 mm2 for 







Figure 4.8 Histomorphometric analysis of critical cranial defect sections. (A) Area of 
repair before and after calcein labelling at 3 weeks, n=6 animals (2 measurements per 
animal). (B) Area of mineralisation determined using Masson-Goldner trichrome 
stain, n=6 animals (2 measurements per animal). (C) Area of mineralisation 
determined using von Kossa stain, n=6 animals (2 measurements per animal) (D) 
Manual quantification of osteocytes within regenerated defect using Masson-Goldner 
trichrome stained sections, n=6 animals (4 fields of view per section each with an area 
of 0.31 mm2). 
  
4.5 Discussion 
The overall aim of this work was to develop and characterise a siponimod loaded 
implantable scaffold for the localised and controlled release of siponimod, to augment 




electrospun scaffold loaded with siponimod and collagen. The aim of adding 
siponimod was to exploit its ability to attract endothelial cells and enhance pre-
osteoblast differentiation (Sartawi et al., 2020a) within a bone defect, over a timeframe 
relevant to bone repair. The choice of siponimod was further based on a body of 
literature investigating the impact of another S1P modulator, fingolimod, on critical 
bone defects, which showed increases in bone area and vascularisation of defects (Das 
et al., 2013). Siponimod is more selective than fingolimod, does not require activation 
by phosphorylation, and has potentially fewer side effects (Behrangi et al., 2019). The 
concentration of siponimod was similarly chosen based on previous studies 
investigating the S1P analogue, fingolimod (Huang et al., 2012, Das et al., 2014b, Das 
et al., 2013). To the best of our knowledge, this is the first study examining siponimod 
for bone regeneration and the first to evaluate its delivery from a controlled release 
polymer system. Therefore, we initially determined the solid and liquid stability of 
siponimod preparations at different temperatures and showed that siponimod 
degradation was reduced when entrapped within the polymer matrix. This 
conservation of drug stability is essential given the extended timeframe required for 
research targeting bone regeneration. Other groups investigating S1P for bone 
regeneration have also investigated formulation design to tailor drug release. For 
instance, S1P has been prepared as part of silicon-PLGA-chitosan scaffolds for tissue 
engineering applications, providing a steady release of S1P and an adequate surface 
for cell proliferation (Pandolfi et al., 2016). Keeping in mind the grade of PLGA 
(50:50) used was of a variant with relatively more rapid degradation giving rise to 
release over a mere 11 days. In comparison, the formulation described herein releases 




purposes. This is attributed to the grade of PLGA (85:15) used in this study, which 
degrades more slowly due to its more hydrophobic properties associated with the 
increased portion of lactic acid monomer (Makadia and Siegel, 2011). Indeed, SEM 
images of the fibrous constructs retrieved from the release study after 90 days 
demonstrated the scaffolds were still intact, albeit with evidence of ubiquitous pore 
formation. 
Looking more closely at siponimod release, the release patterns depended on the 
solvent used in their preparation although the profiles were similar across respective 
samples processed in each of the different solvents. Siponimod release from samples 
prepared in CLF/DMF was biphasic showing an initial burst followed by a slow linear 
release, while samples prepared using HFIP showed little to no initial burst release, 
correlating more closely with zero-order release throughout. In reality, release from 
these electrospun scaffolds is likely complex and affected by several variables. 
Collagen samples processed with HFIP demonstrated reductions in polymer Tg close 
to physiological temperature, smaller and a narrower distribution of fibre diameter and 
lower % drug release. Previous research has demonstrated that thinner fibre meshes 
exhibited faster drug release (Okuda et al., 2010). It was expected that scaffolds 
processed with CLF/DMF, which had higher polymer Tg and larger fibre diameters 
(Si 0:5:100 (CLF/DMF)) would have smaller specific surface areas that could lead to 
lower drug release. However, these samples displayed a burst release component, and 
greater drug release over the analysis period compared to samples with significantly 
smaller fibre diameters (SiCol 0.5:100 - HFIP)). As contact angle goniometry 
confirmed both materials are hydrophobic, the smaller and denser fibre network may 




medium, resulting in linear release profile and a reduction in drug release. Another 
factor influencing drug release is distribution of drug in the polymer fibre during the 
formulation step. The processing solvents employed have different boiling points, and 
viscosities. HFIP has a higher density and viscosity (Costa et al., 1982) and is more 
volatile due to its lower boiling point 52 °C (Xia et al., 2014), whereas the co-solvent 
mix of CLF and DMF have boiling points of 61.6 and 153.1, respectively (Ye et al., 
2009). It is possible that the increased viscosity and higher evaporation rate associated 
with HFIP resulted in more uniform drug distribution in the polymer, and the drug was 
entrapped throughout the polymer fibre rather than partitioning to the polymer surface 
as the fibre formed. Uniform distribution of drug throughout polymer fibres 
electrospun with HFIP has been shown in the literature (Wu et al., 2020, Hall 
Barrientos et al., 2017). In all cases, the cumulative drug release did not exceed 60 % 
of total encapsulated drug. It should be noted that as polymer degradation increases a 
phase of rapid drug release may occur, potentially resulting in an increased rate of 
release for the remaining 40-50 % of encapsulated siponimod (Wu et al., 2020). 
Following the final drug release sampling point, scaffolds were disintegrated to 
account for the remaining drug within the scaffold. Results indicated that between 80.3 
± 0.4 % to 91.7 ± 1.25 % of drug in total was accounted for. It is possible that the 
remaining (between 8.3-19.7 %) siponimod underwent degradation while in solution 
between sampling points. This theory is supported by the siponimod stability study 
data at 37 °C (Figure 4.2A), which demonstrated that the drug degraded when stored 
in PBS solution at 37 °C, over 90 days.  
Thermal analysis indicated a marked reduction in the polymer Tg of the scaffolds 




in the texture and brittleness of implantable materials when used in vivo (Park and 
Jonnalagadda, 2006), and was attributed to the known plasticizing effect of HFIP (Jose 
et al., 2009b, Zong et al., 2002). Tensile strength data also indicates that the 
electrospun material containing collagen had significantly higher values, which may 
be attributed to a denser network of smaller fibres (Wong et al., 2008). The addition 
of collagen to formulations resulting in fibres with smaller diameters has been shown 
in other studies utilising a similar technique (Hall Barrientos et al., 2017). 
Additionally, it is possible that the plasticising effect of the solvent altered the ductile 
properties of the polymer (Lim and Hoag, 2013). The tensile strength of the 
electrospun materials is several orders of magnitude lower than human bone 80 
MN/m2 (Wall et al., 1979), and so could be used in tandem with a mechanically 
competent material, as a replacement in non-weight bearing defects (Turan et al., 
2016, Davies et al., 2018) or indeed to augment fracture repair. 
The grade of PLGA was chosen for its slow degradation behaviour. However, the 
increased hydrophobicity was expected to pose a challenge with respect to cellular 
interaction and adhesion. Despite this, biological characterisation of electrospun 
materials demonstrated that cells were growing on the surface of the scaffolds after 5 
days and showed signs of infiltration within the fibrous matrix of the Si 0.5:100 
scaffold. At these early time-points, this was not observed in collagen containing 
samples and is most likely associated with the density of the fibre network due to the 
smaller fibre diameter, which was more suited to cell spreading rather than promoting 
cell infiltration (Ko et al., 2016). Added to this, the Si 0.5:100 sample also 
demonstrated the clearest functional effects with respect to the impact of released 




study using a similar ratio of fingolimod, which resulted in increased bone volume in 
vivo (Das et al., 2014b). The lack of an effect or indeed an additive effect with 
increasing ratios of siponimod was unexpected but not surprising given that siponimod 
(Sartawi et al., 2020a) has been shown to achieve its maximal effect at low nanomolar 
concentration with effects plateauing thereafter as receptors become desensitised. The 
effect of siponimod is likely similar to that of fingolimod (Mullershausen et al., 2009), 
which is known to exhibit delayed persistent signalling following receptor 
internalisation, while S1P has been observed to exhibit both time and dose dependant 
effects on cell proliferation (Dziak et al., 2003).  
The addition of collagen was intended to improve the biocompatibility of the 
hydrophobic PLGA polymer as the addition of collagen even at low concentrations 
(≈1 % w/w) has been shown to improve cellular adhesion to polymer scaffolds, by 
increasing sites for cellular attachment (Chiu et al., 2007). However, this was not 
found to be the case in our results with no clear added advantage in quantitative assays 
of metabolic activity or qualitative histology. HFIP has previously been shown to be 
a suitable solvent for electrospinning collagen without causing denaturation (Pham et 
al., 2006), and in this study no evidence that processing the polymer composite using 
HFIP adversely impacted the collagen stability was determined using DSC. In 
particular, an endotherm in the region of 80 °C, which has previously been shown to 
indicate denaturation (Jose et al., 2009a), was not evident here. Other studies have also 
indicated electrospinning collagen results in substantial loss of the triple helix 
structure (Zeugolis et al., 2008, Yang et al., 2008), which may have reduced the 
likelihood of observing positive results. It is also likely that higher concentrations are 




would result in more substantial results as reported elsewhere (Ngiam et al., 2009). 
Ultimately, a selection of scaffolds was chosen for evaluation in vivo in a critical 
cranial defect, with the aim of comparing several siponimod loaded scaffolds with a 
fingolimod loaded scaffold informed by the available literature (Das et al., 2013). At 
the end of the 12 weeks, there was a reduction in the measured area of the defect. 
However, there was no significant difference in mineralisation when comparing drug 
loaded and drug-free scaffolds. This was despite the positive differentiation and 
migration results observed in vitro for the Si 0.5:100 scaffold. It must be noted, that 
the fingolimod loaded sample, which was used for comparative purposes, did not 
result in a significant increase in histomorphometric measures of defect 
mineralisation. However, there were some differences between the fingolimod loaded 
samples used here (PLGA based implant, 8 mm cranial defect, mineralised area 
determined by histomorphometry) and that used in the study cited (PCL/PLGA 
polymer composite implant, 5 mm mandibular defect, mineralised area determined by 
3-D microCT). Moreover, the methodologies used in the literature to determine drug 
release in vitro (Huang et al., 2012, Sefcik et al., 2011, Das et al., 2013, Das et al., 
2014b, Petrie Aronin et al., 2010b) and in vivo (Ogle et al., 2014) differ from those 
used here. Finally, fingolimod’s effect on bone regeneration in the literature has been 
attributed to its impact on vascular network formation (Petrie Aronin et al., 2010a, 
Sefcik et al., 2011), and the local recruitment of regenerative immune cells (Ogle et 
al., 2014) rather than direct activity on bone cells. However, these effects were not 
examined here and represents a limitation in our study as it complicates our ability to 




There were some other limitations to the work conducted here, in the case of the 
release study, the experiment was a single compartment in vitro experiment that did 
not involve enzymatic activity or biorelevant medium, therefore it is expected that in 
vivo concentrations will not closely correlate with in vitro data. Cell culture 
experiments present another drawback, insofar as cells grown in 2-D isolation are a 
relatively poor substitute for the living environment of regenerating tissue. All of 
which may go some way to explaining the disparity that still exists between the in 
vitro and in vivo effect of siponimod loaded scaffolds. Additionally, regarding the in 
vivo cranial defect, it was clear that initial estimates of variability across the 
regenerating defects led to an underestimation in the sample size required to 




This work aimed to deliver the selective S1P1 receptor agonist siponimod in a 
controlled manner to a critical cranial defect. It involved the design of a polymer-based 
scaffolds loaded with siponimod and co-spun with collagen as a potential replacement 
material in cases of non-weight bearing critical bone defects and represents the first 
application of siponimod as part of a controlled release system. The electrospun 
samples developed showed efficient drug loading and controlled release over 
timeframes suitable for regeneration. In vitro the added components had mixed results, 
siponimod increased osteoblast differentiation (ALP activity) and endothelial cell 




not increase cell attachment or promote enhanced cell interaction over 5 days. 
Formative animal studies showed that the scaffolds support the regeneration of critical 
bone defects, however the addition of siponimod did not result in a significant 
regenerative effect. Ultimately, the validity of targeting S1P receptors in bone repair 
is questionable due to the contradictory findings between studies. However, it is 
possible that modifying drug release from scaffolds, increasing collagen 





5 Chapter 5 
 
 
Developing porous scaffolds for the localized 
delivery of siponimod using electrosprayed 





Bone tissue engineering regularly necessitates the preparation of 3-D porous scaffolds 
that mimic the natural extracellular matrix of bone, ideally using simple and efficient 
techniques. The combination of electrospraying, gas-foaming and porogen leaching 
represents a relatively simple and cost-effective approach to prepare scaffolds that 
possess a porous architecture suitable for bone regenerative applications while also 
providing a vehicle for the delivery of the specific S1P1/5 receptor modulator 
siponimod.  
Scaffolds composed of electrosprayed PLGA microparticles and HA were produced 
using CO2 gas-foaming and porogen (NaCl) leaching. The polymer microparticles 
were loaded with siponimod at a drug:polymer mass ratio of 0.5:100. Thereafter, 
scaffolds underwent in vitro physicochemical characterisation using FTIR, DSC and 
SEM, as well as indirect and direct cytocompatibility analysis with osteoblast and 
endothelial cells. The scaffolds demonstrated pore volumes in the range of 70.1-83.7 
% and pore sizes in the range 200-300 µm. Drug-loaded scaffolds showed controlled 
release of siponimod over the 3 month experimental timeframe, and furthermore, 
scaffolds showed compatibility with osteoblast and endothelial cells. To our 
knowledge, this is the first scaffold design combining siponimod and HA in a 3-D 
porous construct. In vitro studies confirmed desirable porosity and drug release 
attributes, however, further optimisation of the scaffold design supported by more 
extensive in vitro functional studies is warranted.  






Three-dimensional (3-D) polymeric scaffolds for bone tissue engineering must fulfil 
some important criteria if they are to support the regeneration of bone tissue and 
achieve good integration between the implanted scaffold and native tissue. Desirable 
properties include the presence of a porous and interconnected architecture (Abbasi et 
al., 2020), fabrication from biocompatible, osteoconductive materials with sufficient 
mechanical integrity (Qu et al., 2019, Hutmacher, 2000), and degradation 
contemporaneous with the regeneration of new tissue (Alsberg et al., 2003). 
A porous scaffold is important when attempting to replicate bone extracellular matrix 
by enabling cell infiltration, proliferation and differentiation, nutrient and waste 
exchange and the development of functional vasculature and tissue growth throughout 
the structure (Henkel et al., 2013), in addition to providing sufficient surface area for 
cell adhesion (Dhandayuthapani et al., 2011). Studies investigating the implications of 
pore size in bone tissue engineering indicate the optimal pore size is in the range 100-
350 µm (Yang et al., 2001). However, a balance must be struck as high porosity in the 
scaffold structure will negatively impact a scaffold’s mechanical properties leading to 
collapse under high weight-bearing loads, conversely insufficient porosity will 
adversely impact drug release, cell infiltration through the construct, and ultimately 
the scaffolds osteoconductivity (Byrne et al., 2007). An osteoconductive scaffold 
material, is one that is capable of supporting the formation of new bone by supporting 
cell attachment, proliferation, survival, and the deposition of bone matrix (Blokhuis 
and Arts, 2011). Osteoinductive materials have the capacity to evoke biological 
responses, and can be used to introduce bioactivity to the most commonly used 




The ability of a scaffold material (such as biodegradable polymers) to degrade and to 
do so in a timeframe commensurate with bone regeneration, gives the newly 
regenerated bone sufficient time to develop mechanical competency and restore its 
functionality (Ge et al., 2008). Numerous degradable materials have been used to 
prepare scaffolds for bone tissue engineering purposes, including degradable polymers 
such as polyanhydrides, poly(ortho esters), polyesters and polycyanoacrylates (Rey-
Vinolas et al., 2019). Degradable or bioresorbable ceramics include calcium phosphate 
ceramics (Tan et al., 2013) as well as the bioactive glass ceramics first developed by 
Hench et al. (Hench et al., 1971). Calcium phosphates (CaP) including hydroxyapatite 
(HA) (Ca10(OH)2(PO4)6 (Gradinaru et al., 2015)) and tricalcium phosphates (TCP) 
(Ca3(PO4)2 (Jeong et al., 2019)), have been investigated due to their structural and 
functional similarity to bone mineral (Ramesh et al., 2018). One of the most common 
approaches to recapitulate the native bone tissue is to produce composite scaffolds 
composed of polymers and mineral phases, which can help address the limitations of 
individual materials. The inclusion of HA can improve the osteoconductive behaviour 
of synthetic polymer scaffolds, as polymers lack the biological properties of bone 
extracellular matrix (Kretlow and Mikos, 2007, Ahern et al., 2013). One recent 
example shows this, whereby PLGA/HA microsphere-based scaffolds promoted the 
adhesion, proliferation, and alkaline phosphatase activity of BMSC seeded directly on 
the scaffolds (He et al., 2016). While HA can contribute to improving the overall 
osteoconductivity of a scaffold, polymers (e.g. PLGA) contribute flexibility 
(Schneider et al., 2011), degradability (Makadia and Siegel, 2011), and a platform to 




The method of fabrication is an important factor that influences scaffold properties. 
Numerous techniques have been utilised to prepare 3-D scaffold constructs (Li et al., 
2019a, Yan et al., 2019, Zhai et al., 2018) including solvent-leaching (Sola et al., 
2019), gas-foaming (Costantini and Barbetta, 2018), freeze-drying (Deville et al., 
2006), 3-D printing (Kačarević et al., 2018), and electric field assisted techniques such 
as electrospinning and electrospraying (Zhu and Chen, 2013).  
Porogen leaching has been used to create macroporous scaffolds with an 
interconnected pore architecture (Costantini and Barbetta, 2018). Leaching is 
considered an easy and cost-effective method of preparing macroporous (300-500 µm) 
scaffolds, possessing a high pore volume (>90 % pore volume) (Costantini and 
Barbetta, 2018). High-pressure CO2 has been used to sinter pre-prepared PLGA 
microspheres in the preparation of 3-D porous constructs, which supported cellular 
growth and infiltration throughout the scaffold (Singh et al., 2010). Although without 
a porogen, the overall porosity was limited to < 50 %. Compared to scaffolds prepared 
using mould-compressed HA, PLGA, and porogen leaching (Kim et al., 2006), 
resulted in scaffolds with pore volumes of >85 % with larger macropores (100-200 
µm) and smaller interconnected pores (10-45 µm). All of which promoted rat calvarial 
osteoblast proliferation and differentiation in vitro as well as bone formation in 
subcutaneous implants in mice (Kim et al., 2006). Another study combined polymer 
microparticles with gas foaming and porogen leaching to fabricate an interconnected 
porous scaffolds (94 % porosity) preloaded with plasmid DNA that were released in a 




There are several other potential therapeutic options that can be incorporated into 
implantable materials that were discussed earlier in Chapter 1. Briefly, these included 
growth factors (e.g. BMP, VEGF, PDGF) (Perez et al., 2018), and small molecule 
therapeutics (e.g. bisphosphonates, vitamin D3) (Carbone et al., 2014). Of particular 
interest in this thesis has been sphingosine 1-phosphate (S1P) receptor modulation 
which has been shown to positively influence outcomes in bone defect studies, by 
supporting vascularization and chemotaxis of specific cellular contributors to bone 
repair (Huang et al., 2012, Das et al., 2013, Das et al., 2014b, Wang et al., 2016a, Das 
et al., 2015, Das et al., 2014a). Siponimod (Mayzent®), which is approved for the 
management of secondary progressive multiple sclerosis (Behrangi et al., 2019), is a 
specific agonist of S1P receptors 1 and 5 and similarly shows evidence of osteoblast 
differentiation and endothelial cell chemokinesis (Sartawi et al., 2020a). 
The overall aim of this body of work was to design a siponimod loaded, porous, 
osteoconductive scaffold composed of PLGA and HA, whereby the hypothesized 
improvement in osteoconductivity, and the controlled localised release of siponimod 
would result in the induction of osteoblastic differentiation of local progenitors, 
ultimately contributing to enhanced bone regeneration. 
 
5.3 Materials & methods 
5.3.1 Materials 
Electrospray materials included: poly (D, L-lactide-co-glycolide) Resomer® RG 858 




Aldrich, USA), and siponimod hemifumarate was kindly gifted from Novartis (Basel, 
Switzerland). 
Hydroxyapatite ((Ca5(OH)(PO4)3, nanopowder <200 nm particle size), dimethyl 
sulfoxide (DMSO), Dulbecco’s phosphate buffer saline (PBS), foetal bovine serum 
(FBS), L-glutamine solution, Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 Ham (DMEM/F12), Thiazolyl Blue Tetrazolium Bromide (MTT), were acquired 
from Sigma Aldrich. Human umbilical vein endothelial cells (HUVEC) and their 
growth medium (ECGM) with associated supplements were acquired from PromoCell, 
Germany. The human foetal osteoblast cell line hFOB 1.19 was acquired from ATCC 
(ATCC® CRL-11372™).  
5.3.2 Electrospray procedure 
Solutions of PLGA (85:15) were formulated as 3 % w/w preparations in a mixture of 
chloroform (CLF) and dimethylformamide (DMF) at a 9:1 ratio. Reagents were 
dissolved in glass vials overnight at 4 °C. Prior to starting the electrospray process, 
solutions were equilibrated to room temperature to avoid viscosity changes. For 
siponimod loaded preparations, siponimod were physically mixed at a mass ratio of 
siponimod:PLGA 0.5:100 (henceforth termed Si 0.5:100) before dissolving reagents 
as before. The electrospray set-up consisted of a Spraybase® (Spraybase, Ireland) 
electrospray instrument kit (CAT000002), and an AL-2000 syringe pump (World 
Precision Instruments, USA). Sample solutions were decanted into a 10 mL glass 
syringe. The solutions were then primed in 1 mm diameter tubing connecting the 
syringe to the emitter nozzle (0.9 mm diameter). The syringe pump was set at a flow 




foil and placed at a working distance of 10-15 cm from the emitter nozzle. A voltage 
of 12 kV was then applied, with samples processed continuously until solution volume 
was dispensed. Microparticles were stored in the fume hood overnight to allow 
evaporation of any remaining solvent. Microparticles were then gently removed and 
stored in sealed plastic vials at room temperature away from light until further use. 
5.3.3 Scaffold preparation  
Scaffold preparation involved mixing PLGA/drug microparticles (7-10 mg) with NaCl 
porogen (size range, 250-400 µm) at a mass ratio of PLGA microparticles:NaCl, 1:19. 
The mixture was compressed in a 6 mm diameter die at a pressure (1 Ton) for 2 min. 
For scaffolds containing HA, the powder was combined with PLGA at a 1:6 ratio 
(HA:PLGA), prior to mixing with the NaCl porogen (e.g. PLGA 6 mg, HA 1 mg, NaCl 
133 mg). Resultant cylindrical compacts were then saturated in CO2 gas at 800 PSI for 
16 hrs prior to depressurisation. Scaffolds were then leached in MilliQ water for 12 
hrs to remove the NaCl porogen and dried at room temperature, followed by storage 
in sealed plastic vials at room temperature, away from light until further use. 
5.3.4 Scanning electron microscopy  
Images of electrosprayed microparticles and scaffolds were acquired using a JEOL 
JSM-5510 scanning electron microscope (SEM). Samples were mounted on stubs with 
double-sided carbon tape and sputter-coated with a 10 nm thick layer of gold-
palladium (80:20). Standard working distance was 8 mm, spot size 20-25, and a 3-5 
kV accelerating voltage. For microparticles, images were used to investigate the 
morphology of samples and measure particle diameters. Three images (magnification 




image manually measured using Olympus Stream software (Mason Technology Ltd, 
Ireland). For scaffolds, 3 images (magnification 70x) of scaffold cross-sections were 
acquired and used as a qualitative assessment of scaffold pore morphology. 
5.3.5 Pore volume 
To determine the porosity of prepared scaffolds, PLGA control scaffolds and 
composite PLGA/HA scaffolds (n=4 of each) of known dry mass (Wdry) and 
theoretical cylindrical volumes (V= πr2h, V:volume, r:radius, h:height) were 
submerged in deionised water for 30 min with gentle agitation. Thereafter, surface 
water was carefully removed, and scaffold wet mass (Wwet) was acquired. The mass 
of water occupying the pore volume in the scaffolds was calculated by subtracting 
Wdry from Wwet, which is converted to a volume assuming a water density of 1 g/ml. 
The pore volume was then calculated using the following equation: pore volume = 
Volume of (Wwet-Wdry) / Volume of cylinder (calculated using scaffold dimensions) x 
100 %.  
5.3.6 HPLC method for drug quantitation 
Liquid chromatography was used to detect and quantify the concentration of 
siponimod using the method detailed below. The protocol used an Agilent 
Technologies 1120 Compact LC instrument (max= 278 nm), the stationary phase 
consisted of a Zorbax Eclipse Plus C18 column (4.6 x 150 mm, 5 m). The mobile 
phase was composed of acetonitrile and water at a ratio of 65:35, supplemented with 
formic acid 0.5 % v/v (pH ≈ 3.0), and operating conditions included a flow rate of 1.2 
ml min-1 and an injection volume of 10 µl. UV spectrometry of siponimod solutions 




5.3.7 Drug loading and release 
Drug loading was determined by disintegrating samples of known mass in HPLC 
mobile phase to release and dissolve total siponimod content. The resulting solution 
underwent HPLC analysis following the protocol described above. The acquired 
values were divided by the theoretical loading for each scaffold, assuming ideal 
loading, giving a % loading efficiency. 
In vitro release of siponimod was investigated using Si 0.5:100 scaffolds. Samples of 
known initial mass (ranging from 9.2-11.7 mg) were incubated in 1.5 ml PBS at 37 °C 
in a water bath, a volume sufficient to achieve sink conditions. The complete release 
medium was collected at defined time-points over a 12-week period and stored at -20 
°C prior to analysis. An equal volume of fresh PBS medium was replaced in the sample 
vial. Prior to HPLC analysis samples were vacuum-dried overnight, and the residue 
re-dissolved in mobile phase, with drug content quantified following the protocol 
described earlier. 
5.3.8 Differential scanning calorimetry (DSC) 
In order to investigate any changes in the solid-state properties of the polymeric 
constituent of the scaffolds due to processing, residual solvent, inclusion of siponimod 
or HA, scaffolds underwent thermal analysis using a TA Q1000 differential scanning 
calorimeter (TA instruments, USA). All samples were evaluated using modulated-
DSC (MDSC) in aluminium pans (DSC Consumables, USA), using the following 
settings: modulation temperature amplitude ± 1.0 °C, modulation 60 s, ramp rate 3 




5.3.9 Young’s modulus 
Given the cylindrical shape of the scaffolds, Young’s modulus was measured by 
subjecting scaffold to uniaxial compression under limited strain (30 %) to avoid 
scaffold rupture. Tests used a p-35 probe attached to TA texture analyser (Stable Micro 
Systems, UK) with associated Exponent® software. Scaffold of known dimensions 
were compressed at 0.1mm/sec until 30 % strain. Stress/Strain curves were produced 
and used to calculate the modulus of the scaffolds. 
5.3.10 Cell culture 
hFOB were maintained in DMEM/F12 supplemented with FBS (10 %), L-glutamine 
(1 %), and penicillin-streptomycin (1 %) at 34 °C and 5 % CO2. HUVEC were 
maintained in ECGM as per supplier’s recommendations at 37 °C and 5 % CO2. All 
experiments were conducted within 10 passages for HUVEC and within 20 passages 
for hFOB. 
5.3.11 Evaluation of metabolic activity 
5.3.11.1 Indirect assessment 
The metabolic activity of cells indirectly exposed to scaffolds was evaluated in order 
to determine the impact of eluted drug and polymer breakdown products on cells in 
close proximity to the scaffolds. PLGA controls, and Si 0.5:100 scaffolds were 
sterilised in 70 % ethanol for 5 min, then washed in PBS and dried overnight. 
Thereafter, scaffolds were added to 24 well plates pre-seeded with 5*104 cells/well of 
hFOB or HUVEC in 600 µl of their respective cell culture medium. The scaffolds 
were incubated with the cells for 5 days, with culture medium changed every other 




µl thiazolyl blue tetrazolium bromide (5 mg/ml solution) was added directly to 600 µl 
of cell culture medium for 2 hrs. Resultant formazan crystals were solubilized with 
600 µl DMSO. 100 µl of each well was transferred to a 96-well plate to measure 
absorbance at 570 nm using a Wallac Victor2 plate reader (Perkin Elmer, USA). 
5.3.11.1 Direct assessment 
The metabolic activity of hFOB seeded directly on scaffolds was evaluated in order to 
determine the impact of physical and chemical properties of the scaffolds on osteoblast 
cell metabolic activity. Selected scaffolds of PLGA, PLGA/HA, Si 0.5:100, and Si/HA 
0.5:100 were sterilised in 70 % ethanol for 5 mins, washed in PBS, then incubated in 
FBS for 5 mins, before being dried overnight. 
On the day of the experiment, scaffolds were placed in 24 well plates, and hFOB 
(2*105 cells in 20 µl) were added to both the top and bottom of the scaffold, allowing 
10 min before the scaffold was flipped over. Thereafter, cell culture medium was made 
up to 600 µl slowly to avoid disturbing scaffold seeding. After 24 hrs (and again on 
days 3 and 5), scaffolds were transferred to new wells, and resazurin (120 µl of a 560 
µM stock) was added to 600 µl of freshly added cell culture medium and incubated 
for 3.5 h. Subsequently, 100 µl of medium from each sample was transferred to a 96 
well plate for fluorescent plate reading at excitation 488 nm/emission 595 nm using a 
Wallac Victor2 plate reader (Perkin Elmer, USA). 
5.3.12 Statistical analysis 
Results are expressed as mean ± standard deviation (SD), unless otherwise stated. 




followed by Bonferroni post-test for multiple comparisons. In all cases differences 






5.4.1 Preparation of porous scaffolds 
Guided by the published literature, the electrospray parameters were optimised by 
varying voltage, working distance and spray rate. Finalised parameters produced 
microparticles that were generally concave, biconcave, or raisin shaped. The particle 
size distribution of PLGA control and drug loaded Si 0.5:100 microparticles are 
presented in Figure 5.1. There was a statistically significant difference in microparticle 
diameter distribution between the PLGA control (3.4 µm; 0.47 µm) compared to Si 
0.5:100 (4.1 µm; 1.0 µm) (p<0.05). Furthermore, the PLGA control exhibited a narrow 
size distribution compared to the siponimod loaded microparticles. 
 
Figure 5.1 Electrosprayed microparticle diameter determined from manual 
measurements of SEM images (Inset: representative image). (A) PLGA control 
microparticles (n=1 batch, 3 images total) (B) Si 0.5:100 microparticles (n=3 batches, 




frequency of particle diameter distribution as determined by manual measurements 
taken from SEM images (3 images per batch, 34 individual particle measurements per 
image). Inset values represent the median and interquartile range. Statistical analysis 
of the two populations involved Mann-Whitney U test to determine statistical 
significance. Diameters are given as median diameter; interquartile range. 
 
Scaffolds composed of electrosprayed particles together with NaCl were processed 
with CO2 foaming and subsequent leaching of the NaCl produced a 3-D porous 
structure Figure 5.2. A qualitative assessment of cross-sectional images showed the 
outlines of pores with diameters (≈200-300 µm) corresponding to the porogen 
diameter (perimeter indicated in Figure 5.2). Additionally, Si/HA 0.5:100 appeared to 




Figure 5.2 SEM images of scaffold cross-sections. (A) PLGA control scaffold (B) Si 
0.5:100 (C) Si/HA 0.5:100. Image magnification 70x (200 µm scale bar). Red dashed 




For a quantitative measure of porosity, pore volume was measured for PLGA control 
and PLGA/HA scaffolds. Results showed that PLGA control scaffolds had pore 
volume of 70.1 ± 3.3 % while PLGA/HA scaffolds exhibited a porosity of 83.7 ± 9.5 
%, which was statistically significantly different (p<0.05).  
5.4.2 Loading efficiency and drug release 
Drug loading efficiency corresponded to 48.5 ± 2.2 % of theoretical mass of drug with 
actual drug loading ranging from 22.3-28.4 µg. Figure 5.3 shows the results of 
cumulative siponimod release from porous scaffolds. By day 90, the cumulative drug 
release from Si 0.5:100 scaffolds was 36.7 ± 0.1 % of actual drug loading. Following 
the terminal sampling point in the release study, scaffolds were disintegrated, and the 
remaining drug was dissolved in HPLC mobile phase to quantify the remaining 
entrapped drug. Results showed that 64.5 ± 3.2 % of actual drug loaded mass was 
accounted for. Using the Korsmeyer-Peppas equation Mt/M∞ = Ktn where Mt/M∞ is 
the fraction of drug released over time, K is the release rate constant, n is the release 
exponent the value of which characterises the release mechanism of the drug. The Si 
0.5:100 had an ‘n’ value of 0.57, indicating siponimod release from these samples was 





Figure 5.3 Controlled release of siponimod from porous scaffolds over 90 days. Data 
represents samples of Si 0.5:100 (n=3 batches, each with 3 technical replicates). Data 
was multiplied by a correction factor taking into account actual scaffold loading 
efficiency. The triangle represents the total amount of siponimod quantified including 
cumulative release at day 90 and drug remaining in the scaffold following the final 
time point (acquired by disintegrating scaffolds in HPLC mobile phase). Each data 
point is presented as mean ± SD. 
5.4.3 Physical characterisation – DSC & Young’s modulus 
As part of the characterisation of a selection of scaffolds, PLGA control, PLGA/HA, 
Si 0.5:100, and Si/HA 0.5:100 were analysed alongside starting materials to 
investigate any changes in their solid-state behaviour due to processing (Figure 5.4A). 
The unprocessed PLGA starting material showed a glass transition temperature (Tg) 
at 53.35 °C, HA base material showed no discernible thermal signals, while siponimod 
displayed a melting endotherm at 135.80 °C. The scaffolds showed no distinct changes 
































(53.40 °C), PLGA/HA (52.28 °C), Si 0.5:100 (53.45 °C) and Si/HA 0.5:100 (54.57 
°C) exhibiting similar values. The addition of HA and siponimod similarly did not 
result in any observable signals in their respective scaffolds. 
Scaffolds were investigated for their Young’s modulus (Figure 5.4B). The scaffolds’ 
moduli are shown for PLGA control (0.22 ± 0.09 MPa), PLGA/HA (0.09 ± 0.05 MPa), 
Si 0.5:100 (0.22 ± 0.14 MPa), and Si/HA 0.5:100 (0.19 ± 0.09 MPa). There was no 
statistically significant difference between the experimental groups (p=0.28), despite 
HA-containing samples appearing to show a reduction in Young’s modulus. This is 






Figure 5.4 Physical properties of scaffolds. (A) Differential scanning calorimetry of 
scaffolds and starting materials using MDSC. (B) Young’s modulus of scaffolds (30 
% strain), data represents scaffold samples of PLGA, PLGA/HA, Si 0.5:100, and 
Si/HA 0.5:100. In all cases n=1 batch with 4 scaffolds per condition evaluated. Data 




























5.4.4 Evaluation of metabolic activity – Indirect & direct assessment 
In order to determine the indirect effect of scaffolds on the metabolic activity of hFOB 
and HUVEC, scaffolds were incubated with each of the two cell types for 5 days 
(Figure 5.5A&B). HUVEC incubated with PLGA control scaffolds exhibited 
absorbance values of 0.81 ± 0.11, which was similar to the scaffold free condition 
(0.86 ± 0.13). While HUVEC incubated with Si 0.5:100 scaffolds showed an 
absorbance of 0.59 ± 0.15, this difference was not statistically significant (p=0.10). In 
the experiment using hFOB, PLGA control scaffolds exhibited absorbance values of 
0.73 ± 0.12, which was comparable to the absorbance (0.73 ± 0.15) data for the 
scaffold free conditions. Again, the reduction in metabolic activity for cells incubated 
with Si 0.5:100 scaffolds was not statistically significant (p=0.35).  
The results of the direct assessment of the metabolic activity of hFOB incubated with 
scaffolds over 7 days are shown in Figure 5.5C. There were no statistically significant 
changes in the metabolic activity of hFOB directly seeded on scaffolds. However, a 
similar trend was observed across the experimental groups. Specifically, from day 1 
to day 7 fluorescence values (*103) for the PLGA control scaffold increased from 45.3 
± 11.7 to 57.7 ± 2.9, PLGA/HA scaffolds showed values of 53.0 ± 12.6 increasing to 
72.0 ± 8.1, drug-loaded Si 0.5:100 scaffolds resulted in values of 50.3 ± 10.9 
increasing to 57.3 ± 2.8, and finally Si/HA 0.5:100 scaffolds which resulted in 
fluorescence values of 47.9 ± 11.2 increasing to 68.5 ± 6.7. 





Figure 5.5 Metabolic activity of cells incubated indirectly and directly with scaffolds 
over time. Indirect assessment using MTT after 5 days (A) HUVEC, n=3 (3 technical 
replicates) (B) hFOB, n=3 (3 technical replicates), data represents the mean ± SD of 
absorbance at 570 nm. Direct assessment using resazurin assay over 7 days (C) hFOB, 
n=2 (3 technical replicates), data represents the mean ± SD of fluorescence units at 
excitation 488 nm/emission 595. ‘’n=’’ represents the number of independently 
repeated experiments. Statistical analysis used one-way (for A & B) and two-way (for 
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The aim of this chapter was to develop and characterise a siponimod loaded, porous, 
osteoconductive scaffold composed of PLGA and HA. Siponimod loaded polymer 
microparticles were prepared using electrospraying, followed by high-pressure CO2 
foaming, and porogen leaching. These scaffolds underwent investigations to be 
followed by investigations into whether they can contribute to enhancing bone 
regeneration in tissue engineering applications. 
Electrospraying is a highly efficient technique for the generation of particles, and 
which is of increasing interest in tissue engineering research (Correia et al., 2014, 
Jeyhani et al., 2017), due to flexibility in processing a wide array of materials, the 
capability to entrap a range of drug cargoes, and good production capacity (Deng et 
al., 2006, Parhizkar et al., 2017). The electrospray process resulted in microparticles 
with a collapsed morphology. The sphericity of electrosprayed particles has been 
associated with the concentration of added solutes and the concentration of the sprayed 
polymer (Bohr et al., 2012). Generally, sphericity is considered to increase with 
increasing concentrations of added solutes or of the base polymer, up to a point. 
However, after a defined concentration the jet of particles can deform and elongate 
into a jet of fibres (Jeyhani et al., 2017, Almería et al., 2010). Particle sizes can also 
be reduced by altering processing variables including decreasing the needle-collector 
distance, or the flow rate, or by increasing conductivity of the electrosprayed solution 
(Yao et al., 2008). The median particle sizes were 3.4 µm for PLGA control particles 
and were significantly smaller than Si 0.5:100 particles at 4.1 µm, this may be due to 
slight differences in the concentration of electrospray solution concentration, caused 




Si 0.5:100 scaffolds, or indeed small changes to the conductivity of electrospray 
solutions containing siponimod might also have played a role. All told, perfectly 
spherical particles were not a prerequisite given the additional fabrication steps 
employed subsequently (compression, gas foaming, porogen leaching). 
The purpose of combining gas foaming with porogen leaching was to produce a 
macroporous structure. In this work, scaffolds exhibited pores in the range of 200-300 
µm with smaller interconnected pores also evident. This range is known to be suitable 
to enabling cell infiltration (Yang et al., 2001).  
 High-pressure CO2 has been used for a number of scaffold materials, including 
ceramics (Kim et al., 2002), and polymers such as PLA, PCL, and PLGA (Matuana, 
2008, Jang and Shea, 2003, Moghadam et al., 2017). One study illustrated the benefits 
of coupling gas foaming with porogen leaching, whereby polycaprolactone/HA 
scaffolds prepared using only supercritical CO2 gas foaming supported human 
mesenchymal stem cell growth. But the limited volume of pores (40-60 %) was said 
to impede more favourable cell adhesion and proliferation (Moghadam et al., 2017). 
In order to obtain scaffolds with high pore volumes, the polymer microparticles 
prepared herein were mould-compressed with a porogen and processed using high-
pressure CO2. This duly resulted in scaffolds with large pore volumes, with 
statistically significant differences in pore volume between PLGA control scaffolds 
(70.1 ± 3.3 %) and PLGA/HA scaffolds (83.7 ± 9.5 %), which may be due to the 
increased presence of in micropores and subsequently increased pore 
interconnectivity. However, there is the possibility that some of the smaller pores were 




Regarding drug loading, the electrospray process is known to result in good loading 
efficiencies upwards of 80 %, with high batch-to-batch reproducibility (Nguyen and 
Jeong, 2018). However, the scaffolds prepared in this study had a loading efficiency 
of 48.5 ± 2.2 %, which was attributed to drug loss that occurred during the porogen 
leaching step. The loss suggests that siponimod was distributed both within and on the 
surface of the foamed polymer scaffolds. The loss of surface entrapped drug during 
the leaching step also explains the lack of burst effect in the early stages of the drug 
release study. The duration of the observed release pattern (months) was in line with 
timeframes associated with bone regeneration, and other similarly designed scaffolds 
for long-term applications (Zhang et al., 2017). The quantity of siponimod released, 
36.7 ± 0.1 % of the drug in the scaffold by day 90, suggests that local concentrations 
would be equivalent to ≈500 nM (assuming a volume of 1 ml and 0.5 % release per 
day), a concentration sufficient (Sartawi et al., 2020a) to elicit a response from in vitro 
cell targets (e.g. osteoblast differentiation). However, disintegration of scaffolds after 
the release tests to account for the remaining entrapped drug, highlighted that only 
64.5 ± 3.2 % of total drug loading was accounted for. This may have been due to the 
influence of experimental conditions i.e. experimental temperature of 37 °C on the 
stability of siponimod, which has been shown to have an adverse impact on the drug’s 
stability (Sartawi et al., 2020b). 
Considering physicochemical characterisation, DSC results did not show any 
indication of changes to thermal behaviour of the polymeric constituent of the 
scaffolds due the addition of HA, or indeed siponimod (a result similar to the scaffold 
design in Chapter 4). In particular, there were no changes in the Tg of the polymeric 




no relevant signals. Siponimod showed a melting endotherm at 135.80 °C (122 – 147 
°C), in comparison to a literature-based polymorphic form with a value of 110 °C (Liu 
et al., 2012). However, it is likely that the sensitivity of the calorimeter precluded 
detecting the small concentrations of siponimod within the scaffold samples. 
Regarding mechanical properties, synthetic polymers such as PLGA have generally 
provided poor structural properties when attempting to mimic the properties of bone 
(Koons et al., 2020). The addition of CaP is one method that has been used to enhance 
the Young’s modulus of polymer composite scaffolds, as the mineral phase is thought 
to increase the low stiffness characteristic of polymers (Sui et al., 2007). Despite this 
there is evidence showing that the addition of HA often fails to improve mechanical 
strength of scaffolds (Wagoner Johnson and Herschler, 2011). Indeed, in our case the 
addition of HA to scaffolds did not result in a significant change in material stiffness, 
with Young’s modulus values ranging from 0.09-0.22 MPa. Although the data was 
variable, and it is difficult to make a conclusive determination, the trend in the data 
suggested those scaffolds that contained HA appeared to have lower Young’s modulus 
values (i.e. lower stiffness), this may have been due to the increased porosity of 
PLGA/HA compared to other scaffolds as increasing porosity can result in 
deterioration of a scaffold’s resistance to compression potentially causing it to collapse 
(Byrne et al., 2007). Contrasting the values acquired for the scaffolds with the 
compressive Young’s modulus of cancellous bone of 489 MPa (Røhl et al., 1991), and 
it remains clear that this type of design should only be considered in non-weight-
bearing settings.  
Experiments evaluating the impact of incubating scaffolds directly and indirectly with 




compared to cell only controls. However, the data did indicate that the scaffolds were 
nonetheless compatible with the growth of osteoblasts and endothelial cells. This 
result is similar to that observed earlier in Chapter 4 (Sartawi et al., 2020b).  
With regard to limitations of this design and the study in general, the mechanical 
properties of the scaffolds were not shown to be consistent with natural bone. 
Additionally, the mechanical testing approach was limited by high variability, a more 
accurate measurements could be undertaken using nanoindentation (Chowdhury et al., 
2005). Other more specific issues related to this work include the lack of uniform 
scaffold mass between some of the experimental procedure, which hindered making 
comparisons throughout the chapter. Another limitation was the lack of functional in 
vitro cell-based experiments to show the functionality of released siponimod. Another 
issue is the low drug-loading efficiency (<50 %), which although anticipated due to 
the porogen leaching step, indicated the need for additional modifications to the 
fabrication process to avoid excessive drug waste.  
To the best of our knowledge siponimod has not previously been prepared as part of 
an electrosprayed, porous scaffold for bone regeneration applications. Siponimod has 
previously been incorporated into an electrospun scaffold that showed promising in 
vitro effects on osteoblasts and endothelial cells, however failed to significantly 
stimulate regeneration in a rat critical cranial defect (Sartawi et al., 2020b), possibly 
due to poor cellular infiltration within the dense fibre matrix limiting scaffold-bone 
interface. With further development the porous scaffold described herein may 






This preliminary work aimed to illustrate the design and in vitro characterisation of a 
porous scaffold fabricated using electrospraying, gas foaming, and porogen leaching. 
The scaffolds were comprised of a siponimod loaded microparticle polymer base, 
coupled with HA to improve osteoconductivity. The scaffold was designed as a 
potential replacement material in cases of non-weight bearing critical bone defects and 
marks a contribution to knowledge as it represents the first application of siponimod 
as part of an electrospray or gas foamed scaffold system. Scaffolds resulted in 
controlled drug release with a linear profile over a suitable timeframe for bone 
regeneration, however the use of porogen leaching likely adversely impacted loading 
efficiency. The scaffolds showed good porosity and were compatible with hFOB 
indicating stable metabolic activity over 7 days. The addition of HA did not result in 
any notable statistically significant results, rather it appeared to weaken the overall 
mechanical integrity of the scaffold, indicating further HA ratio optimisation is 
required. Changes to HA incorporation will most likely lead to positive improvements 
in scaffold osteoconductivity. However, the effects of siponimod in particular must be 
rigorously investigated both in vitro and in vivo using this scaffold design, before this 






6 Chapter 6 
 
 













6.1 Overview and Summary 
Tissue engineering plays an important role in providing replacement materials to assist 
in the regeneration of the form and function of damaged tissue (Vacanti and Vacanti, 
2014). There have been notable successes associated with the field, including the 
Dermal Regeneration Template, Integra®, and the spinal fusion bone graft, INFUSE® 
(Hoffman et al., 2019). However, despite the number of researchers and companies 
undertaking tissue engineering research, the exponential increase in research related 
publications (Hoffman et al., 2019) and even the progression of some products to 
clinical trials, the translation of new innovative products to the clinic has been poor 
(Kim et al., 2019b). It must also be noted that even relatively successful endeavours, 
such as INFUSE®, have limitations including ectopic bone growth and an increased 
likelihood of additional corrective surgeries (Epstein, 2013). Therefore, there remains 
a need to continue investigating and developing novel pharmaceutical and biomaterial 
strategies underpinning BTE research, namely scaffolds, cells and osteoinductive 
cues.  
Research in BTE has taken its inspiration from the composition and structure of native 
bone tissue. Indeed, efforts have concentrated on scaffold constructs that attempt to 
recapture the hierarchical structure of bone (Nijsure and Kishore, 2017, Rho et al., 
1998). This can be achieved by utilising materials that closely match the organic 
extracellular matrix components and inorganic mineral constituents of bone (Shekaran 
and García, 2011, Mohamed, 2008), in an effort to approximate the mechanical 
properties of bone (Wang et al., 2016b, Hench, 2013), and mimic the bioactive 
functionalities inherent in viable bone tissue (Walsh, 2015, Copp and Shim, 1963, 




chemical properties is not a simple proposition, and no single material or biomaterial 
(outside of cortical autograft (Greenwald et al., 2001)) can realistically fulfil all of 
these requirements. Consequently, numerous materials have been investigated 
including natural and synthetic polymers, bioactive ceramics and glasses, and 
composites of the same (Stevens, 2008). Promising materials have also been coupled 
with active agents including biologicals such as growth factors (De Witte et al., 2018), 
small molecule therapeutics (Carbone et al., 2014) and platelet rich plasma (Cheng et 
al., 2018), to further impart beneficial regenerative potential to the BTE design. While 
often producing superior bioactivity, the use of growth factors is limited by side effects 
(Cahill et al., 2015) and biologic instability (Chen and Mooney, 2003). Small molecule 
therapeutics on the other hand, can avoid issues of biologic instability, but also possess 
limitations including weaker and less specific activity (Carbone et al., 2014). 
Taking these factors into account, the general aim of this work has been to investigate 
the bone reparative potential of a novel, small molecule therapeutic agent, siponimod, 
and develop scaffold constructs appropriate for its spatiotemporal presentation for 
BTE applications. The design approach focused on utilising biomaterial orientated 
constructs consisting of the biodegradable and biocompatible polymer, PLGA as the 
base material coupled with additives to impart enhanced bioactivity.  
This thesis began with a general introduction in Chapter 1, which provided context 
pertaining to the ideal and available scaffold materials, scaffold fabrication methods, 
and pharmacological additives. Furthermore, the chapter highlighted the benefits and 
limitations of current materials and scaffold fabrication techniques, providing recent 




targeting of S1P signalling, and its role in bone biology. This analysis of the S1P 
literature informed our hypothesis that the S1P1/5 receptor agonist siponimod would 
be a suitable small molecule bioactive agent in stimulating bone repair due to the 
balance of data supporting the role of the S1P1 receptor in the proliferation, 
differentiation, and migration of osteoblasts and endothelial cells. The role of Chapter 
3 was then to test this hypothesis in vitro and investigate the bone regenerative 
potential of siponimod, by determining its impact on key cell players implicated in 
bone regeneration using relevant metrics - proliferation, differentiation, and migration 
effects on hFOB and HUVEC. 
From the wider literature on bone repair, it was clear that the use of S1P agonists (and 
other small molecules or growth factors) benefit from a localised and controlled 
application rather than systemic delivery. Therefore, Chapters 4 & 5 investigated 
formulation design aspects using electrospinning and electrospray/porogen leaching 
methods to prepare drug-loaded scaffold constructs that could fulfil the localised 
controlled release of siponimod. These techniques were used because electrospinning 
and electrospraying, as described in their respective chapters, are highly efficient 
methods of preparing drug-loaded microstructures that allow the formulation of a 
variety of potential materials and drug cargoes. The developed scaffolds were required 
to display several desirable features including biocompatibility, biodegradation, 
osteoconductivity and ideally appropriate mechanical properties. Only the electrospun 
formulation in Chapter 4 was progressed to the stage of in vivo analysis, due to 
limitations of time and material. However, both Chapter 4 and Chapter 5 provided 




good foundation for future design decisions both for bone regeneration and more 
broadly for other therapeutic applications. 
  
6.2 Contribution to knowledge 
All in all, despite the lack of in vivo bone regeneration seen with the developed 
electrospun scaffolds, this body of work contributes valuable new knowledge to the 
ever-growing fields of bone tissue engineering and S1P receptor research. The specific 
contributions to knowledge can be summarised as follows:  
• Chapter 2 – This survey of the literature informed our choice of a selective 
S1P1/5 agonist, siponimod, as the small molecule of interest. As of writing, the 
published work associated with this chapter is one of only three available 
reviews contributing to our understanding of the involvement of S1P 
signalling, specifically the S1P1 receptor, in bone regeneration. 
• Chapter 3 – This is the first published research utilising a selective S1P1/5 
agonist, siponimod, for its potential role in bone regeneration. It is one of the 
very few publications documenting an effect of siponimod in any biological 
system expressing endogenous S1P1 receptors. The notable findings in this 
chapter were siponimod’s stimulation of endothelial cell migration, and the 
stimulation of osteoblast differentiation with an effect equivalent to that of 
S1P.  
• Chapter 4 – This is the first published research describing the preparation of 
a siponimod loaded scaffold for bone regenerative applications. This work 




or liquid state, temperature, storage time), formulation design (e.g. the effect 
of solvent), and demonstrated that functionally active siponimod was released 
in a controlled and stable fashion across a range of concentrations. Despite 
ultimately showing no significant effect in vivo, this work provided useful 
insights for future experimentation and indeed for other investigators across 
other fields. 
• Chapter 5 – While early in development, this work provided the basis for an 
alternative formulation design with substantial porous architecture, effective 
cytocompatibility and controlled release of siponimod suitable for localised 
delivery. All of which warrants further development and investigation. 
 
6.3 Interpretation and implications of the thesis findings  
The following sections will provide a brief discussion of each of the thesis objectives, 
and their implications. 
6.3.1 Objective Ⅰ: To review the role of S1P signalling in bone repair and identify 
S1P1 receptor agonists as targets for experimental investigation. 
As a first step, the properties of S1P its receptor signalling and their involvement in 
bone biology and the process of bone repair were reviewed (Chapter 2). The chapter 
reviewed the effects of S1P in stimulating osteoblast precursor cell migration 
(Roelofsen et al., 2008) and differentiation (Brizuela et al., 2014), and discussed the 
mechanism of S1P signalling on osteoblast proliferation (Carpio et al., 1999, 
Lampasso et al., 2001, Grey et al., 2004), and differentiation (Grey et al., 2004, Sato 




highlighted the influence of S1P signalling on osteoclast recruitment (Ishii et al., 2009, 
Lee et al., 2017) and osteoclast-osteoblast crosstalk (Meshcheryakova et al., 2017). 
The chapter concluded with some examples of efforts in S1P delivery, including the 
endogenous compound (Sefcik et al., 2008) as well as the synthetic analogue 
fingolimod (Das et al., 2014b). 
This chapter indicated the knowledge gap that could be filled by investigating a 
specific S1P1 receptor agonist and its potential in bone regeneration. Osteoblasts are 
known to express each of the S1P1, S1P2 and S1P3 receptors (Grey et al., 2004, Ryu et 
al., 2006, Keller et al., 2014), but the overall balance of the literature indicated that 
S1P1 in particular and to a lesser extent S1P3 receptors are promising targets for 
influencing the bone repair process. This narrowing of S1P receptor criteria eliminated 
the less selective agents, S1P and fingolimod. This resulted in a few potential 
therapeutic agents including siponimod (licensed as Mayzent® in January 2020), 
ozanimod (licensed as Zeposia® in March 2020), and ponesimod (in development) 
being considered for experimentation. From these siponimod was selected due to its 
availability and its position as the most advanced in clinical development at the time 
when these studies were initiated. Finally, after scrutinising the existing efforts in S1P 
delivery, it was clear that a localised controlled release approach was the most suitable.  
6.3.2 Objective Ⅱ: To determine the effect of siponimod on key cell players, 
osteoblasts and endothelial cells, implicated in bone regeneration using cell 
proliferation, differentiation, and migration as metrics. 
The work in Chapter 3, aimed to advance the body of knowledge in the literature 




cellular mechanisms fundamental to bone regeneration. Specifically, Chapter 3 
investigated the effects of the S1P1 receptor agonist, siponimod, on osteoblasts and 
endothelial cells.  
Beginning with siponimod’s effect on osteoblasts, results showed that siponimod had 
no effect on osteoblast cell viability and proliferation, which was in contrast to the 
available literature, which had previously shown that stimulation with the endogenous 
and non-subtype selective S1P may support osteoblast viability (Carpio et al., 1999, 
Lampasso et al., 2001). This may indicate that S1P3 plays the more substantial role 
with regards to cell viability, while S1P1 receptor modulation influences 
differentiation rather than proliferation. The latter was confirmed by significant 
findings identifying siponimod’s stimulation of osteoblast differentiation with an 
effect equivalent to that of S1P. Osteoblast differentiation via S1P signalling is known 
to be associated with the S1P1 (Matsuzaki et al., 2013) and S1P3 (Brizuela et al., 2014) 
receptors, however the literature is conflicted over which of the two is more relevant. 
Our results strongly suggest that it is indeed the S1P1 receptor that produces the 
observed effects, this is supported by the high specificity of the siponimod molecule 
signified by it subnanomolar EC50 (Lukas et al., 2014, Gergely et al., 2012). 
With regard to siponimod’s effect on endothelial cells, it is known that S1P receptors 
are implicated in vasculogenesis and angiogenesis (Oyama et al., 2008, Waeber, 
2013a, Takuwa et al., 2010, Lucke and Levkau, 2010), and indeed S1P1 is the 
predominant receptor subtype expressed in endothelial cells (Igarashi et al., 2003). 
Our results confirmed siponimod had no adverse effect on viability nor stimulation of 




(Kwon et al., 2001, Panetti, 2002). With regard to cell migration, siponimod showed 
a significant effect, whereby in scratch assays siponimod stimulated cell motility to an 
extent equivalent to that of S1P. In directional transwell migration assays siponimod 
had no inherent chemotactic effect in the short term (4 hrs), rather it blocked the 
chemotactic effect of FBS (containing high endogenous S1P levels) and exogenously 
added S1P, siponimod also blocked S1P mediated endothelial cell attachment. These 
results were similar to the known effects of fingolimod, which has been shown to 
induce motility in endothelial cells using scratch assays (Mullershausen et al., 2009) 
but to impede transwell HUVEC migration (Ho et al., 2005, LaMontagne et al., 2006, 
Tanaka et al., 2013). However, unlike fingolimod, siponimod produced a delayed 
increase in transwell migration when experimental durations were increased (8 hrs), 
possibly due to persistent signalling of internalised S1P1 receptors (Mullershausen et 
al., 2009). 
From a mechanistic point, it was posited that both the differentiation effect on 
osteoblasts and the migration effect on endothelial cells were associated with the S1P1 
receptor given the receptor affinities of siponimod. As an additional piece of evidence 
in relation to the differentiation effect, an analysis of cAMP was undertaken showing 
that forskolin-induced cAMP is inhibited by siponimod (Sartawi et al., 2020a), which 
is similar to results seen for both S1P and fingolimod (Mullershausen et al., 2009). 
Given that the literature has shown that increased levels of cAMP can decrease ALP 
(Romanello et al., 2001) and suppress osteoblast mineralisation (Nishihara et al., 
2018), it is reasonable to propose that S1P1 receptor-mediated decrease in cAMP levels 
is a possible mechanism through which siponimod may be producing its observed 




Thus Chapter 3 broadened our understanding of the signalling properties of 
siponimod and specifically highlighted the effects of siponimod on some of the 
cellular populations that contribute to bone regeneration. Furthermore, it identified the 
nature of siponimod’s effect (or lack thereof) on osteoblast and endothelial cell 
behaviour in terms of proliferation, differentiation, and migration. Taken together this 
provided enough evidence to justify the inclusion of siponimod as the agent of choice 
for the development of a localised delivery device to augment bone regeneration. This 
was confirmed in vitro in Chapter 4 where electrospun scaffolds loaded with 
siponimod produced similar differentiation and migration effects following release 
from the scaffold highlighting that the drug could be formulated into a delivery system 
that retained its stability and activity in vitro. Ultimately however, the effects did not 
translate into significant bone regeneration in vivo.  
6.3.3 Objective Ⅲ: To develop and characterise drug-loaded electrospun scaffolds 
composed of PLGA and collagen for controlled release of siponimod over 
timeframes relevant for bone regeneration. 
Albeit limited, the literature has shown that the systemic delivery of molecules similar 
to siponimod, specifically fingolimod, did not produce positive results for bone 
regeneration (Heilmann et al., 2013), which was in contrast to the results reported for 
localised delivery (Das et al., 2014a, Petrie Aronin et al., 2010a, Petrie Aronin et al., 
2010b, Sefcik et al., 2008). Therefore, in order to administer siponimod locally to 
support bone regeneration, it was necessary to develop a suitable delivery vehicle. The 
selection of electrospinning as the production method was influenced by previous 
experience in the literature that used electrospinning to prepare fingolimod loaded 




electrospinning were the versatility of electrospinning in the processing of materials 
with diverse properties, (e.g. growth factors (Zhang et al., 2019b) and natural 
extracellular matrix components (Yang et al., 2018)), as well as its ability to produce 
constructs that mimic the fibrillar properties and dimensions of bone extracellular 
matrix (Hendrikson et al., 2017). We therefore aimed to prepare electrospun scaffolds 
composed of PLGA and collagen, loaded with siponimod, with the goal of targeting 
the S1P1 receptor effects identified in Chapter 3.  
The electrospun formulations resulted in a flexible, fibrous polymer mat. Results from 
Chapter 4 showed that electrospun scaffolds had high drug-loading efficiencies and 
controlled the release of siponimod over 90 days, which was in line with planned in 
vivo experiments (also described in Chapter 4). Importantly, siponimod released from 
electrospun formulations was shown in vitro to produce the same differentiation and 
migration effects demonstrated with free siponimod in Chapter 3, indicating the 
formulation could provide functionally active cargo and that the concentrations 
released were appropriate to elicit these effects. Furthermore, the controlled release 
profiles were similar as the concentration of siponimod in the scaffolds was increased, 
indicating the capability to control local concentrations by modifying initial drug 
loading concentrations within the formulation. The electrospun scaffolds supported 
increased osteoblast metabolic activity in the case of cells grown directly on the 
scaffold surface. However, over the short timeframe of the experiment, cellular in-
growth throughout the fibre matrix was only observed for the Si 0.5:100 sample. The 
relatively poor cell infiltration overall may have been hampered by the packing density 
of hydrophobic fibres, especially in the case of the samples containing collagen, which 




2011). It may be possible to reduce fibre density by altering the topology of the 
collection dish, by creating an abundance of irregular surfaces for fibre deposition 
rather than a single uniform flat surface (Phipps et al., 2012a). Another possibility is 
the addition of water-soluble sacrificial fibres to the formulation, which could then be 
subsequently leached out of the matrix to decrease overall fibre density (Phipps et al., 
2012a, Wu and Hong, 2016).  
In order to increase the osteoconductivity of the scaffold, the design included the 
addition of collagen, which is a primary component of bone (Shekaran and García, 
2011, Mohamed, 2008). However, the addition of collagen had no discernible effect 
on the scaffold’s cytocompatibility performance, despite evidence in the literature 
showing that similar concentrations can improve cellular adhesion to polymer 
scaffolds by increasing sites for cellular attachment (Chiu et al., 2007). Given 
collagen’s importance in bone regeneration, the most likely path to maximise the 
impact of collagen is to investigate increased collagen concentrations (Ngiam et al., 
2009). Reducing fibre packing may also be useful in this context by increasing the 
exposure of cells to the available collagen binding sites.  
This chapter thus highlighted that siponimod can be incorporated at different 
concentrations into electrospun composite polymer formulations efficiently and 
easily. Additionally, controlled release of functionally active siponimod was 
successfully achieved, and the potential of the electrospun matrix to mimic bone 
extracellular matrix showed promising results when incubated directly with cells. 
However, longer-term studies supported by histology and immunohistochemistry are 




acknowledged to provide the clearest indication of the scaffolds’ potential to promote 
regeneration of bone defects. Consequently, selected samples were progressed for in 
vivo experimentation.  
6.3.4 Objective Ⅳ: To investigate the ability of the electrospun scaffold design to 
promote bone regeneration in rat critical cranial defects using fluorescent 
labelling and bone staining histomorphometry. 
The results of Chapter 4 showed that the prepared siponimod-loaded scaffolds 
released functionally active cargo in a controlled manner over 90 days, and that the 
scaffold constructs supported osteoblast growth. The next step involved the evaluation 
of the scaffolds in a critical cranial defect study to ascertain whether the in vitro 
differentiation effects translated into in vivo mineralisation and regeneration of bone 
tissue. The cranial defect model is commonly used in the literature as a model of 
critical bone defects (Spicer et al., 2012), and a similar study has been conducted for 
alternative designs of fingolimod loaded scaffolds (Petrie Aronin et al., 2010a).  
Results from this in vivo study showed that the implanted scaffolds all produced a 
small reduction in defect size with signs of mineralisation. However, there was no 
significant difference in the histomorphometric results of drug-loaded and drug-free 
experimental groups, using fluorochrome analysis, von Kossa staining, or Masson’s-
Goldners trichrome staining. Supplementary H&E staining (Appendix B) data 
provided interesting, albeit qualitative data on defect morphology after the 12-week 
study, whereby most scaffolds exhibited degradation, and replacement by regenerating 
tissue. The SiCol 0.5:100 sample was a notable exception, the remains of which 




infiltration. Given that cell viability studies (direct and indirect) did not indicate 
adverse effects related to scaffolds (Chapter 4), it is postulated that this may be due 
to issues relating to fibre size and packing density. Another point of note, scaffolds 
containing fingolimod had been prepared to act as a positive control, however it failed 
to replicate the significant mineralisation that has been shown using similar 
electrospun designs (Das et al., 2013), and alternative microsphere-based moulded 
scaffolds (Das et al., 2014b). There were differences in the experimental conditions 
(i.e. defect size and type), methods and measures to assess regeneration (i.e. 
histomorphometry compared to microCT), and indeed the outcomes of those studies 
compared to the data presented herein, and so it is difficult to make like for like 
comparisons and conclude why fingolimod was unsuccessful as a positive control. 
Thus, the cranial defect study described in Chapter 4 highlighted that there remains a 
discrepancy between siponimod’s stimulation of osteoblast differentiation in vitro, and 
the detection of significant mineralisation in vivo. And unless in vivo mineralisation 
or new bone formation can be detected, then the significance of siponimod’s 
differentiation effects, and indeed the validity of using siponimod for bone 
regeneration will remain questionable. 
6.3.5 Objective Ⅴ: To develop porous drug-loaded scaffolds composed of 
electrosprayed PLGA microparticles and HA, using gas foaming and porogen 
leaching, for controlled release of siponimod over timeframes relevant for 
bone regeneration.  
An additional formulation design strategy, which again took inspiration from 




microparticles of PLGA loaded with siponimod together with HA and a porogen prior 
to compression into a scaffold compact (Chapter 5), the compact was then exposed 
to high-pressure CO2 foaming, followed by porogen leaching. The motivation 
underpinning this strategy was to design a scaffold with good porosity to facilitate 
enhanced cell infiltration, combined with the osteoconductive mineral, HA to enhance 
cell integration, and the S1P1/5 agonist siponimod to stimulate osteoblast 
differentiation. This approach produced an interconnected, macroporous structure 
with pore volumes ranging from 70.1-83.7 %. Qualitative estimations of pore size 
were in the range of 200-300 µm, which is within the range (100-350 µm) deemed 
necessary to support the growth and survival of osteogenic cells (Yang et al., 2001). 
This method of preparing porous scaffolds was based on the literature (Harris et al., 
1998, Mooney et al., 1996), and has been used to prepare scaffolds that support cell 
differentiation in vitro and bone formation in an in vivo subcutaneous model (Kim et 
al., 2006). The processing approach endowed samples with a porous architecture, 
which was hypothesised to be more amenable to cell infiltration representing an 
advantage over the more tightly packed electrospun samples, which appeared to 
present a highly dense microstructure that may have impeded cell infiltration 
(Chapter 4, in vitro and in vivo findings). 
Siponimod loading was 48.5 ± 2.2 % of theoretical drug mass and was substantially 
lower than the electrospun scaffolds developed in Chapter 4, which exhibited loading 
efficiencies of 80-94 % of theoretical drug mass. This difference was likely due to the 
inclusion of a 12 hrs porogen leaching step, which contributed to the loss of surface 
bound siponimod, an issue that may have been exacerbated by the high pore volume 




experimental duration, and by the 90 day time point, the porous scaffolds had released 
36.7 ± 0.1 % of actual drug loading, compared to 57.7 ± 0.25 % for their electrospun 
counterpart. The difference in release patterns was attributed to the removal of the 
surface bound drug during leaching, which otherwise could have contributed to a burst 
release component.  
Results of DSC and mechanical properties analysis did not highlight any significant 
consequences related to the addition of the different components of the scaffolds nor 
the fabrication process itself. However, the mechanical properties of HA-containing 
scaffolds showed a trend of impaired scaffold integrity, possibly due to higher porosity 
measured for HA-containing scaffolds which may have resulted from HA lost during 
leaching. Another possible explanation for the impaired integrity of HA samples may 
be due to inconsistent manual mixing of the HA and polymer microparticles. A 
possible modification that may remedy these potential issues (HA loss through 
leaching, inconsistent mixing), may be to incorporate HA prior to mould-compression, 
possibly as a PLGA/HA suspension electrosprayed as microparticles (Yuan et al., 
2019).  
Cell culture experiments conducted using osteoblasts and endothelial cells indicated 
that the scaffolds did not adversely affect the metabolic activity of these cells. The 
addition of siponimod and HA did not result in statistically significant changes in cell 
metabolic activity, a result similar to those seen in Chapters 3 & 4 (Sartawi et al., 
2020a, Sartawi et al., 2020b), although there were some differences between the 
experimental design of the respective studies due to the distinct dimensions and 




These data provide useful formative information although further work is warranted 
to again confirm siponimod functionality in vitro, and then to interrogate more deeply 
the exact impact of the scaffold on osteoblast and endothelial cell behaviour using 
longer-term cell culture and histology experiments. Only then could these porous 
scaffolds be considered as a candidate for further in vivo investigation. 
 
6.4 Limitations  
• In Chapter 3, the effects of siponimod were attributed to S1P1 receptor 
signalling. Although this is a fair hypothesis given siponimod’s known 
selectivity and its effect on cAMP levels, additional experiments showing 
detailed receptor expression (e.g. PCR followed by Western blot to document 
the presence of S1P1 receptors and the lack of S1P5 receptors, for which 
siponimod also shows a high affinity) would have provided stronger evidence. 
• Regarding the cranial defect study described in Chapter 4, the high variability 
across the quantitative results clearly indicated that it was an error to divide 
the ex-plant samples in order to progress the samples using undecalcified and 
decalcified techniques. Instead all samples should have underwent 
undecalcified analysis according to initial estimates of sample size which were 
calculated based on the existing literature (Sikavitsas et al., 2003, Chesmel et 
al., 1998, van de Watering et al., 2012). However, it should be noted that the 
trend of the undecalcified results suggested that there was unlikely to be a 
significant difference even if the remaining samples had been included. 




which were to be used to quantify the inter-label distance between the two 
calcium chelators (Sun et al., 1992). However, the unsuccessful detection of 
alizarin hampered the quantitation of this outcome measure.  
• In Chapter 5, formative in vitro characterisation experiments have been 
conducted on the scaffolds prepared using electrospraying/porogen leaching 
which makes determinative statements on its efficacy currently difficult. 
  
6.5 Recommendations for future work 
The thesis provides new insights into the role and use of the selective agent, 
siponimod, in bone regeneration applications. It is the first work investigating 
siponimod for this application and provides a valuable starting point for the 
exploration of alternative small, molecule drug cargoes that may be used to direct cell 
activities and regenerative outcomes. Future work is recommended in the following 
areas. 
• Further in vitro cell-culture studies investigating cell behaviour e.g. 
differentiation supported by qPCR and immunohistochemistry analysis to 
achieve a greater understanding concerning the impact of siponimod on bone 
forming cells. It would also be interesting to explore siponimod’s effect on 
osteoclasts and indeed co-culture experiments of osteoclasts together with 
osteoblasts in order to investigate the impact of siponimod on the cross-talk 
between the two cell populations that control bone growth and remodelling, 
which might provide greater mechanistic insights. Furthermore, siponimod’s 




formation studies. Additionally, a more thorough investigation of the 
mechanism of action is warranted, including a study of the signalling pathways 
involved, especially regarding persistent signalling of internalised S1P 
receptors. 
• The electrospun formulations in Chapter 4 resulted in a flexible, fibrous 
polymer mat, which could be promising to augment bone regeneration when 
used as a part of a combination approach with metallic bone fixation devices 
or alone as a bone void filler or flexible bone graft substitute. However, based 
on the results in the thesis, this design must yet be further optimised by 
enhancing the osteoconductivity by increasing the concentration of collagen to 
improve cell interaction. It was clear that samples incorporating collagen 
produced more densely packed compacts, hence strategies to increase the 
porosity and cell infiltration in these constructs should be investigated, e.g. by 
co-spinning water-soluble sacrificial fibres. Finally, and importantly, any 
bioactivity induced by the added sphingolipid must be confirmed in vivo.  
• The research shown in Chapter 5 highlighted formative data pertaining to 
another localised scaffold to control delivery of siponimod. Further 
optimisation of siponimod loading efficiency and HA incorporation can be 
achieved by optimising the electrospraying and porogen leaching steps. 
Additionally, this scaffold should undergo in vitro functional studies to 
confirm cellular infiltration, osteoblast differentiation and ideally 
vasculogenesis using key markers. If meritorious, this should be followed by 




6.6 Thesis conclusions 
• A detailed survey of the literature shows that S1P receptor modulators 
contribute to bone growth and by extension bone healing. The receptors most 
likely associated with bone biology are S1P1, S1P2, and S1P3, with compelling 
indications that the S1P1 subtype is of particular significance. 
• Siponimod, an S1P1/5 receptor agonist, was for the first time shown to increase 
osteoblast differentiation and simulate endothelial cell migration both when 
formulated as a solution and in polymer scaffold presentations.  
• Siponimod was readily incorporated into polymer constructs alone or as part 
of composite systems using electrospraying and electrospinning methods. 
These different composite scaffolds exhibited distinct properties in terms of 
morphology, presentation, and mechanical properties e.g. flexibility in 
electrospun mats compared to a more rigid conformation for the 
foamed/porogen-leached scaffolds. This offers the prospect to exploit their 
usage in bone applications with diverse requirements. Both systems showed 
acceptable drug loading and controlled drug release, with the electrospun 
scaffold also confirming functionally effective concentrations which persisted 
over prolonged timeframes relevant for bone regeneration.  
• Under the experimental design set-up employed in this work, siponimod 
loaded electrospun scaffolds do not produce statistically significant 
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7 Appendix A 
 
 








S1P receptor induced proliferation has previously been shown for both rat and human 
osteoblasts (Carpio et al., 1999, Lampasso et al., 2001, Dziak et al., 2003). And while 
osteoblasts are known to express S1P1, S1P2 and S1P3 receptors (Grey et al., 2004, 
Ryu et al., 2006, Keller et al., 2014), the response appears to be S1P1-mediated 
(Lampasso et al., 2001, Grey et al., 2004). Therefore Chapter 3 explored the effects 
of the S1P1 receptor agonist siponimod on the proliferation effects of osteoblasts, 
alongside determining its effects on osteoblast differentiation and migration. 
The following supplementary data describes viability and proliferation experiments 
conducted on additional osteoblastic cell models, MC3T3-E1 and Saos-2. 
 
7.2 Materials and methods 
7.2.1 Materials 
The cell lines Saos-2 (ATCC® HTB-85™), and MC3T3-E1 Subclone 4 (ATCC® CRL-
2593™) were acquired from ATCC. The alamarBlue™ Cell Viability Reagent was 
acquired from Thermo Fisher Scientific, USA. All other materials were identical to 
those listed in Chapter 3 materials section. 
7.2.2 Cell culture materials 
MC3T3-E1 cells were maintained in α-MEM supplemented with FBS (10 %), L-
glutamine (1 %), and penicillin-streptomycin (1 %). Saos-2 cells were maintained in 
McCoy’s 5α supplemented with FBS (15 %), L-glutamine (1 %), and penicillin-




7.2.3 Viability and proliferation of MC3T3-E1 and Saos-2 
Initial investigations using the osteoblast cell lines MC3T3-E1 and Saos-2 were 
performed to explore the effect of siponimod on cell metabolic activity and 
proliferation, and to a lesser extent evaluate the impact of reduced serum concentration 
(1 % FBS) that was necessary to limit the effect of serum lipids. 
MC3T3-E1 and Saos-2 were seeded at a density of 5*103 cells per well in 96-well 
plates. Cells were then incubated for 24 hrs in medium with reduced serum (1 % FBS) 
to induce quiescence. Thereafter, MC3T3-E1 and Saos-2 cell were treated for 2 and 3 
days respectively with three concentrations of siponimod (1, 10, and 100 nM). 
Following incubation, 10 µl of alamarBlue™ was added for 4 hrs. Thereafter, 
absorbance was acquired at 570 and at 595 nm to correct for overlap between oxidised 
and reduced forms of alamarBlue™ according to manufacturer’s protocol. 
 
7.3 Results 
The results of alamarBlue™ and cell count assays are shown in Figure 7.1, and are 
presented as a percentage of the positive control. Incubating MC3T3-E1 cells with 
three concentrations of siponimod showed no statistically significant difference 
compared to controls (77.7 ± 5.3 % for 1 nM, 79.4 ± 6.3 % for 10 nM, and 77.4 ± 5.4 
% for 100 nM compared to 75.6 ± 4.0% for the control). Results of cell counting were 
in agreement, with no statistically significant change in cell counts with the addition 
of siponimod (69.4 ± 29.9 % for 1 nM, 67.0 ± 13.2 % for 10 nM, and 72.7 ± 16.6 % 
for 100 nM compared to 75.5 ± 33.4 % for the control). For the Saos-2 cells there was 




siponimod (76.8 ± 3.7 % for 1 nM, 76.0 ± 5.3 % for 10 nM, and 72.6 ± 5.5 % compared 
to 75.5 ± 4.0 % for the control). Again, cell counting data was in agreement with the 
alamarBlue™ assay with no statistically significant effects following incubation with 
siponimod (71.3 ± 20.2 % for 1 nM, 71.2 % ± 23.4 % for 10 nM, and 61.7 ± 11.5 % 
for 100 nM compared to 74.5 ± 28.2 % for the control). 
There was no significant change in metabolic activity for the addition of high (10 or 
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Figure 7.1 Viability and proliferation assays for MC3T3-E1 and Saos-2 cells. (A & 
B) MC3T3-E1 alamarBlue™ assay and cell count after 48 hrs, n=3 (5 technical 
replicates) (C & D) Saos-2 alamarBlue™ assay and cell count after 72 hrs, n=3 (5 
technical replicates). For A-D, data is expressed as a percentage (positive control set 
to 100 %). For both cell types, siponimod was added to cell culture medium containing 
1 % FBS serum supplement, with standard growth medium acting as positive control 
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represents the number of independently repeated experiments. Data is presented as 
mean ± SD, statistical analysis by one-way ANOVA. NS: No statistical significance. 
 
7.4 Discussion 
As was the case in Chapter 3, there was no significant effect on the viability and 
proliferation of MC3T3-E1 and Saos-2 cells. This data provides some additional 
evidence that there is no short term impact from siponimod on the viability and 
proliferation of osteoblasts as expressed in the literature (Carpio et al., 1999, Lampasso 
et al., 2001, Dziak et al., 2003). Rather it appears that siponimod stimulates osteoblast 














8 Appendix B 
 
 








Despite bone having excellent regenerative properties in most cases, in severely 
injurious situations the size of a defect can limit recovery. These are termed critical 
bone defects, which are defects that do not naturally recover over time. As described 
in earlier chapters, normal bone repair requires a combination of early immunogenic 
response followed by intramembranous or endochondral ossification with associated 
development of new vasculature. In critical defects, each of these aspects of repair 
represent possible targets when developing new treatment methodologies to compete 
with the current gold standard, autologous bone grafts.  
An ideal material to replace the inherently limited supply of autograft would aim to be 
highly conducive to new bone formation by mimicking the natural inorganic-organic 
split in bone composition (Kuttappan et al., 2018). Replicating the osteogenic nature 
of bone in an implantable material is even more difficult than replicating 
osteoconductivity, and has so far has most promisingly been achieved through the 
combination of biocompatible materials with mesenchymal stem cells prior to 
implantation within defects (Szivek et al., 2019). 
There are a number of well-developed models available to investigate critical bone 
defects which include femoral (Mohiuddin et al., 2019), mandibular (Marei et al., 
2018), and cranial defects (Das et al., 2014b). Although the latter two models do not 
take into account the effect of weight bearing and mechanotransduction on bone repair 
(Huang and Ogawa, 2010), this also means that there is no requirement for defect 




clearly identifying bone regeneration induced by added growth factors or small 
molecules therapeutics.  
Recently, various electrospun materials have been investigated as replacement implant 
materials, and as vectors for the delivery of medicinal cargoes in critical cranial 
defects. For example, electrospun polycaprolactone terminally enriched with bone 
marrow stromal cells (Isoglu et al., 2019), and polycaprolactone and poly vinyl alcohol 
coaxially spun with platelet-rich plasma (Cheng et al., 2018), and PLGA, which has 
been electrospun and coated with BMP fragments for use in a cranial defect (Lee et 
al., 2013). Our own data in Chapter 4 showed that siponimod could easily and 
efficiently be incorporated into an electrospun delivery system that produced a 
controlled release of functionally active siponimod. However, scaffolds ultimately did 
not result in significant enhanced bone regeneration in rat critical cranial defects.  
The following supplementary data shows additional in vitro and qualitative in vivo 
results from using the aforementioned electrospun scaffolds design in the critical 
cranial defect described in Chapter 4. Specifically, the in vitro data is included to 
confirm the cytocompatibility of the same batch of electrospun scaffolds that was soon 
after used in the cranial defect study. While the qualitative in vivo H & E staining 






8.2 Materials and methods 
8.2.1 Materials 
Hematoxylin, Eosin Y, and HistoChoice® Clearing Agent were all acquired from 
Sigma-Aldrich. Permount™ Mounting Medium was acquired from Thermo Fisher 
Scientific. All other materials were identical to those listed in Chapter 4 materials 
section. 
8.2.2 Electrospun sample preparation 
Sample preparation is identical to that described in Chapter 4 electrospinning 
procedure section.  
8.2.3 Cell culture 
Human foetal osteoblasts (hFOB) were cultured in DMEM/F12 supplemented with 
FBS (10 %), L-glutamine (1 %), and penicillin-streptomycin (1 %). Incubation was at 
34 °C and 5 % CO2. 
Electrospun samples (8 mm diameter) were incubated with pre-seeded hFOB (5*104 
cells/well) for 5 days in 24 well plates. Thereafter, viability of cells was determined 
by 2 h incubation with MTT solution (5 mg/ml stock) directly added to wells. 
To determine scaffold surface compatibility with cell growth, hFOB (5*104 cells/well) 
were seeded directly onto the surface of scaffolds that had been shaped to the bottom 
of 96-well plates. Incubation was continued for 5 days, at which time metabolic 
activity was determined by 2 hrs incubation with MTT solution (5 mg/ml stock) 




8.2.4 Procedure for H&E staining of cranial bone tissue 
Following extraction of cranial bones, 6 samples per group were set aside for 
undecalcified sectioning (results shown in Chapter 4) and 4 samples per group were 
assigned to undergo decalcified sectioning (results included in this supplement). H&E 
staining was used to observe defect healing, cellular infiltration into the scaffolds, and 
the integration of scaffolds with the surrounding tissue. 
Samples were decalcified using a 10 % EDTA solution for 5 days prior to embedding 
in Shandon™ M-1 Embedding Matrix (Thermo Fisher Scientific, USA), 20 µm 
sections were cut using a cryostat microtome set at -20 °C and collected on poly lysine 
coated glass slides. 
Light microscope images were acquired using a BX51 microscope, with images used 
qualitatively to inspect the defect region and scaffold remains at the end of the 12-
week experimental timeframe. 
8.2.4.1 Haematoxylin and eosin staining reagents 
• Mayer’s haematoxylin: 5 % Ammonium aluminium sulfate (ammonium 
alum), 0.1 % haematoxylin, 0.02 % sodium iodate, 2 % (v/v) acetic acid in 
deionised water. 
• Eosin Y stock solution: 1 % eosin Y in 5:1 mixture of 95 % ethanol and 
deionised water 
• Eosin Y working solution: 0.25 % eosin Y stock solution, 0.5 % acetic acid 
in 80 % ethanol. 
8.2.4.2 Haematoxylin and eosin staining procedure 




• 8 min in Mayer’s haematoxylin. 
• 2 min wash in deionised water.  
• 1 min Eosin Y working solution. 
• 1 min in 70 % ethanol, 1 min in 95 % ethanol, 1 min 100 % ethanol. 
• 1 min clearing agent. 
• Mount 
Interpretation: 
• Nuclei: blue/black 
• Cytoplasm: various shades of pink 
• Muscle/fibrin: deep pink 
 
8.3 Results 
8.3.1 Cell culture 
Results from incubating hFOB with electrospun samples are shown in Figure 8.1A. 
There were no significant differences in cell metabolic activity between any of the 
experimental conditions after 5 days incubation, as determined by MTT. Additionally, 
there was no significant difference in metabolic activity between cells incubated alone, 
and cells incubated with any of the experimental conditions. 
Figure 8.1B shows the metabolic activity of hFOB seeded directly on the scaffolds 
surface and incubated for a period of 5 days. For PLGA and for Si 0.5:100, there were 
statistically significant increases in metabolic activity compared to the other scaffolds. 




higher than those of Si 2:100 (0.14 ± 0.07) (p<0.01) and Fi 0.5:100 (0.10 ± 0.02) 
(p<0.001). The Si 0.5:100 scaffold (0.34 ± 0.01) showed a significant increase 
compared to each of Si 2:100 (0.14 ± 0.07) (p<0.001), SiCol (0.21 ± 0.02 ) (p<0.05), 
and Fi 0.5:100 (0.10 ± 0.02) (p<0.001). However, there was no significant difference 
between PLGA control and Si 0.5:100 scaffolds. 
 
 
Figure 8.1 Indirect and direct metabolic activity of hFOB incubated with electrospun 
scaffolds. (A) hFOB Indirect metabolic activity and (B) hFOB direct metabolic 
activity was determined using MTT assay after a 5 day exposure of cells to the various 
samples, for both A & B n=3 independently repeated experiments with 3 technical 
replicates. Data represents the average absorbance values at 570 nm. Data is presented 
as mean ± SD. For A & B, statistical analysis was by one-way ANOVA. *: p < 0.05, 
**: p < 0.01, ***: p< 0.001. 
8.3.2 Haematoxylin and Eosin staining of decalcified cranial defect samples 
Four samples were decalcified over 5 days using EDTA and processed to produce 
























































samples were used, qualitatively, to investigate the interaction between the implanted 
material and the regenerating tissue (Figure 8.2). 
Results indicated a small difference between the experimental groups PLGA, Si 
0.5:100, Si 2:100, and Fi 0.5:100 (Figure 8.2A-C & E) which appeared to integrate 
well with surrounding tissue, and the SiCol 0.5:100 group (Figure 8.2D) which 
showed signs of poor degradation of the polymer material and little to no cellular 
infiltration. Furthermore, although the samples were decalcified, there is a clear 
delineation in stain intensity between the original bone tissue and the new tissue in the 
centre of the defect; the difference is more easily seen when juxtaposed with the image 









Figure 8.2 H&E staining of representative decalcified samples. (A) PLGA (B) Si 
0.5:100 (C) Si 2:100 (D) SiCol 0.5:100 (E) Fi 0.5:100 (F) control with no defect. Black 
arrows indicate the scaffold remains (stained blue), while dotted lines indicate the 





The work described in Chapter 4 showed that all the developed electrospun scaffolds 
produced some mineralisation within the critical cranial defects, albeit with no 
significant differences between the experimental groups. Here, supplementary data 
was presented that sheds additional light on the behaviour of the scaffolds immediately 
following the 12-week cranial defect study.  
Cell-based metabolic activity studies were conducted before commencing the in vivo 
study and showed that none of the electrospun scaffolds altered hFOB metabolic 
activity after 5 days indirect incubation. Interestingly however, the direct metabolic 
activity study showed that the PLGA and Si 0.5:100 provided a significantly better 
surface for the growth and viability of osteoblasts than Si 2:100, SiCol 0.5:100, and Fi 
0.5:100. This was somewhat similar to the results seen in the main body of Chapter 
4, which hinted that Si 0.5:100 showed superior metabolic activity and cell infiltration, 
despite not being statistically significant. All in all, the potentially superior growth and 
metabolic activity data for the PLGA and Si 0.5:100 scaffolds did not translate to 
significant mineralisation of the defect, but all available evidence pointed to these two 
samples being the most likely to induce significant results and should therefore be 
investigated further to confirm these effects. 
 The results of H&E staining of decalcified samples were used qualitatively, and so 
cannot be used to make definitive statements. However, the trend in the available data 
indicated that the scaffolds PLGA, Si 0.5:100, Si 2:100, and Fi 0.5:100 all underwent 
substantial degradation and were replaced with regenerating tissue. The remaining 




12 weeks there appeared to be no cellular infiltration within the fibre matrix with the 
scaffold surrounded by only a thin layer of tissue. The result seen with SiCol 0.5:100 
was likely due to the density of fibres observed in collagen containing samples 
described in Chapter 4 (Sartawi et al., 2020b). Overall, this supplementary data 
contributed to our understanding that increased cellular infiltration within the scaffolds 
may be necessary to achieve better results with future scaffold designs, by reducing 
the density of packed fibres, especially in scaffolds containing collagen. 
 
